

**BETH C. DRAIN, CA CSR NO. 7152**

BEFORE THE  
INDEPENDENT CITIZENS' OVERSIGHT COMMITTEE AND THE  
APPLICATION REVIEW SUBCOMMITTEE  
TO THE  
CALIFORNIA INSTITUTE FOR REGENERATIVE MEDICINE  
ORGANIZED PURSUANT TO THE  
CALIFORNIA STEM CELL RESEARCH AND CURES ACT  
REGULAR MEETING

LOCATION: VIA ZOOM

DATE: DECEMBER 14, 2021  
9 A.M.

REPORTER: BETH C. DRAIN, CA CSR  
CSR. NO. 7152

FILE NO.: 2021-29

**133 HENNA COURT, SANDPOINT, IDAHO 83864  
208-920-3543 DRAIBE@HOTMAIL.COM**

**BETH C. DRAIN, CA CSR NO. 7152**

**I N D E X**

<b>ITEM DESCRIPTION</b>	<b>PAGE NO.</b>
<b>OPEN SESSION</b>	
1. CALL TO ORDER	4
2. ROLL CALL	4
3. CHAIRMAN'S REPORT CONSIDERATION OF RESOLUTION HONORING DR. OSWALD STEWARD	8 10
4. PRESIDENT'S REPORT - CONSIDERATION OF CIRM FIVE-YEAR STRATEGIC PLAN	29
<b>CONSENT CALENDAR</b>	61
5. CONSIDERATION OF SCIENCE SUBCOMMITTEE MISSION STATEMENT	
6. CONSIDERATION OF FINANCE SUBCOMMITTEE MISSION STATEMENT	
7. CONSIDERATION OF MINUTES FROM THE MAY THROUGH NOVEMBER 2021 ICOC MEETINGS	
<b>ACTION ITEMS</b>	
8. CONSIDERATION OF INCREASE TO EDUC 3: SUMMER PROGRAM TO ACCELERATE REGENERATIVE MEDICINE KNOWLEGE AWARDS PROGRAM BUDGET.	73
9. CONSIDERATION OF APPLICATIONS SUBMITTED IN RESPONSE TO EDUC 3: SUMMER PROGRAM TO ACCELERATE REGENERATIVE MEDICINE KNOWLEDGE AWARDS PROGRAM BUDGET	77

**BETH C. DRAIN, CA CSR NO. 7152**

**I N D E X (CONT'D.)**

<b>ITEM DESCRIPTION</b>	<b>PAGE NO.</b>
10. CONSIDERATION OF REVISED CIRM RESEARCH BUDGET FOR THE FISCAL YEAR 21/22	92/107
11. CONSIDERATION OF REVISED CIRM ADMINISTRATIVE BUDGET FOR THE FISCAL YEAR 21/22	118
<b>CLOSED SESSION</b>	119
12. DISCUSSION OF PERSONNEL [EVALUATION OF CIRM ICOC CHAIR, VICE-CHAIR AND PRESIDENT/CEO] (GOVERNMENT CODE SECTION 11126, SUBDIVISION (A); HEALTH & SAFETY CODE SECTION 125290.30(F) (3) (D))	
13. DISCUSSION OF CONFIDENTIAL INTELLECTUAL PROPERTY OR WORK PRODUCT, PREPUBLICATION DATA, FINANCIAL INFORMATION, CONFIDENTIAL SCIENTIFIC RESEARCH OR DATA, AND OTHER PROPRIETARY INFORMATION RELATING TO APPLICATIONS SUBMITTED IN RESPONSE TO AGENDA ITEM 9 ABOVE (HEALTH & SAFETY CODE 125290.30(F) (3) (B) AND (C))	
<b>ACTION ITEMS</b>	
14. CONSIDERATION OF IP AND INDUSTRY SUBCOMMITTEE MISSION STATEMENT	65
15. CONSIDERATION OF COMPENSATION FOR ICOC CHAIR/VICE CHAIR	122
16. CONSIDERATION OF COMPENSATION FOR CEO/PRESIDENT	119
17. CONSIDERATION OF ICOC PATIENT ADVOCATE MEMBER COMPENSATION	103
<b>DISCUSSION ITEMS</b>	
18. PUBLIC COMMENT	NONE
19. ADJOURNMENT	127

**BETH C. DRAIN, CA CSR NO. 7152**

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25

TUESDAY, DECEMBER 14, 20/21; 9 A.M.

CHAIRMAN THOMAS: OKAY. THANK YOU, MARIA.  
A GOOD BUT RAINY TUESDAY MORNING TO YOU. WELCOME TO  
THE DECEMBER 2021 MEETING OF THE ICOC AND THE  
APPLICATION REVIEW SUBCOMMITTEE. MARIA, WILL YOU  
PLEASE CALL THE ROLL.

MS. BONNEVILLE: LAUREN ALVING.

DR. ALVING: HERE.

MS. BONNEVILLE: KIM BARRETT.

DR. BARRETT: PRESENT.

MS. BONNEVILLE: DAN BERNAL.

MR. BERNAL: PRESENT.

MS. BONNEVILLE: GEORGE BLUMENTHAL.

DR. BLUMENTHAL: HERE.

MS. BONNEVILLE: MICHAEL BOTCHAN. LINDA  
BOXER. LEONDRA CLARK-HARVEY.

DR. CLARK-HARVEY: I'M HERE.

MS. BONNEVILLE: DEBORAH DEAS.

DR. DEAS: HERE.

MS. BONNEVILLE: ANNE-MARIE DULIEGE. I  
SEE ANNE-MARIE. I'M GOING TO MARK HER PRESENT.  
SHE'S TALKING WITH SOMEONE.

YSABEL DURON.

MS. DURON: HERE.

**BETH C. DRAIN, CA CSR NO. 7152**

1 MS. BONNEVILLE: MARK FISCHER-COLBRIE.  
2 DR. FISCHER-COLBRIE: HERE.  
3 MS. BONNEVILLE: FRED FISHER.  
4 DR. FISHER: HERE.  
5 MS. BONNEVILLE: ELENA FLOWERS.  
6 DR. FLOWERS: PRESENT.  
7 MS. BONNEVILLE: JUDY GASSON.  
8 DR. GASSON: HERE.  
9 MS. BONNEVILLE: LARRY GOLDSTEIN.  
10 DR. GOLDSTEIN: HERE.  
11 MS. BONNEVILLE: DAVID HIGGINS.  
12 DR. HIGGINS: HERE.  
13 MS. BONNEVILLE: STEPHEN JUELSGAARD.  
14 MR. JUELSGAARD: HERE.  
15 MS. BONNEVILLE: RICH LAJARA.  
16 MR. LAJARA: HERE.  
17 MS. BONNEVILLE: PAT LEVITT. LINDA  
18 MALKAS. DAVE MARTIN.  
19 DR. MARTIN: HERE.  
20 MS. BONNEVILLE: SHLOMO MELMED.  
21 DR. MELMED: HERE.  
22 MS. BONNEVILLE: CHRISTINE MIASKOWSKI.  
23 DR. MIASKOWSKI: HERE.  
24 MS. BONNEVILLE: LAUREN MILLER-ROGEN.  
25 MS. MILLER-ROGEN: HERE.

**BETH C. DRAIN, CA CSR NO. 7152**

1 MS. BONNEVILLE: ADRIANA PADILLA.  
2 DR. PADILLA: HERE.  
3 MS. BONNEVILLE: JOE PANETTA.  
4 MR. PANETTA: HERE.  
5 MS. BONNEVILLE: AL ROWLETT.  
6 MR. ROWLETT: PRESENT.  
7 MS. BONNEVILLE: BARRY SELICK.  
8 DR. SELICK: HERE.  
9 MS. BONNEVILLE: MICHAEL STAMOS.  
10 DR. STAMOS: HERE.  
11 MS. BONNEVILLE: JONATHAN THOMAS.  
12 CHAIRMAN THOMAS: HERE.  
13 MS. BONNEVILLE: ART TORRES.  
14 MR. TORRES: HERE.  
15 MS. BONNEVILLE: KRISTINA VUORI.  
16 DR. VUORI: HERE.  
17 MS. BONNEVILLE: KAROL WATSON.  
18 DR. WATSON: HERE.  
19 MS. BONNEVILLE: THANK YOU. WE HAVE A  
20 QUORUM.  
21 CHAIRMAN THOMAS: THANK YOU. AL, ARE YOU  
22 IN GERMANY?  
23 MR. ROWLETT: I AM, J.T. I'M IN BERLIN,  
24 GERMANY.  
25 CHAIRMAN THOMAS: EXCEPTIONAL DEDICATION.

**BETH C. DRAIN, CA CSR NO. 7152**

1       THANK YOU FOR PHONING IN. WE APPRECIATE IT.

2               MR. ROWLETT: I'LL APOLOGIZE IN ADVANCE  
3       FOR MY WI-FI CONNECTION HERE IF I HAVE TO GET OFF,  
4       BUT I'LL DO MY BEST TO STAY IN THE MEETING. THANK  
5       YOU.

6               CHAIRMAN THOMAS: THANK YOU VERY MUCH. SO  
7       FIRST ORDER OF BUSINESS, AS YOU ALL MAY HAVE  
8       NOTICED, WE HAVE TWO NEW MEMBERS ON THE ROLL CALL  
9       HERE. I'M GOING TO ASK THEM TO INTRODUCE THEMSELVES  
10      STARTING IN ALPHABETICAL ORDER WITH DR. LAUREN  
11      ALVING FROM UCSF FRESNO. LAUREN.

12              DR. ALVING: LAUREN ALVING, COGNITIVE AND  
13      BEHAVIORAL NEUROLOGIST FROM UCF FRESNO. I RUN THE  
14      UCSF FRESNO ALZHEIMER MEMORY CENTER, AND I ALSO AM  
15      THE DIRECTOR OF THE S.J.V. PRIME MEDICAL STUDENT  
16      PROGRAM WHICH IS A TRACK OF THE UCSF MEDICAL SCHOOL  
17      WHERE THE STUDENTS SPEND THEIR CLINICAL YEARS IN THE  
18      SAN JOAQUIN VALLEY. THANK YOU.

19              CHAIRMAN THOMAS: THANK YOU. AND NEXT,  
20      DR. KIM BARRETT FROM UC DAVIS.

21              DR. BARRETT: MORNING, EVERYBODY. VERY  
22      PLEASED TO BE HERE. I'M KIM BARRETT. I SINCE LAST  
23      MONTH WAS APPOINTED AS THE VICE DEAN FOR RESEARCH AT  
24      THE UC DAVIS MEDICAL SCHOOL. PRIOR TO THAT I SPENT  
25      36 YEARS AT UC SAN DIEGO IN THE MEDICAL SCHOOL AS A

**BETH C. DRAIN, CA CSR NO. 7152**

1 FACULTY MEMBER. I'M A GASTROINTESTINAL PHYSIOLOGIST  
2 BY TRAINING AND INCLINATION. AND AS I SAID, I'M  
3 HONORED TO BE SERVING ON THIS BOARD.

4 CHAIRMAN THOMAS: THANKS VERY MUCH.

5 WE WILL START HERE WITH A CHAIR'S REPORT.  
6 AS EVERYBODY KNOWS, POST-NOVEMBER 2020 AND THE  
7 SUCCESSFUL PASSAGE OF PROP 14, WE QUICKLY RAMPED  
8 BACK UP AND HAVE BEEN GOING FULL SPEED AHEAD FOR THE  
9 LAST YEAR. THOSE OF YOU WHO HAVE BEEN DIRECTLY  
10 INVOLVED KNOW THAT WE HAVE HAD -- THE GWG HAS BEEN  
11 EXTREMELY ACTIVE. WE HAVE HAD 16 MEETINGS OVER THE  
12 COURSE OF THE YEAR, TEN CLIN, TWO TRAN, TWO DISC,  
13 AND THREE EDUCATIONAL REVIEWS WHICH HAVE ENDED UP  
14 AWARDING AT THIS POINT \$282 MILLION WORTH OF GRANTS.  
15 I'M NOT COUNTING THE TWO THAT ARE ON TODAY'S AGENDA  
16 FOR YOUR CONSIDERATION. IT'S BEEN A VERY BUSY YEAR  
17 FOR REVIEW.

18 DR. SAMBRANO AND TEAM HAVE DONE THEIR  
19 USUAL STELLAR JOB IN TEEING UP ALL OF THAT AND  
20 ALLOWING US TO GET BACK INTO FULL SWING VERY  
21 QUICKLY. THE BOARD, OF COURSE, HAS BEEN VERY  
22 ACTIVE. WE HAVE HAD, I BELIEVE, 13 MEETINGS  
23 COUNTING THIS ONE, MAYBE 14 IF YOU ADD IN THINGS  
24 LIKE THE SCIENTIFIC STRATEGIC ADVISORY PANEL  
25 SESSION, ET CETERA, WHICH, AS YOU MAY RECALL, WAS

**BETH C. DRAIN, CA CSR NO. 7152**

1 BACK IN FEBRUARY WHICH BROUGHT TOGETHER AN ALL-STAR  
2 CAST OF ADVISORS FROM THE STEM CELL WORLD OUTSIDE OF  
3 CALIFORNIA TO HELP ADVISE THE AGENCY AS IT WAS  
4 CONTEMPLATING THE DEVELOPMENT OF THE STRATEGIC PLAN  
5 THAT IS NEXT UP WITH DR. MILLAN ON THE AGENDA.

6 WE HAD A MANUFACTURING WORKSHOP THAT  
7 SHAYAM PATEL AND OTHERS PUT TOGETHER. IT WAS VERY  
8 SUCCESSFUL. WE HAD THE BRIDGES PROGRAM, THE SPARK  
9 PROGRAM. WE'VE BEEN GOING FULL BORE. WE'VE, AS YOU  
10 WILL HEAR, RAMPED UP THE MEMBERS OF THE TEAM, HAVING  
11 DOWNSIZED LAST YEAR NOT KNOWING WHAT THE RESULTS  
12 WERE GOING TO BE IN THE ELECTION, AND CONTINUE TO  
13 ADD BEST-IN-CLASS PEOPLE TO THE TEAM OVERALL, WHICH  
14 CONTINUES TO FUNCTION UNDER DR. MILLAN AT AN  
15 EXCEPTIONAL AND PROFESSIONAL RATE.

16 WE HAD IN NOVEMBER THE ANNUAL MEETING WITH  
17 THE STATE CONTROLLER'S OVERSIGHT GROUP CALLED THE  
18 CFAOC, OR CITIZENS FINANCIAL ACCOUNTABILITY  
19 OVERSIGHT COMMITTEE, AT WHICH OUR DIRECTOR OF  
20 FINANCE, POUNEH SIMPSON, PRESENTED THE STATE OF THE  
21 UNION WITH CIRM'S FINANCES AND BUDGETS, ET CETERA.  
22 AND DR. MILLAN PRESENTED ON THE PROGRESS THAT CIRM  
23 HAS MADE OVER THE COURSE OF LAST YEAR, WHICH HAS  
24 BECOME AN ANNUAL HIGHLIGHT OF THAT MEETING. THE  
25 COMMITTEE IS ALWAYS VERY INTERESTED TO HEAR WHAT WE

**BETH C. DRAIN, CA CSR NO. 7152**

1 HAVE FUNDED AND THE PROGRESS WE HAVE MADE, AND THE  
2 RELATIONS WITH THE COMMITTEE ARE GREAT, AND  
3 EVERYBODY DOES A WONDERFUL JOB AT THAT MEETING.

4 AND THAT BRINGS US TO TODAY. SO IT'S BEEN  
5 A VERY, VERY FULL YEAR. OBVIOUSLY COVID CONTINUES  
6 TO MAKE THINGS DIFFICULT LOGISTICALLY. ONE OF THE  
7 VERY FEW SILVER LININGS OF THAT IS, BECAUSE NOBODY  
8 HAS TO OR INDEED CAN TRAVEL FOR A VARIETY OF  
9 REASONS, WE HAVE HAD TREMENDOUS PARTICIPATION BY THE  
10 BOARD, WHICH IS SOMETHING THAT WE HOPE WE CAN  
11 CONTINUE AS WE MOVE INTO 2022.

12 SO WITH THAT SORT OF BRIEF SUMMARY, I WANT  
13 TO GET TO THE MAIN POINT OF THE CHAIR'S REPORT,  
14 WHICH IS WE HAVE A VERY DISTINGUISHED GUEST ON, OS,  
15 WHO HAS COME HERE TO TODAY'S BOARD MEETING SO WE CAN  
16 PROPERLY CELEBRATE HIS TENURE AS THE LONGEST  
17 STANDING MEMBER OF THE CIRM BOARD IN ITS HISTORY.  
18 WE HAVE A RESOLUTION WHICH, BECAUSE IT'S SO  
19 IMPRESSIVE, I'M GOING TO READ ITS ENTIRETY FOR OS.  
20 AND THEN WE WILL ASK FOR FOLKS TO COMMENT. SO IF  
21 YOU WILL JUST BEAR WITH ME HERE, I'M GOING TO READ  
22 THIS RESOLUTION:

23 WHEREAS, OSWALD STEWARD RECEIVED HIS  
24 BACHELOR OF SCIENCE IN PSYCHOLOGY FROM THE  
25 UNIVERSITY OF COLORADO, BOULDER, IN 1970.

**BETH C. DRAIN, CA CSR NO. 7152**

1           WHEREAS, DR. STEWARD RECEIVED HIS PH.D. IN  
2           PSYCHOBIOLOGY FROM THE UNIVERSITY OF CALIFORNIA  
3           IRVINE IN 1974.

4           WHEREAS, DR. STEWARD SERVED AS A PROFESSOR  
5           IN THE DEPARTMENT OF NEUROSURGERY AT THE UNIVERSITY  
6           OF VIRGINIA SCHOOL OF MEDICINE FROM 1974 TO 1986.

7           WHEREAS, THE NIH RECOGNIZED DR. STEWARD'S  
8           EARLY WORK BY AWARDING HIM WITH THE NIH RESEARCH  
9           CAREER DEVELOPMENT AWARD.

10          WHEREAS, DR. STEWARD SERVED AS A PROFESSOR  
11          OF NEUROSCIENCE AND NEUROSURGERY AT THE UNIVERSITY  
12          OF VIRGINIA FROM 1986 TO 1989.

13          WHEREAS, DR. STEWARD SERVED AS THE  
14          FOUNDING CHAIR AND HARRISON FOUNDATION PROFESSOR OF  
15          NEUROSCIENCE AND NEUROSURGERY AT THE UNIVERSITY OF  
16          VIRGINIA FROM 1990 TO 1999.

17          WHEREAS, DR. STEWARD WAS THE CO-RECIPIENT  
18          OF THE OASI BRAIN DYSFUNCTION RESEARCH IN 1991 AND  
19          RECEIVED THE NATIONAL ALLIANCE FOR RESEARCH ON  
20          SCHIZOPHRENIA AND DEPRESSION DISTINGUISHED  
21          INVESTIGATORS AWARD IN 1998.

22          WHEREAS, DR. STEWARD SERVES AS THE ENDOWED  
23          REEVE IRVINE DISTINGUISHED PROFESSOR OF ANATOMY AND  
24          NEUROBIOLOGY AND HOLDS JOINT APPOINTMENTS IN THE  
25          DEPARTMENTS OF NEUROBIOLOGY AND BEHAVIOR AND

**BETH C. DRAIN, CA CSR NO. 7152**

1 NEUROSURGERY AT THE UNIVERSITY OF CALIFORNIA IRVINE  
2 SCHOOL OF MEDICINE.

3 WHEREAS, DR. STEWARD IS THE FOUNDING  
4 DIRECTOR OF THE REEVE IRVINE RESEARCH CENTER, A  
5 WORLD RENOWNED BASIC SCIENCE RESEARCH CENTER DEVOTED  
6 TO THE STUDY OF REPAIR, REGENERATION, AND RECOVERY  
7 OF FUNCTION AFTER SPINAL CORD INJURY, AT THE  
8 UNIVERSITY OF CALIFORNIA IRVINE SCHOOL OF MEDICINE.

9 WHEREAS, DR. STEWARD IS WELL KNOWN FOR HIS  
10 RESEARCH ON HOW NERVE CELLS CREATE AND MAINTAIN  
11 THEIR CONNECTION WITH EACH OTHER AND HOW THE  
12 SYNAPSES ARE MODIFIED AFTER INJURY.

13 WHEREAS, DR. STEWARD IS PRESIDENT-ELECT OF  
14 THE SOCIETY OF NEUROSCIENCE, LARGEST NEUROSCIENCE  
15 PROFESSIONAL SOCIETY IN THE WORLD.

16 WHEREAS, DR. STEWARD IS A MEMBER OF THE  
17 AMERICAN SOCIETY FOR CELL BIOLOGY AND AMERICAN  
18 ASSOCIATION FOR THE ADVANCEMENT OF SCIENCE.

19 WHEREAS, DR. STEWARD SERVED ON THE COUNCIL  
20 OF THE SOCIETY FOR NEUROSCIENCE FROM 2013 TO 2017.

21 WHEREAS, DR. STEWARD WAS A FOUNDING  
22 DIRECTOR OF CIRM, HELPING ESTABLISH THE AGENCY'S  
23 FOUNDATIONAL PROCEDURES AND POLICIES AND SERVING IN  
24 LEADERSHIP ROLES THROUGHOUT HIS TENURE ON THE BOARD,  
25 INCLUDING AS CO-CHAIR OF THE GRANTS WORKING GROUP

**BETH C. DRAIN, CA CSR NO. 7152**

1 AND THE CHAIR OF THE SCIENCE SUBCOMMITTEE.

2 WHEREAS, DR. STEWARD, THROUGH HIS  
3 EXPERIENCE, COMMITMENT, KNOWLEDGE, AND LEADERSHIP,  
4 CONTRIBUTED GREATLY TO THE MOMENTUM OF DISCOVERY AND  
5 THE FUTURE THERAPIES WHICH WILL BE THE ULTIMATE  
6 OUTCOME OF THE DEDICATED WORK OF THE RESEARCHERS  
7 RECEIVING CIRM FUNDING.

8 BE IT RESOLVED, THAT THE GOVERNING BOARD  
9 OF THE CALIFORNIA INSTITUTE FOR REGENERATIVE  
10 MEDICINE, ON BEHALF OF THE PEOPLE OF STATE OF  
11 CALIFORNIA, WISHES TO EXPRESS ITS DEEPEST GRATITUDE  
12 TO DR. OSWALD STEWARD FOR HIS SERVICE ON CIRM'S  
13 GOVERNING BOARD AND FOR HIS DEDICATION TO THE  
14 ADVANCEMENT OF STEM CELL RESEARCH AND TO THE MISSION  
15 OF CIRM TO ACCELERATE STEM CELL TREATMENTS TO  
16 PATIENTS WITH UNMET MEDICAL NEEDS.

17 OS, EXCEPTIONALLY IMPRESSIVE LITANY. AND  
18 BEFORE I GIVE SOME COMMENTS AT THE END, I WANTED TO  
19 SEE IF A FEW OTHERS ON THE BOARD WOULD SAY A FEW  
20 WORDS IN YOUR HONOR. SO WHO WOULD LIKE TO SPEAK UP  
21 ON OS' BEHALF HERE? LET'S SEE. JUDY.

22 DR. GASSON: THANK YOU VERY MUCH. YOU  
23 KNOW THE OLD SAYING IS THAT NO ONE IS IRREPLACEABLE  
24 IN AN ORGANIZATION. BUT FROM MY PERSPECTIVE IT'S  
25 GOING TO BE INCREDIBLY DIFFICULT TO REPLACE MY

**BETH C. DRAIN, CA CSR NO. 7152**

1 COLLEAGUE, DR. STEWARD. I DON'T KNOW HOW HE WAS  
2 ABLE TO DO ALL OF THE THINGS HE WAS DOING AT IRVINE,  
3 IN THE ICOC, IN HIS OWN RESEARCH PORTFOLIO, AND  
4 STILL PLAY SUCH AN INCREDIBLY IMPRESSIVE ROLE IN GWG  
5 AND IN THE SCIENCE SUBCOMMITTEE.

6 OS, I LEARNED A LOT FROM LISTENING TO YOU.  
7 AND WHAT I WOULD SAY IS THAT WE'RE AN ORGANIZATION  
8 THAT KNOWS WHERE WE ARE TRYING TO GO, BUT  
9 OCCASIONALLY WE'RE NOT QUITE SURE HOW TO GET THERE.  
10 AND EVERY NOW AND THEN KIND OF AN EXCITING DEBATE  
11 WILL BREAK OUT ABOUT WHETHER WE SHOULD DO THIS OR DO  
12 THAT OR DO THE OTHER THING, WHICH IS EXTREMELY  
13 HEALTHY AND IT'S REALLY GOOD FOR THE ORGANIZATION,  
14 BUT USUALLY I WOULD WAIT FOR OS TO RAISE HIS HAND.  
15 AND THEN OS WOULD BE VERY CALM AND VERY COLLECTED  
16 AND VERY THOUGHTFUL, AND HE WOULD SAY, WELL, HE WAS  
17 VERY WISE, AND HE WOULD USUALLY COME IN WITH WHAT I  
18 CONSIDERED TO BE A VERY CREATIVE RESOLUTION THAT  
19 WOULD ACCOMPLISH THE GOAL THAT WE HAD ALL AGREED  
20 UPON, BUT MIGHT TAKE A SLIGHTLY DIFFERENT PATH FROM  
21 WHAT WE WERE TALKING ABOUT.

22 SO IT'S REALLY BEEN MY PLEASURE TO KNOW  
23 YOU, OS, AND TO SERVE WITH YOU ON THIS BOARD. AND  
24 REALLY BEST WISHES GOING FORWARD, AND  
25 CONGRATULATIONS ON ALL OF YOUR ACCOMPLISHMENTS.

**BETH C. DRAIN, CA CSR NO. 7152**

1 CHAIRMAN THOMAS: THANK YOU, JUDY.

2 DR. DEAS: I'D LIKE TO GO AFTER JUDY.

3 CHAIRMAN THOMAS: SURE. DEBORAH.

4 DR. DEAS: OS, IT'S REALLY BEEN SUCH A  
5 PLEASURE WORKING WITH YOU OVER THE YEARS. I'VE BEEN  
6 ON THE BOARD NOW FOR FIVE YEARS. AND JUST TO HEAR  
7 YOUR VOICE WITHIN THE VARIOUS CONSULTATIONS OR  
8 DISCUSSIONS THAT WE HAVE HAD ON THE BOARD BROUGHT  
9 NEW LIGHT.

10 WHAT I REALLY ENJOYED AND ADMIRERD ABOUT  
11 YOU IS THAT YOU TRULY REPRESENT THE SPIRIT OF TRUE  
12 CONSULTATION. AND WHAT I MEAN BY THAT IS THAT WHEN  
13 THINGS ARISE AND WE PUT ISSUES ON THE TABLE, EVEN IF  
14 YOU PLACE THEM THERE, YOU DON'T TAKE THEM  
15 PERSONALLY. AND SO OFTEN IN THE CONSULTATION YOU  
16 MAY CHANGE YOUR MIND AND GO WITH WHAT IS BEST OR  
17 WHAT YOU SEE AS THE RIGHT OR PROPER OUTCOME FOR THE  
18 TEAM. AND IF SO MANY OF US CAN JUST ASPIRE TO  
19 CONSULT THAT WAY, THINGS WOULD BE SO MUCH BETTER AND  
20 THE WORLD WOULD BE A BETTER PLACE.

21 I WISH YOU THE VERY BEST, AND WE WILL MISS  
22 YOU. AND HOPEFULLY WE WILL BE CALLING ON YOU IN ONE  
23 FORM OR ANOTHER.

24 CHAIRMAN THOMAS: THANK YOU, DEBORAH.  
25 JOE, YOU'RE NEXT.

**BETH C. DRAIN, CA CSR NO. 7152**

1 MR. PANETTA: THANKS, J.T.

2 OS, I WISH WE COULD BE THERE IN PERSON TO  
3 PROPERLY SEND YOU OFF. I WISH I COULD BE THERE TO  
4 SHAKE YOUR HAND AND THANK YOU.

5 I'VE BEEN ENGAGED WITH CIRM SINCE, I  
6 THINK, LARRY GOLDSTEIN CALLED ME BACK IN 2004 AND  
7 SAID WE HAVE GOT TO GO UP AND TALK TO THIS GUY WHO'S  
8 GOT A PROPOSAL TO CREATE A STEM CELL AGENCY AND GET  
9 BEHIND IT, AND YOU'VE BEEN INVOLVED IN IT FOR A  
10 LONG, LONG TIME. BUT TO ADD TO WHAT WE HAVE JUST  
11 HEARD, FROM MY PERSPECTIVE THERE ARE A LOT OF  
12 EMINENT M.D.'S AND PH.D.'S, RESEARCHERS ON THIS  
13 ICOC, AND THEN THERE ARE THOSE OF US WHO ARE NOT OR  
14 WHO ARE JUNIOR SCIENTISTS WITH MASTER'S DEGREES WHO  
15 DON'T ALWAYS UNDERSTAND THE ENTIRETY OF THE  
16 DISCUSSION AROUND SOME OF THE SCIENCE THAT WE HAVE  
17 TO MAKE DECISIONS ON. AND YOU'RE THE GUY WHO I'VE  
18 ALWAYS WAITED TO HEAR FROM BECAUSE OF YOUR CLARITY  
19 AND YOUR INQUISITIVENESS AND BECAUSE YOU ASK THE  
20 QUESTIONS THAT I WISH I COULD COME UP WITH MYSELF  
21 SOMETIMES. AND THEN I RELY ON YOU TO ENSURE THAT WE  
22 GET SOME OF THE ANSWERS THAT I NEEDED TO HELP TO  
23 MAKE DECISIONS.

24 SO FROM ONE OF THE NONSCIENTISTS ON THE  
25 COMMITTEE, I JUST WANT TO THANK YOU AND TELL YOU HOW

**BETH C. DRAIN, CA CSR NO. 7152**

1 MUCH GRATITUDE I HAVE FOR YOUR LEADERSHIP AND YOUR  
2 STABILITY THROUGHOUT ALL THE TIME THAT I'VE BEEN ON  
3 THE ICOC AND THAT YOU'VE BEEN ON THE ICOC. SO  
4 THANKS. AND I KNOW THAT YOU'VE GOT A LOT AHEAD  
5 STILL. SO BEST OF LUCK. AND IN THE SHORT TENURE  
6 THAT I HAVE LEFT ON THIS COMMITTEE, I'M GOING TO  
7 MISS YOU A LOT.

8 CHAIRMAN THOMAS: THANK YOU, JOE. DAVID.

9 DR. HIGGINS: WELL, SO MUCH HAS BEEN SAID,  
10 ALL OF IT TRUE. BUT SO I WAS TRYING TO THINK OF  
11 MAYBE IF WE DISTILL EVERYTHING THAT JOE AND DEBORAH  
12 AND JUDY SAID AND DISTILL IT INTO ONE WORD TO  
13 DESCRIBE OS AND HIS CONTRIBUTIONS TO CIRM, WHAT  
14 WOULD THAT WORD BE? AND THE WORD I CAME UP WITH IS  
15 INTEGRITY. I THINK THAT OS EMBODIES INTEGRITY, NOT  
16 ONLY IN THE WAY HE PRACTICES SCIENCE AND TECHNOLOGY,  
17 EVEN THE WAY HE INTERACTS WITH OTHER PEOPLE. HE  
18 TREATS EVERYONE WITH RESPECT AND VALUES EVERYONE'S  
19 OPINION AND HAS PROVEN THE OLD SAYING, AT LEAST  
20 WHERE I GREW UP, THAT YOU CAN ATTRACT MORE FLIES  
21 WITH HONEY THAN WITH VINEGAR. AND HONEY TO OS IS  
22 RESPECT FOR HIS CO-WORKERS.

23 SO I'D LIKE TO ECHO EVERYTHING YOU'VE  
24 HEARD AND ADD TO THAT THAT YOU BRING ALL THAT  
25 TOGETHER IN ONE PACKAGE. AND THANK YOU FOR APPLYING

**BETH C. DRAIN, CA CSR NO. 7152**

1 THOSE SKILLS TO OUR CAUSE AND OUR NEEDS, AND YOU  
2 WILL BE MISSED TERRIBLY. THANK YOU.

3 CHAIRMAN THOMAS: THANK YOU, DAVID.  
4 KRISTINA.

5 DR. VUORI: SO MANY THINGS HAVE BEEN SAID,  
6 SO I NEED TO COME UP WITH SOMETHING, I THINK, A  
7 LITTLE DIFFERENT. SO IN EVERY MARVEL MOVIES THERE  
8 ARE SUPERHEROES. AND AFTER THEY HAVE SAVED THE  
9 WORLD SEVERAL TIMES, JUST LIKE OS HAS DONE FOR CIRM,  
10 IT'S TIME TO GO TO THE BEGINNING OF TIMES AND TO THE  
11 ORIGIN OF THE STORY AND THE REFINED OS, I THINK,  
12 AGAIN WITH BEGINNING OF THE SUPERHERO SAGA OF THE  
13 CIRM UNIVERSE. AND YOU TRULY HAVE BEEN THERE, AS  
14 JOE NOTED, EVEN BEFORE CIRM CAME ABOUT AND THEN FROM  
15 VERY BEGINNING AND REALLY CONTRIBUTED IN IMMENSE  
16 WAYS TO THE SUCCESS THAT CIRM IS TODAY.

17 REMEMBERING THE EARLIER DAYS WITH THE  
18 PROGRAMMATIC REVIEW AS PART OF THE GRANTS WORKING  
19 GROUP, I THINK YOU CO-CHAIRLED THIS WITH JEFF.  
20 LOOKING BACK, I THINK THAT WAS A VERY IMPORTANT TIME  
21 WHEN IT WAS NOT ONLY THE SCIENCE THAT CIRM HAD TO  
22 REALLY PAY ATTENTION TO, BUT ALSO THE PROGRAMMATIC  
23 EVALUATION AND BALANCE OF WHAT CIRM IS DOING SO THAT  
24 WE AS AN AGENCY ARE TRULY FOR ALL CALIFORNIANS, NOT  
25 SOMETHING THAT'S FANCY OR SEXY AT ANY GIVEN TIME,

**BETH C. DRAIN, CA CSR NO. 7152**

1 BUT TRULY VERY BROADLY HOW CIRM CAN HAVE IMPACT FOR  
2 EVERYONE. SO YOU HAVE BEEN ABSOLUTELY INSTRUMENTAL  
3 IN DOING THAT.

4 WE HAD AT SOME POINT IN TIME A REALLY FUN  
5 PROCESS CALLED EXTRAORDINARY PETITION. THIS IS, I  
6 THINK, THE TIME WHERE MANY OF US WERE WAITING FOR  
7 YOU TO SPEAK BEFORE WE ENTERED THE BATTLEFIELD.  
8 THERE WERE SCIENTISTS WHO SOME ASKED NICELY WHETHER  
9 WE WOULD RECONSIDER THEIR GRANTS, OTHERS DEMANDED  
10 THEIR APPLICATIONS TO BE FUNDED REGARDLESS. AND WE  
11 HEARD REALLY VERY TOUCHING STORIES FROM PATIENTS AND  
12 PATIENT ADVOCATES WHO KNEW THAT CIRM MIGHT BE THE  
13 LAST HOPE OR AT LEAST AT THAT TIME FOR THEM. THESE  
14 WERE VERY EMOTIONAL TIMES. AND YOU WERE ALWAYS THE  
15 VERY RATIONAL, VERY CALM VOICE WHO CLEARLY  
16 ARTICULATED WHAT MADE SENSE AND, MORE IMPORTANTLY,  
17 WHY IT MADE SENSE. AND IT WAS VERY, VERY EASY TO  
18 FOLLOW YOUR LEAD AT THOSE TIMES.

19 AND SO I WISH YOU ALL THE BEST. I KNOW  
20 YOU ARE GOING TO CONTINUE TO BE SUPERHERO WHEREVER  
21 YOU ARE NEXT AND PROBABLY HAVE A GREAT TIME ALSO, I  
22 HOPE, A LITTLE BIT OUTSIDE OF WORK. YOU DESERVE  
23 THAT.

24 CHAIRMAN THOMAS: THANK YOU, KRISTINA.  
25 ART.

**BETH C. DRAIN, CA CSR NO. 7152**

1 MR. TORRES: YES. OS IS ONE OF MY  
2 FAVORITE MEMBERS AND THE REASON WHY TERM LIMITS IS  
3 SUCH A FRICKING MISTAKE. HERE, BECAUSE OF TERM  
4 LIMITS, WE'VE LOST A LOT OF GREAT PEOPLE, BUT ON THE  
5 OTHER HAND WE'VE GOTTEN RID OF SOME REAL WACKOS TOO  
6 OVER THE YEARS IN THE LEGISLATURE. BUT THE FACT OF  
7 THE MATTER REMAINS, THAT OS WAS A VERY IMPORTANT  
8 PIONEER ON OUR BOARD. NOT ONLY DOES MY EXPERIENCE  
9 WITH HIM WORKING IN THE GRANTS WORKING GROUP, BUT  
10 ALSO OUTSIDE OF CIRM, AND IT WAS ALWAYS A PLEASURE  
11 AS WE WERE UPSTAIRS IN THE CLAREMONT HOTEL TO SEE  
12 THIS CHAMPIONSHIP SWIMMER SWIM THE LAPS AT THE  
13 CLAREMONT POOL, BUT ALSO MORE IMPORTANTLY WHAT A  
14 STAMINA.

15 AND NO. 2, I JUST WANT TO THANK HIM AGAIN  
16 BECAUSE HE IS THE BEST REFERENCE FOR GREAT MEXICAN  
17 RESTAURANTS IN LAGUNA BEACH. HE FOUND THOSE ALL THE  
18 TIME WITH HIS INCREDIBLE WIFE AS WELL WHO'S AN  
19 INCREDIBLE ARTIST. OS, I WILL MISS YOU, BUT I'M  
20 SURE WE WILL BE IN TOUCH. TAKE CARE, MY FRIEND.

21 CHAIRMAN THOMAS: THANK YOU. MICHAEL.

22 DR. STAMOS: THANK YOU. YES. AT THE RISK  
23 OF BEING TOLD BY MARIA THAT I HAVE A CONFLICT OF  
24 INTEREST, I HAD TO SAY A FEW WORDS ABOUT OS. I'M  
25 GLAD TO SEE THE REST OF THE WORLD HAS DISCOVERED

**BETH C. DRAIN, CA CSR NO. 7152**

1 WHAT WE HAVE KNOWN FOR A COUPLE DECADES AT UCI. AND  
2 I THINK THE ONE WORD I WOULD ADD IN HERE, NOT TO BE  
3 TOO WORDY HERE, IS SELFLESSNESS BECAUSE OS HAS  
4 ACHIEVED ALL THOSE GREAT THINGS AND HAS CONTRIBUTED  
5 GREATLY, SOMETIMES AT THE EXPENSE OF HIS OWN  
6 INTERESTS, IF YOU WOULD. SO THANK YOU FOR THAT, OS.  
7 BY THE WAY, HE'S NOT GOING TO ANYWHERE. HE'S VERY  
8 BUSY BACK AT UCI. SO THANK YOU, OS.

9 CHAIRMAN THOMAS: THANK YOU, MICHAEL.  
10 STEVE.

11 MR. JUELSGAARD: YES. FIRST OF ALL, I  
12 WOULD JUST LIKE TO THANK YOU, OS, FOR BEING THERE  
13 ALL THOSE YEARS THAT WE HAVE OVERLAPPED, ELEVEN  
14 YEARS THAT I'VE BEEN ON THE ICOC SO FAR. YOU HAVE  
15 ALWAYS BEEN THE VOICE OF REASON, THE VOICE OF  
16 FINDING A SOLUTION, THE VOICE OF COMPROMISE. I  
17 CAN'T REALLY ADD A LOT MORE TO WHAT'S ALREADY BEEN  
18 SAID OTHER THAN I'VE ALWAYS APPRECIATED WHAT YOU'VE  
19 HAD TO SAY, THE WAY YOU THOUGHT ABOUT THE WORLD. WE  
20 DIDN'T NECESSARILY ALWAYS SEE EYE TO EYE. WE DID  
21 MOST OF THE TIME, BUT WE HAD OUR DIFFERENCES. BUT  
22 NONETHELESS, I HAVE A GREAT DEAL OF RESPECT FOR YOU  
23 AND FOR WHAT YOU BROUGHT TO CIRM. AND, AGAIN, JUST  
24 THANK YOU FOR BEING SUCH A GREAT BOARD MEMBER.

25 CHAIRMAN THOMAS: THANK YOU, STEVE. AND

**BETH C. DRAIN, CA CSR NO. 7152**

1 I'LL ADD A FEW COMMENTS HERE AS WELL. SO, OS, WHEN  
2 I THINK OF THE WORD THAT I WOULD USE TO DESCRIBE  
3 YOU, IT'S ACTUALLY THREE WORDS FROM THE STANDPOINT  
4 OF WHAT YOU BROUGHT TO CIRM, WHICH ARE THE TOTAL  
5 PACKAGE. AND BY THAT I MEAN YOU WERE ABLE TO  
6 COMBINE SCIENTIFIC EXPERTISE WITH PROCEDURAL RIGOR.  
7 YOU ALWAYS KEPT US ON THE STRAIGHT AND NARROW DOING  
8 THINGS JUST EXACTLY AS THEY SHOULD BE APPROACHED.  
9 AND YOU BROUGHT AT ALL TIMES THE EMPATHY OF THE  
10 PATIENT ADVOCATE, WHICH IS AT THE CORE OF CIRM'S  
11 MISSION AND EVERYTHING THAT WE ARE ALL ABOUT HERE.  
12 AND YOU BLENDED TOGETHER ALL OF THOSE TRAITS  
13 SEAMLESSLY IN A WAY THAT MADE YOU NOT ONLY SOMEBODY  
14 TO WHOM EVERYBODY TURNED, BUT YOU DID IT SO  
15 EFFORTLESSLY AND WITH GREAT GRACE. AND YOU'RE  
16 SOMEBODY THAT IMMEASURABLY ADVANCED THE BALL OF CIRM  
17 AS IT MARCHES DOWN THE FIELD OF OUR GRAND  
18 EXPERIMENT.

19 YOU WERE SOMEBODY, WHEN I STARTED IN 2011,  
20 THAT I IMMEDIATELY TURNED TO AS SOMEBODY WHO COULD  
21 HELP TEACH ME THE ROPES OF THINGS THAT WERE  
22 IMPORTANT TO THE ORGANIZATION. GOT TO WATCH YOU  
23 FIRSTHAND, NOT JUST ON THE BOARD, BUT MOST  
24 IMPRESSIVELY AS WELL IN THE GWG WHERE YOUR  
25 SCIENTIFIC EXPERTISE WAS BROUGHT TO BEAR TIME AFTER

**BETH C. DRAIN, CA CSR NO. 7152**

1 TIME, AND YOU WERE ABLE TO INTERJECT VERY MEANINGFUL  
2 COMMENTS THAT HELPED IN THE DELIBERATIONS THAT THAT  
3 BODY UNDERTOOK REGARDLESS OF WHAT TYPE OF GRANT WAS  
4 ON THE LINE.

5 WE HAVE HAD TALKS OVER THE YEARS BECAUSE  
6 WHEN YOU WERE HEADING UP THE SCIENCE SUBCOMMITTEE  
7 WITH JEFF, THAT YOU WERE ABLE TO SET THE DIRECTION  
8 FOR THE SCIENTIFIC AND RESEARCH AWARD ELEMENTS OF  
9 WHAT WE DO, WHICH, OF COURSE, IS THE BIGGEST SINGLE  
10 THING, AND DID SO BY SPENDING ENORMOUS AMOUNTS OF  
11 YOUR TIME AND ENERGY AND ALL VERY MUCH APPRECIATED.  
12 SO WHEN YOU ADD IT ALL TOGETHER, OS, FOR ME YOU WERE  
13 THE TOTAL PACKAGE ON THE BOARD. AND I ECHO WHAT  
14 EVERYBODY SAID, WHICH IS WE SO APPRECIATED  
15 EVERYTHING YOU DID FOR THE ICOC, FOR PATIENTS  
16 EVERYWHERE, AND FOR THE CITIZENS OF CALIFORNIA WHO  
17 WE ARE REPRESENTING. SO THANK YOU SO MUCH. AND  
18 WITH THAT, OS, I WILL TURN TO YOU FOR A FEW  
19 COMMENTS.

20 MS. BONNEVILLE: OH, NO. I THINK HE  
21 DISAPPEARED.

22 CHAIRMAN THOMAS: NO WAY.

23 MS. BONNEVILLE: I THINK HE DID. OH, NO.  
24 YSABEL HAS HER HAND RAISED. MAYBE YSABEL CAN SAY A  
25 FEW WORDS TILL OS GETS BACK ON THE LINE.

**BETH C. DRAIN, CA CSR NO. 7152**

1 DR. FISHER: ULTIMATE MIC DROP.

2 MS. BONNEVILLE: I KNOW.

3 MS. DURON: ACTUALLY I WAS JUST RAISING MY  
4 HAND TO CLAP FOR HIM. I KNOCKED HIM OFF THE RADAR.  
5 MAYBE HE CAN HEAR US; BUT IF HE CAN'T, NONETHELESS,  
6 I'M VERY SORRY THAT I DIDN'T HAVE MORE TIME TO SPEND  
7 WITH OS AND MOST OF IT IN THE BOX AND NOT IN PERSON.  
8 BECAUSE WITH ALL OF THE EXPERIENCES I'VE HAD WITH  
9 HIM, I FIND HIM TO BE A MOST GENTLE SOUL, AND I  
10 APPRECIATE HIS EMPATHY AND HIS INTELLIGENCE. SO I  
11 HOPE WE GET HIM BACK, IF NOTHING ELSE, TO HAVE A  
12 FINAL GOODBYE THERE.

13 CHAIRMAN THOMAS: I WONDER IF HE HEARD ANY  
14 OF THAT.

15 MS. BONNEVILLE: HE DID. HE FROZE UP AT  
16 THE VERY END. SO I KNOW THAT HE DID HEAR MOST OF  
17 IT. I WAS WATCHING. BUT HE'S NOT ON.

18 MR. TORRES: WE CAN ALWAYS SEND HIM A  
19 TRANSCRIPT.

20 CHAIRMAN THOMAS: SEND HIM THE YOUTUBE  
21 VERSION.

22 MR. TORRES: RIGHT.

23 MS. DURON: I'LL ADD A SONG OR SOMETHING.

24 MS. BONNEVILLE: I WOULD PROBABLY MOVE TO  
25 THE MOTION. AND THEN IF HE COMES ON LATER, WE CAN

**BETH C. DRAIN, CA CSR NO. 7152**

1 DO SOMETHING THEN.

2 CHAIRMAN THOMAS: OKAY. SO WE HAVE A  
3 RESOLUTION HERE WHICH, AS YOU KNOW, I JUST READ.  
4 AND I BELIEVE WE WANT TO APPROVE THAT RESOLUTION AS  
5 A BOARD. SO DO I HEAR A MOTION TO APPROVE?

6 MR. TORRES: MOVE TO APPROVE.

7 CHAIRMAN THOMAS: MOVED BY SENATOR TORRES.

8 MS. DURON: SECOND.

9 CHAIRMAN THOMAS: SECONDED BY IS THAT  
10 YSABEL?

11 MS. DURON: YES.

12 CHAIRMAN THOMAS: MARIA, I DON'T KNOW THAT  
13 WE NEED TO CALL A ROLL ON THIS ONE. I THINK WE KNOW  
14 THE ANSWER ON THIS ONE. UNLESS KEVIN TELLS ME WE  
15 HAVE TO TAKE THE ROLL.

16 MS. BONNEVILLE: NO. FINE.

17 CHAIRMAN THOMAS: WE WILL RECORD A  
18 UNANIMOUS, ROUSING APPROVAL FOR THIS AND HOPE THAT  
19 OS GETS BACK ON.

20 MS. BONNEVILLE: I SEE THAT HE'S JUST  
21 JOINING NOW WITH HIS IPHONE. SO IT WILL JUST BE A  
22 COUPLE SECONDS FOR HIM TO GET ACCESS.

23 CHAIRMAN THOMAS: OKAY. WE WILL WAIT  
24 THEN.

25 MS. BONNEVILLE: HE'S ON. OS, ARE YOU ON?

**BETH C. DRAIN, CA CSR NO. 7152**

1 IF YOU'RE ON, YOU'RE ON MUTE.

2 DR. STEWARD: I AM ON.

3 MS. BONNEVILLE: WE CAN'T HEAR YOU.

4 MR. TORRES: HE'S PLAYING THE SITAR.

5 DR. VUORI: I THINK THE BAND WIDTH IS NOT  
6 ENOUGH FOR THE VIDEO.

7 MR. TORRES: IS THAT GEORGE HARRISON  
8 COMING IN?

9 MS. BONNEVILLE: OS, YOU NEED TO TURN OFF  
10 YOUR CAMERA. WE MIGHT BE ABLE TO HEAR YOU.

11 DR. STEWARD: (INAUDIBLE.)

12 CHAIRMAN THOMAS: OS, WE'RE GETTING ABOUT  
13 EVERY TENTH SYLLABLE.

14 DR. STEWARD: WELL, OUR ELECTRICITY WENT  
15 OFF.

16 CHAIRMAN THOMAS: THERE YOU GO.

17 DR. STEWARD: I THINK PERHAPS THAT WAS A  
18 MESSAGE FROM SOMEONE SAYING, OH, NO, THAT WONDERFUL  
19 STUFF YOU WERE SAYING COULD ACTUALLY BE TRUE. AND  
20 I'M SO DEEPLY HONORED BY EVERYTHING THAT EVERYONE  
21 SAID. I MISS YOU GUYS SO MUCH. IT'S BEEN SUCH A  
22 WONDERFUL TIME SERVING ON THE ICOC.

23 I HAVE TO SAY THAT I WAS BOTH EXTREMELY  
24 HONORED AND GRATEFUL, BUT ALSO GRATEFUL TO MARIA  
25 THAT SHE KEPT A STRAIGHT FACE WHEN PEOPLE WERE

**BETH C. DRAIN, CA CSR NO. 7152**

1 COMMENTING ABOUT MY RATIONALITY AND CALMNESS.

2 SHE KNOWS OTHERWISE, BUT THAT'S OKAY.

3 JUST BECAUSE THIS IS SO AWKWARD WITHOUT  
4 ELECTRICITY, I WON'T SAY ALL THE THINGS I WANT TO,  
5 BUT I DO WANT TO SAY IT'S SUCH A WONDERFUL  
6 COMPLETION OF THE CIRCLE THAT RICH LAJARA WAS  
7 APPOINTED AS THE INCOMING REPRESENTATIVE PATIENT  
8 ADVOCATE FOR SPINAL CORD INJURY.

9 SOME OF YOU MAY KNOW RICH WAS, OF COURSE,  
10 THE FIRST RECIPIENT OF ANY STEM CELL. IT WAS  
11 ACTUALLY A PRODUCT OF GERON THAT CAME FROM RESEARCH  
12 AT OUR CENTER HERE AT UC IRVINE, HANS KIERSTEAD'S  
13 RESEARCH. IT'S JUST FANTASTIC THAT RICH IS NOW  
14 THERE.

15 I JUST WANT TO SAY HOW WONDERFUL IT WAS  
16 OVER THE YEARS TO SERVE WITH AN AMAZING GROUP OF  
17 PEOPLE. EVERYONE -- I LOOK BACK ON THE EARLY DAYS  
18 AND ALL OF THE OTHER PATIENT ADVOCATES WHO SERVED SO  
19 HONORABLY AND SO LONG. AND EVERY ONE OF THEM SERVED  
20 SELFLESSLY, BUT ALWAYS WITH DUE RESPECT AND  
21 CONSIDERATION FOR WHAT WAS REALLY IMPORTANT IN TERMS  
22 OF THE FACT THAT WE WERE ALSO A STATE AGENCY, AND  
23 THEY WERE ALL CONSCIOUS OF THE FACT THAT WE WERE  
24 SPENDING TAXPAYER MONEY. THOSE TWO THINGS TOGETHER,  
25 I THINK, REPRESENT WHAT IS THE TRUE STRENGTH OF CIRM

**BETH C. DRAIN, CA CSR NO. 7152**

1 GOING FORWARD.

2 LOOKING BACK, I THINK IT IS SAD THAT SOME  
3 OF THE THINGS WE THOUGHT WE COULD DO --

4 CHAIRMAN THOMAS: OS, YOU'RE BREAKING UP A  
5 LITTLE.

6 DR. STEWARD: -- WEREN'T ABLE TO  
7 ACCOMPLISH. WE HAVEN'T REALLY SEEN VERY MUCH  
8 PROGRESS IN SOMETHING WE ALL THOUGHT WOULD BE AN  
9 EARLY -- SORRY. AM I BETTER? WE HAVE ZERO POWER  
10 DOWN HERE, FOLKS. THE WIND IS VERY HIGH HERE.  
11 LOOK, I'M JUST GOING TO STOP. AND IT'S TOO AWKWARD  
12 TO TRY TO SAY ALL THE THINGS I WANT TO SAY HERE, BUT  
13 I JUST WANT TO ACTUALLY SAY THANK YOU TO ALL OF THE  
14 NEW MEMBERS. CIRM IS IN GREAT HANDS WITH YOU. CIRM  
15 IS IN GREAT HANDS. THANK YOU ALL RATHER THAN TRYING  
16 TO CONTINUE HERE WITH BAD CONNECTION. THANK YOU.

17 CHAIRMAN THOMAS: OS, I DON'T KNOW IF  
18 YOU'RE STILL ON, BUT WE HEARD MOST OF THAT. AND  
19 SORRY FOR THE POWER SITUATION DOWN THERE, BUT JUST  
20 KNOW HOW GRATEFUL WE ALL ARE. AND WE ABSOLUTELY  
21 WILL MISS YOU VERY MUCH. SO THANK YOU AGAIN FOR  
22 EVERYTHING.

23 OKAY. THAT CONCLUDES THE CHAIRMAN'S  
24 REPORT. AND NEXT ON THE AGENDA IS THE PRESIDENT'S  
25 REPORT. DR. MILLAN.

**BETH C. DRAIN, CA CSR NO. 7152**

1 DR. MILLAN: THANK YOU SO MUCH. DOUG, IF  
2 YOU CAN PLEASE DISPLAY THE PRESENTATION.

3 THANK YOU, CHAIRMAN THOMAS, MEMBERS OF THE  
4 BOARD, MEMBERS OF THE PUBLIC, AND CIRM COLLEAGUES.  
5 IT'S WITH GREAT ENTHUSIASM THAT WE BRING CIRM'S NEW  
6 FIVE-YEAR STRATEGIC PLAN FOR BOARD CONSIDERATION  
7 TODAY. WITH THE RESOLUTION AND HONORING OF DR. OS  
8 STEWARD, I THOUGHT IT WAS APPROPRIATE TO REMIND US  
9 OF A QUOTE, STANDING ON THE SHOULDERS OF GIANTS,  
10 SHOULDERS OF GIANTS. AND I BELIEVE THAT WE ARE IN  
11 AN EXTREMELY STRONG POSITION WITH THIS NEW STRATEGIC  
12 PLAN BECAUSE OF YOU, AS CURRENT BOARD MEMBERS, PAST  
13 BOARD MEMBERS, AND THE FOUNDING MEMBERS OF CIRM.

14 NEXT SLIDE PLEASE. SO WRITING THIS PLAN  
15 WAS EXTREMELY FULFILLING. IT'S BEEN AN EXTREMELY  
16 FULFILLING ENDEAVOR AND IN EVERY RESPECT WAS A TEAM  
17 EFFORT. WE HAVE HAD THE OPPORTUNITY TO ENGAGE WITH  
18 THE BOARD EVERY STEP ALONG THE WAY AND TO GAIN  
19 IMPORTANT INPUT FROM OUR SCIENTIFIC STRATEGY  
20 ADVISORY PANEL THAT J.T. HAD MENTIONED THAT WAS  
21 ASSEMBLED IN FEBRUARY OF THIS PAST YEAR. OUR GRANTS  
22 WORKING GROUP, OUR CALIFORNIA SCIENTIFIC, INDUSTRY,  
23 AND PATIENT COMMUNITY. A HUGE THANK YOU TO THIS  
24 BOARD FOR YOUR SUPPORT AND YOUR INSIGHTFUL INPUT  
25 MOST RECENTLY AS THE OCTOBER ICOC MEETING AND THEN

**BETH C. DRAIN, CA CSR NO. 7152**

1 AT THE NOVEMBER SCIENCE SUBCOMMITTEE MEETING.

2 THIS HAS LED TO THE FINAL ROUND OF  
3 REFINEMENT AND REVISIONS THAT ARE NOW INCORPORATED  
4 INTO THE STRATEGIC PLAN FOR WHICH WE SEEK YOUR  
5 APPROVAL TODAY. YOU ALL SHOULD HAVE RECEIVED A COPY  
6 OF THIS PLAN ELECTRONICALLY, AND IT'S POSTED ON THE  
7 CIRM WEB SITE.

8 ONCE THIS PLAN IS APPROVED, IT WILL GIVE  
9 US A FRAMEWORK TO GUIDE PROGRAM AND CONCEPT AND  
10 BUDGET DEVELOPMENT IN THE UPCOMING YEARS. SO JUST  
11 FOR PURPOSES OF MAKING SURE THAT EVERYBODY HAS HAD A  
12 CHANCE TO REVIEW THE PLAN AND ADDRESS ANY INPUT OR  
13 FINAL COMMENTS, I WANTED TO JUST GIVE A BRIEF  
14 OVERVIEW.

15 IN THE FIRST SIX PAGES OF THE STRATEGIC  
16 PLAN, WE PROVIDE A BACKGROUND OF WHERE WE ARE TODAY.  
17 IT HIGHLIGHTS HOW CIRM HAS ESTABLISHED A STRONG  
18 TRACK RECORD AS A PATIENT-CENTERED FUNDER, PARTNER,  
19 ACCELERATOR, AND DERISKER FOR BASIC, TRANSLATIONAL,  
20 AND CLINICAL RESEARCH, HOW IT HAS CREATED CRITICAL  
21 INFRASTRUCTURE AND EDUCATION PROGRAMS. CIRM HAS  
22 FOSTERED THE GROWTH OF A NEW FIELD IN RESEARCH AND  
23 MEDICINE AND HAS BUILT A VIBRANT REGENERATIVE  
24 MEDICINE ECOSYSTEM IN CALIFORNIA WITH IMPACT BEYOND  
25 THE CALIFORNIA BORDERS.

**BETH C. DRAIN, CA CSR NO. 7152**

1 THE NEXT FEW SLIDES ARE A REMINDER OF  
2 CIRM'S ACCOMPLISHMENTS AND VALUE PROPOSITIONS THAT  
3 SERVE AS THE FOUNDATION FOR THE NEW STRATEGIC PLAN.

4 NEXT SLIDE PLEASE, DOUG. YOU'VE SEEN THIS  
5 SLIDE BEFORE. BUT AS A REMINDER, CIRM HAS BUILT ONE  
6 OF THE LARGEST PORTFOLIOS OF REGENERATIVE MEDICINE  
7 PROGRAMS SPANNING FROM DISCOVERY RESEARCH THROUGH  
8 CLINICAL TRIALS. AND A DISTINGUISHING AND  
9 DIFFERENTIATING FEATURE OF CIRM IS THE SUPPORT OF  
10 PROGRAMS IN THE SO-CALLED TRANSLATIONAL STAGE, ALSO  
11 REFERRED TO AS THE VALLEY OF DEATH, WHERE PROMISING  
12 SCIENCE OFTEN FAILS TO GET THE SUPPORT AND FUNDING  
13 IT NEEDS TO TRANSLATE INTO POTENTIAL THERAPEUTIC  
14 CANDIDATES.

15 CIRM HAS ONE OF THE LARGEST PORTFOLIO  
16 PROGRAMS GOING TO THE CLINICAL STAGE WITH OVER 76  
17 CLINICAL TRIALS AND OVER 3,000 PATIENTS ENROLLED ON  
18 THESE OFTEN FIRST-IN-HUMAN TRIALS IN A BROAD RANGE  
19 OF INDICATIONS FROM RARE DISEASE TO MORE COMMON  
20 DISEASES. AND WE HAVE ALREADY SEEN PROOF OF CONCEPT  
21 THAT SINGLE OR LIMITED ADMINISTRATION, CURATIVE  
22 INTENSE THERAPIES HAVE SHOWN DURABLE EFFECT IN  
23 PATIENTS SUCH AN EVIE AND OTHERS IN THE ADA-SCID  
24 TRIAL AND BRENDON IN THE X-LINKED CHRONIC  
25 GRANULOMATOUS DISEASE TRIAL THAT YOU'VE SEEN

**BETH C. DRAIN, CA CSR NO. 7152**

1 PRESENTED IN OUR ANNUAL REPORTS AND PREVIOUS  
2 PRESENTATIONS.

3 NEXT SLIDE PLEASE. WHILE CIRM IS  
4 WELL-KNOWN FOR FUNDING TRANSLATIONAL AND CLINICAL  
5 REGENERATIVE MEDICINE RESEARCH, WE'VE FUNDED CLOSE  
6 TO \$900 MILLION IN INVESTMENT IN BASIC RESEARCH AND  
7 ENABLING SCIENTIFIC INFRASTRUCTURE AS LISTED HERE.  
8 THIS IS CRITICAL. AND GOOD MEDICINE STARTS WITH  
9 STRONG BASIC SCIENCE. AND THE NEW STRATEGIC PLAN IS  
10 COMMITTED TO THE CONTINUED FUNDING OF BASIC,  
11 DISCOVERY, AND FOUNDATIONAL SCIENCE.

12 NEXT SLIDE PLEASE. WE HAVE ESTABLISHED A  
13 FIRST IN KIND AND EXTREMELY SUCCESSFUL STEM CELL AND  
14 REGENERATIVE MEDICINE CLINICAL NETWORK CALLED THE  
15 ALPHA STEM CELL CLINICS NETWORK. AND OUR PROGRAMS  
16 ARE PART OF THE NEW REGULATORY PARADIGM IN THE  
17 DEVELOPMENT OF THESE SO-CALLED LIVING MEDICINES OR  
18 NOVEL REGENERATIVE MEDICINE PROGRAMS. YOU WILL SEE  
19 THAT WE WILL BUILD ON THIS CAPACITY AND EXPERTISE IN  
20 THE STRATEGIC PLAN. NEXT SLIDE PLEASE.

21 CIRM HAS ALREADY STARTED TO BUILD A  
22 VIBRANT REGENERATIVE MEDICINE ECOSYSTEM, FUNDING  
23 EDUCATION AND TRAINING PROGRAMS OF ITS FUTURE  
24 WORKFORCE. IT'S INCREDIBLE TO ME THAT WHEN I GIVE  
25 LECTURES AT THE VARIOUS UNIVERSITIES AND SOMETIMES

**BETH C. DRAIN, CA CSR NO. 7152**

1 OUTSIDE OF CALIFORNIA, THAT STUDENTS, EXTREMELY  
2 PROMISING STUDENTS WITH BRIGHT FUTURES AHEAD OF  
3 THEM, TELL ME THAT THEIR MENTORS WERE PREVIOUS  
4 CIRM-FUNDED BRIDGES STUDENTS OR SCHOLARS. IT'S  
5 TRULY INCREDIBLE THAT CIRM HAS ALREADY HAD A LASTING  
6 IMPACT ON BUILDING THE FUTURE LEADERSHIP AND  
7 SCIENTIFIC WORKFORCE IN THE NEW FIELD OF  
8 REGENERATIVE MEDICINE.

9 CIRM HAS STIMULATED THE ECONOMY AS HAS  
10 BEEN HIGHLIGHTED PREVIOUSLY IN THE ECONOMIC IMPACT  
11 REPORT AND HAS CREATED NOVEL PARTNERSHIP AND  
12 INVESTMENT OPPORTUNITIES THROUGH INDUSTRY  
13 ENGAGEMENT, ENABLING OVER \$18 BILLION, JUST MOST OF  
14 THEM OVER THE PAST FIVE YEARS, IN INDUSTRY FUNDING  
15 INTO OUR CIRM PORTFOLIO PROGRAM.

16 NEXT SLIDE PLEASE. SO EVERYTHING THAT I  
17 JUST REVIEWED SET UP FOR THE NEXT ERA OF CIRM HAS  
18 BEEN MADE POSSIBLE BY PROP 14, PROPOSITION 14. THEY  
19 SERVE AS A SOLID FOUNDATION FOR THE NEW STRATEGIC  
20 PLAN THAT SERVES AN EXPANDED MISSION STATEMENT WHICH  
21 YOU WILL RECOGNIZE BECAUSE THIS IS THE SUBJECT AND  
22 TOPIC OF A LOT OF DISCUSSION, ESPECIALLY THE OCTOBER  
23 BOARD MEETING AND THEN ADDITIONAL AT THE NOVEMBER  
24 SCIENCE SUBCOMMITTEE MEETING, ACCELERATING  
25 WORLD-CLASS SCIENCE, TO DELIVER TRANSFORMATIVE

**BETH C. DRAIN, CA CSR NO. 7152**

1 REGENERATIVE MEDICINE TREATMENTS IN AN EQUITABLE  
2 MANNER TO A DIVERSE CALIFORNIA AND WORLD.

3 THIS MISSION STATEMENT IS INTENDED TO  
4 REFLECT THE ESSENCE OF WHAT ONE OF THE BOARD MEMBERS  
5 ASTUTELY POINTED OUT WHAT A MISSION STATEMENT SHOULD  
6 DO IS IDENTIFY WHO WE ARE, WHAT WE PROPOSE TO  
7 ACCOMPLISH, AND HOW WE KNOW THAT WE HAVE SUCCEEDED.  
8 THE MISSION STATEMENT IS ON PAGE 7 OF THE STRATEGIC  
9 PLAN.

10 NEXT SLIDE PLEASE. THE MISSION AND THE  
11 STRATEGY THAT'S OUTLINED IN THE STRATEGIC PLAN AND  
12 THAT I WILL BRIEFLY OUTLINE TODAY THAT WE ARE  
13 BRINGING TO YOU FOR APPROVAL IS BOLD, BUT WE BELIEVE  
14 IT'S ACHIEVABLE. AND THE OUTPUT OF THE STRATEGIC  
15 PLAN WILL LEAVE A LASTING LEGACY TO THE DEVELOPMENT  
16 OF NOVEL SCIENTIFIC AND COLLABORATIVE APPROACHES AND  
17 MODELS, HEALTHCARE DELIVERY MODELS, AND THE  
18 EXPANSION OF CIRM'S EDUCATION AND TRAINING PROGRAMS.  
19 GIVE RISE TO THE LEADERS AND SCIENTISTS AND  
20 WORKFORCE OF TOMORROW. NEXT SLIDE PLEASE.

21 THE APPROACH THAT WE OUTLINE IN THE PLAN  
22 WILL BUILD ON CIRM'S PROVEN ACCELERATED FUNDING  
23 MODEL. IT WILL ENHANCE, ORGANIZE, AND INTERCONNECT  
24 THE ESTABLISHED, AS WELL AS FUTURE PROGRAMS, THAT WE  
25 WILL BE BRINGING TO THE BOARD FOR APPROVAL, TO

**BETH C. DRAIN, CA CSR NO. 7152**

1 ACHIEVE THE STRATEGIC GOALS WHICH WE ORGANIZED INTO  
2 THREE STRATEGIC THEMES: ADVANCE WORLD-CLASS  
3 SCIENCE, DELIVER REAL-WORLD SOLUTIONS, PROVIDE  
4 OPPORTUNITY FOR ALL.

5 NOW I'LL JUST GO THROUGH THE FIVE-YEAR  
6 GOALS UNDER THESE STRATEGIC THEMES.

7 NEXT SLIDE. THE FIRST THEME IS RELATED TO  
8 AN AREA WHERE CIRM HAS TRULY ESTABLISHED ITS  
9 IDENTITY. IT IS A MAJOR FUNDER AND BUILDER OF STEM  
10 CELL AND REGENERATIVE SCIENTIFIC AND MEDICAL  
11 RESEARCH. NEXT SLIDE.

12 IN THE NEW ERA, CIRM SEEKS TO CREATE A  
13 PARADIGM SHIFT IN HOW WE SUPPORT COLLABORATIVE  
14 RESEARCH AND ENABLE REGENERATIVE MEDICINE SCIENTIFIC  
15 RESEARCH AND CLINICAL TRIAL DEVELOPMENT BY  
16 CONTINUING TO FUND HIGH RISK, HIGH REWARD PROJECTS  
17 WHILE DEVELOPING NEXT GENERATION TECHNOLOGY HUBS.  
18 THE FIRST EXAMPLE OF A TECHNOLOGY HUB BEING THE  
19 SHARED LABS AS STIPULATED IN PROPOSITION 14. AND  
20 CREATING SYSTEMS AND RESOURCES TO ASSEMBLE DATA AND  
21 KNOWLEDGE NETWORKS AND DATA SHARING. WE BELIEVE  
22 THAT THIS WILL ENABLE AND EXTRACT THE MOST VALUE  
23 FROM THE SCIENTIFIC PROGRAMS WE FUND. AND THIS IS  
24 DETAILED IN THE SECTION OF THE STRATEGIC PLAN  
25 BEGINNING ON PAGE 10.

**BETH C. DRAIN, CA CSR NO. 7152**

1                   NEXT SLIDE PLEASE. UNDER THEME TWO, WE  
2                   SEEK TO MEET THE CHALLENGES OF A MATURING FIELD  
3                   WHERE MORE PROGRAMS ARE GOING INTO THE CLINICAL  
4                   STAGE. WE ARE ALREADY STARTING TO SEE EARLY  
5                   SUCSESSES, BUT OUR UNDERSTANDING THE HURDLES IN THIS  
6                   NEW INDUSTRY. IN ADDITION TO CONTINUING TO SUPPORT  
7                   RESEARCH AND ADDRESS CHALLENGES IN THE LABORATORY  
8                   AND IN THE CONTEXT OF CONTROLLED CLINICAL TRIALS,  
9                   WHICH ARE MORE LIMITED IN SCOPE, WE HAVE OUR SIGHTS  
10                  SET ON ADDRESSING THE REAL-WORLD CHALLENGES OF  
11                  BRINGING THESE TECHNOLOGIES TO MARKETING APPROVAL,  
12                  COMMERCIALIZATION, AND ADOPTION INTO THE HEALTHCARE  
13                  SETTING. THIS SECTION IS COVERED ON PAGE 15 OF THE  
14                  PLAN.

15                  THE FIVE-YEAR STRATEGIC GOALS RELATED TO  
16                  THIS PARTICULAR THEME ADDRESS THE HURDLES AND  
17                  CHALLENGES TO DELIVER THESE THERAPIES IN THE  
18                  REAL-WORLD SETTING. WE INTEND TO CREATE NEXT  
19                  GENERATION SOLUTIONS TO ADDRESS REGULATORY AND  
20                  DEVELOPMENT CHALLENGES, A MANUFACTURING PARTNERSHIP  
21                  NETWORK TO OVERCOME KEY BOTTLENECKS, AND HEALTHCARE  
22                  DELIVERY INFRASTRUCTURE TO SUPPORT BROAD AND  
23                  INCLUSIVE PARTICIPATION IN THE RAPIDLY DEVELOPING  
24                  REGENERATIVE MEDICINE CLINICAL TRIAL SPACE AND  
25                  APPROVED TREATMENTS.

**BETH C. DRAIN, CA CSR NO. 7152**

1 TO EXPAND A BIT MORE ON THIS, WE WILL  
2 DEPLOY THE INTEGRATED APPROACH OF CIRM'S THERAPEUTIC  
3 DEVELOPMENTS PROGRAM TO ADDRESS HURDLES IN MARKETING  
4 APPROVAL AND POSTMARKET CONSIDERATIONS. WE ARE  
5 UNIQUELY POSITIONED TO DO SO IN A PORTFOLIO  
6 APPROACH. AND ASSEMBLED WITH THE PLAN TO HAVE THE  
7 EVIDENCE BASE AND KNOWLEDGE NETWORK, WE ARE VERY  
8 WELL POSITIONED TO HAVE MEANINGFUL CONVERSATIONS AND  
9 PARTNERSHIPS WITH EXTERNAL STAKEHOLDERS, REGULATORS,  
10 AND PAYERS. WE HAVE A VERY ESTABLISHED CLINICAL  
11 ADVISORY PANEL AND TRANSLATIONAL ADVISORY PANEL.  
12 AND THE TEAM PROPOSES TO BUILD UPON THIS SO THAT WE  
13 CAN ADDRESS ISSUES THAT WILL ARISE LATER ON TOWARD  
14 MARKETING APPROVAL AND POSTMARKET CONSIDERATIONS,  
15 BUT HAVE THAT BUILT INTO THE CONVERSATIONS EVEN IN  
16 THE TRANSLATIONAL STAGE OR EARLY CLINICAL TRIAL  
17 STAGE. NEXT SLIDE PLEASE.

18 MANUFACTURING IS A VERY WELL-KNOWN  
19 CHALLENGE AND A MAJOR HURDLE TO COMMERCIALIZATION OF  
20 PROMISING REGENERATIVE MEDICINE. EVEN PROGRAMS  
21 WHERE THERE'S SOME EARLY SUCCESSES IN EARLY STAGE  
22 TRIALS OFTEN FIND A HICCUP OR EVEN A MAJOR BARRIER  
23 TO GOING OUT TO FINAL MARKETING APPROVAL AND  
24 COMMERCIALIZATION BECAUSE THERE ARE SOME CHALLENGES  
25 WITH TECH TRANSFER OUT TO INDUSTRIALIZATION OF THE

**BETH C. DRAIN, CA CSR NO. 7152**

1 PROCESS AND TO DISTRIBUTION OF THESE PROGRAMS.  
2 THERE'S A UNIFORM AGREEMENT OF THIS CHALLENGE BY THE  
3 RESEARCH COMMUNITY, INDUSTRY, AND THE FDA. AND TO  
4 OVERCOME THESE BARRIERS, CIRM PROPOSES TO DEVELOP A  
5 PUBLIC-PRIVATE PARTNERSHIP MANUFACTURING MODEL THAT  
6 WILL OPTIMIZE THE CO-DEVELOPMENT BY OUR ACADEMIC GMP  
7 FACILITIES OF APPROACHES AND STANDARDS TO OVERCOME  
8 TECHNICAL CHALLENGES, ADVANCE STANDARDS, AND PROMOTE  
9 QUALITY-BY-DESIGN PRINCIPLES, ALL OF WHICH INCREASE  
10 THE ABILITY TO CREATE MORE OF AN EVIDENCE BASE.  
11 SYNERGIES BETWEEN THESE CENTERS REALLY PROVIDES AN  
12 OPPORTUNITY TO DEMOCRATIZE SPECIALIZATION AND  
13 SPECIALTY ASSETS OF THESE CENTERS AS WELL TO  
14 CONTINUE TO ITERATE AND IMPROVE UPON THESE  
15 CAPABILITIES.

16 FOR THIS TYPE OF STRUCTURE, CIRM WILL  
17 FACILITATE EARLY INDUSTRY INVOLVEMENT IN  
18 PARTNERSHIPS, INCLUDING WITH OUR INDUSTRY ALLIANCE  
19 PROGRAMS, FOR PROVISION OF SERVICES, RESOURCES, AND  
20 POTENTIALLY EVEN INVESTMENT INTO THESE PROGRAMS.  
21 THIS WILL BE DESIGNED IN A WAY TO ADVANCE STANDARDS,  
22 CREATE EFFICIENCIES, AND DERISK THE PATH TO  
23 COMMERCIALIZATION, AND TO TRAIN AND BUILD A  
24 REGENERATIVE MEDICINE MANUFACTURING LEADERSHIP AND  
25 WORKFORCE, WHICH EVERYBODY AGREES AT THIS POINT

**BETH C. DRAIN, CA CSR NO. 7152**

1     THERE IS A TRUE NEED FOR AND THERE IS A GAP IN THAT  
2     ARENA.

3             NEXT SLIDE PLEASE.    FINALLY, THE ULTIMATE  
4     GOAL OF ALL THESE EFFORTS IS THAT PATIENTS IN NEED  
5     WILL RECEIVE THESE TREATMENTS.   AS STIPULATED IN  
6     PROPOSITION 14, WE WILL EXPAND THE ALPHA CLINICS  
7     NETWORK TO ENABLE INNOVATIVE CLINICAL RESEARCH,  
8     INCREASE PATIENT ACCESS TO TRIALS AND APPROVED  
9     THERAPIES, AND TRAIN EXPERTISE IN THE DELIVERY AND  
10    CARE OF PATIENTS IN THESE TRIALS AND TREATMENTS WITH  
11    REGENERATIVE MEDICINE.   I JUST LOST MY POWER.   CAN  
12    YOU GUYS STILL HEAR ME?

13            MS. BONNEVILLE:   YES.

14            CHAIRMAN THOMAS:   YES.

15            DR. MILLAN:   FANTASTIC.   SO I'M IN  
16    SLIDE -- IN ADDITION, PROP 14 ALSO STIPULATES THE  
17    CREATION OF THESE COMMUNITY CARE CENTERS OF  
18    EXCELLENCE TO BE THE PARTNER ORGANIZATIONS THAT WILL  
19    ADDRESS WHAT THE PATIENTS NEED IN THE COMMUNITY  
20    SETTING IN ORDER FOR THIS ADOPTION AND APPROPRIATE  
21    ACCESS FOR PATIENTS BOTH IN CLINICAL TRIALS AND  
22    TREATMENTS.   NEXT SLIDE PLEASE.

23            SO WITH THESE TWO INITIATIVES OF ALPHA  
24    CLINICS EXPANSION, THE COMMUNITY CARE CENTERS OF  
25    EXCELLENCE, THESE WILL BE OPPORTUNITIES TO CREATE

**BETH C. DRAIN, CA CSR NO. 7152**

1 NEW MODELS FOR HEALTHCARE DELIVERY AS WELL AS  
2 VEHICLES TO UNDERSTAND WHAT IT TRULY TAKES TO BRING  
3 THESE THERAPIES OUT INTO THE WORLD AS WELL AS  
4 PROVIDE THE SETTING FOR BASIC SCIENTISTS TO BE  
5 EXPOSED AND TRAINED IN THE CLINICAL RESEARCH SO WHEN  
6 THEY'RE DOING THEIR WORK CAN ANTICIPATE THE PROBLEM  
7 SETS THAT MAY ARISE LATER. AND THE TRAINED CLINICAL  
8 TRIAL WORKFORCE, INCLUDING NURSES AND CLINICAL  
9 RESEARCH COORDINATORS, AS ONE OF THE PAST BOARD  
10 MEETINGS IT WAS NOTED THAT THERE IS A RARITY OF  
11 TRAINED CLINICAL RESEARCH COORDINATORS, ESPECIALLY  
12 IN THE ACADEMIC CENTERS, AND TO PARTNER WITH  
13 PROFESSIONAL SOCIETIES TO DEVELOP REGENERATIVE  
14 MEDICINE SPECIALTY CERTIFICATION AND ACCREDITATION  
15 PROGRAMS.

16 THE COMMUNITY CARE CENTERS, WHICH ARE  
17 STILL A CONCEPT UNDER DEVELOPMENT, THERE WILL BE AN  
18 INCREDIBLE AMOUNT OF COMMUNITY ENGAGEMENT, INPUT,  
19 AND DISCUSSION OVER THE COURSE OF THE UPCOMING YEAR  
20 SO WE CAN BEST UNDERSTAND WHAT THE COMMUNITY WANTS  
21 AND NEEDS AND HOW THINGS WORK IN THE CURRENT  
22 HEALTHCARE OFFERINGS IN THE COMMUNITY SETTING SO  
23 THAT WE CAN BEST DEVELOP PROGRAMS TO SUPPORT PATIENT  
24 REFERRAL, RECRUITMENT, AND ACCESS TO REGENERATIVE  
25 MEDICINE CLINICAL TRIALS, EDUCATION MATERIALS, AND

**BETH C. DRAIN, CA CSR NO. 7152**

1 ADDRESS THE UNIQUE NEEDS OF A GIVEN COMMUNITY, AS  
2 WELL AS LEVERAGE THE OFFERINGS OF THE ALPHA CLINICS  
3 AND CIRM ACADEMIC INSTITUTIONS.

4 THROUGH BOTH THE ALPHA CLINICS EXPANSION  
5 AND THE COMMUNITY CARE CENTERS INITIATIVE, THE GOAL  
6 IS TO EXPAND ENGAGEMENT AND PARTICIPATION AND BROAD  
7 ACCESS TO DIVERSE COMMUNITIES IN CLINICAL RESEARCH  
8 AND ACCESS TO THE TYPES OF TREATMENTS THAT CIRM WILL  
9 MOVE FORWARD. NEXT SLIDE PLEASE.

10 AND FINALLY, THE THIRD THEME IS PROVIDE  
11 OPPORTUNITY FOR ALL. SO CIRM INTENDS TO BUILD  
12 INCLUSIVE PARTICIPATION AND OPPORTUNITIES FOR ALL  
13 STAKEHOLDERS FROM STUDENTS TO WORKFORCE TO PATIENTS.  
14 SO THE TENETS OF DIVERSITY, EQUITY, AND INCLUSION  
15 HAS BEEN THE TOPIC OF MUCH DISCUSSION AT THE BOARD  
16 LEVEL, HAS BEEN INCORPORATED INTO OUR GRANTING  
17 PROCESS AND THE REVIEW PROCESS, AND IT'S BEEN  
18 CONTINUAL AND EVOLVING DEVELOPMENT BECAUSE WE ARE  
19 TRULY COMMITTED TO EMBEDDING THIS IN HOW WE FUND AND  
20 SUPPORT RESEARCH AS WELL AS HOW WE TRACK WHAT WE CAN  
21 DO BETTER.

22 THE GOAL IN THIS THEMATIC AREA IS TO BUILD  
23 A DIVERSE AND HIGHLY SKILLED WORKFORCE TO SUPPORT  
24 THE GROWING REGENERATIVE MEDICINE ECONOMY IN  
25 CALIFORNIA AS WELL AS, AND THIS IS A SEPARATE, BUT

**BETH C. DRAIN, CA CSR NO. 7152**

1 RELATED TOPIC, TO DELIVER A ROAD MAP FOR ACCESS AND  
2 AFFORDABILITY FOR REGENERATIVE MEDICINE FOR ALL  
3 CALIFORNIA PATIENTS. AND THE SECOND OF THESE GOALS  
4 IS GOING TO BE LARGELY DRIVEN BY THE LEADERSHIP AND  
5 PRIORITIES SET BY THE AFFORDABILITY AND  
6 ACCESSIBILITY WORKING GROUP. NEXT SLIDE PLEASE.

7 JUST TOUCH UPON THE FIRST OF THESE GOALS,  
8 WHICH IS THE EDUCATION AND TRAINING GOALS. CIRM HAS  
9 ALREADY, EVEN PRIOR TO PROP 14 AND ESPECIALLY AFTER  
10 THE PASSAGE OF PROP 14, HAS INVESTED SIGNIFICANTLY  
11 IN EDUCATION PROGRAMS, AS CHAIRMAN THOMAS HAD  
12 HIGHLIGHTED EARLY ON IN HIS CHAIRMAN'S REPORT. AND  
13 THE GOAL IS TO CREATE MULTIPLE ONRAMPS AT MULTIPLE  
14 LEVELS TO PROVIDE ACCESS FOR THE COMMUNITY, FOR A  
15 DIVERSE COMMUNITY, TO ENTER INTO THE FIELD AND  
16 GENERATE LEADERS, SCIENTISTS, CLINICIANS, AND FUTURE  
17 WORKFORCE WITH LIVED EXPERIENCES IN THESE  
18 COMMUNITIES SO THAT TRULY WE CAN CONTINUE TO BUILD  
19 THE TRUST AND UNDERSTANDING OF THE COMMUNITIES THAT  
20 WE SERVE.

21 AND IN ADDITION, THESE TRAINING PROGRAMS  
22 WILL BE INTEGRATED WITHIN THE CIRM SCIENTIFIC AND  
23 INFRASTRUCTURE PROGRAMS TO PROVIDE TRAINING AND  
24 EXPOSURE TO BASIC RESEARCH, TRANSLATIONAL, AND  
25 CLINICAL RESEARCH, MANUFACTURING SCIENCE, DATA

**BETH C. DRAIN, CA CSR NO. 7152**

1 SCIENCE, SCIENCE COMMUNICATION, AND COMMUNITY  
2 ENGAGEMENT. NEXT.

3 IN SUMMARY, THE FIVE-YEAR STRATEGIC GOALS  
4 ARE TO DEVELOP COMPETENCY HUBS AND BUILD KNOWLEDGE  
5 NETWORKS IN ORDER TO ADVANCE WORLD-CLASS SCIENCE,  
6 ADVANCE THERAPIES TO MARKETING APPROVAL, CREATE A  
7 MANUFACTURING PARTNERSHIP NETWORK, EXPAND THE ALPHA  
8 CLINICS NETWORK, CREATE COMMUNITY CARE CENTERS OF  
9 EXCELLENCE, BUILD A DIVERSE AND HIGHLY SKILLED  
10 WORKFORCE, AND DELIVER A ROAD MAP FOR ACCESS AND  
11 AFFORDABILITY. THESE ARE TANGIBLE GOALS. THESE ARE  
12 BOLD GOALS, BUT I AM CONFIDENT WITH THE TEAM THAT WE  
13 HAVE IN PLACE THAT WE HAVE BEEN ABLE TO RECRUIT.  
14 EVEN IN JUST THE PAST YEAR, WE'VE RECRUITED  
15 APPROXIMATELY 19 NEW TEAM MEMBERS, ALL, AS J.T. HAD  
16 MENTIONED, TOPNOTCH, TOP CALIBER TEAM MEMBERS. AND  
17 WE WILL BE GROWING OTHER PARTS OF THE ORGANIZATION  
18 TO ACHIEVE THESE GOALS.

19 WITH THAT, NEXT SLIDE PLEASE. I WANT TO  
20 FIRST OF ALL THANK ALL THE MEMBERS OF THE CIRM TEAM  
21 WHO HAVE BEEN INSTRUMENTAL IN BEING ABLE TO DELIVER  
22 THIS PLAN IN A VERY SHORT TIME FRAME. TO ALL OF YOU  
23 AS MEMBERS OF THE BOARD BECAUSE YOU WILL SEE ALL  
24 THROUGHOUT THE DOCUMENT YOUR FINGERPRINTS, YOUR  
25 INPUT, YOUR WISDOM ARE ALL EMBEDDED IN THE STRATEGIC

**BETH C. DRAIN, CA CSR NO. 7152**

1 PLAN. BUT I'M NOW REQUESTING FOR BOARD ACTION,  
2 APPROVAL OF THE PROPOSED CIRM FIVE-YEAR STRATEGIC  
3 PLAN THAT WILL ENABLE OUR TEAM TO CREATE CONCEPTS  
4 AND PROGRAMS TO BE BROUGHT TO YOU IN THE UPCOMING  
5 YEARS. AND I'LL NOW TURN IT OVER TO CHAIRMAN THOMAS  
6 WHO WILL TAKE QUESTIONS, AND I'M HAPPY TO ADDRESS  
7 ANY QUESTIONS YOU MAY HAVE ABOUT THE PLAN. THANK  
8 YOU.

9 MR. TORRES: MR. CHAIRMAN.

10 CHAIRMAN THOMAS: YES, MR. SENATOR.

11 MR. TORRES: YES. I WOULD LIKE TO  
12 INTRODUCE A MOTION TO APPROVE THIS PROPOSED CIRM  
13 FIVE-YEAR STRATEGIC PLAN. AND ALSO TO ADD A  
14 THANK-YOU TO MARIA AND THE INCREDIBLE LEADERSHIP  
15 TEAM THAT SHE HAS PUT TOGETHER AND HAS BEEN PART OF  
16 THIS PROCESS, AS WELL AS INPUT FROM MANY OF OUR  
17 BOARD MEMBERS. THIS IS A VERY IMPRESSIVE DOCUMENT,  
18 AND I THINK THAT ONCE WE START DISTRIBUTING IT TO  
19 PEOPLE OUTSIDE CIRM, ESPECIALLY THE LEGISLATURE AND  
20 CONSTITUTIONAL OFFICES, I THINK IT WILL BE VIEWED  
21 EVEN WITH MUCH MORE RESPECT AS TO THE SERIOUSNESS BY  
22 WHICH WE'VE TAKEN THE TAXPAYERS MANDATE TO MAKE SURE  
23 THAT WE RUN THIS OFFICE EFFICIENTLY, THIS AGENCY  
24 EFFICIENTLY, MAKING SURE THAT THE PATIENT IS  
25 FOREMOST IN OUR AGENDA.

**BETH C. DRAIN, CA CSR NO. 7152**

1 DR. MARTIN: SECOND.

2 CHAIRMAN THOMAS: THANK YOU. DO WE  
3 HAVE -- BEFORE WE GET ON TO FURTHER COMMENT, DO WE  
4 HAVE A SECOND TO THE MOTION?

5 DR. MARTIN: SECOND.

6 CHAIRMAN THOMAS: YES. THANK YOU. I'LL  
7 HAVE A COMMENT, ONE, AND A QUESTION FOR MARIA. SO  
8 THE COMMENT IS JUST TO REITERATE THAT MARIA STARTED  
9 THIS PROCESS WITH THE LEADERSHIP TEAM BACK IN MARCH  
10 OF 2020 WITHOUT KNOWING AT THAT POINT FOR A NUMBER  
11 OF MONTHS WHETHER CIRM WOULD EVEN BE AROUND FOR AN  
12 ADDITIONAL FIVE YEARS; BUT, NONETHELESS, TOOK MAJOR  
13 ACTION AND INITIATIVE TO BEGIN THE DISCUSSION WITH  
14 THE FULL PANOPLY OF STAKEHOLDERS TO GET EVERYBODY'S  
15 INPUT AND ALLOW FOR AN EXCEEDINGLY WELL THOUGHT OUT  
16 PROCESS WHICH EVERYBODY WAS ABLE TO ADDRESS OVER  
17 MANY, MANY MONTHS. AND THAT HAS LED TO THIS  
18 EXCEPTIONAL DOCUMENT THAT WE HAVE HERE BEFORE US.

19 SO, MARIA, AND TO YOU AND TO THE  
20 LEADERSHIP TEAM, THANK YOU FOR PRESSING ON WITH THIS  
21 AT A TIME WHERE THINGS WERE VERY MUCH UP IN THE AIR,  
22 YET THAT ACTION HAS DIRECTLY BENEFITED THE AGENCY  
23 AND PATIENTS BY ENDING UP WITH A VERY THOUGHTFUL AND  
24 DELIBERATE DOCUMENT THAT WE HAVE HERE BEFORE US. SO  
25 THAT'S MY COMMENT.

**BETH C. DRAIN, CA CSR NO. 7152**

1 MY QUESTION, MARIA, IS IF YOU COULD FOR  
2 THE BOARD'S BENEFIT, THERE ARE A NUMBER OF PROGRAMS  
3 THAT ARE SET FORTH IN PROP 14 THAT ARE EITHER NEW OR  
4 RECONSTRUCTED OLDER PROGRAMS THAT ARE GOING TO BE  
5 BROUGHT BEFORE THE BOARD OVER TIME TO IMPLEMENT.  
6 COULD YOU JUST GIVE THE BOARD A SENSE OF SORT OF  
7 WHAT THE ROLLOUT IS GOING TO BE OF SOME OF THOSE  
8 ELEMENTS?

9 DR. MILLAN: FIRST, I WANT TO THANK YOU  
10 AND SENATOR TORRES FOR YOUR KIND COMMENTS. AND I  
11 WANTED TO REITERATE WE DO HAVE THE RIGHT TEAM IN  
12 PLACE, AND THAT'S WHY WE WERE ABLE TO DELIVER THIS  
13 PLAN.

14 NOW IN TERMS OF YOUR QUESTION, I'LL JUST  
15 START WITH THE SPECIFIC ELEMENTS THAT WERE  
16 STIPULATED IN PROP 14, AND I'LL START WITH THAT. IT  
17 ACTUALLY LINES UP VERY WELL WITH SOME OF THE THINGS  
18 WE ARE THINKING IN THE ROLLOUT. YOU WILL HEAR FROM  
19 MS. SIMPSON, POUNEH SIMPSON, LATER TODAY THE  
20 ADMINISTRATIVE AS WELL AS THE RESEARCH BUDGET. WE  
21 WILL IN THE UPCOMING SIX MONTHS START TO LAUNCH THIS  
22 NEW STRATEGIC PLAN UPON YOUR APPROVAL, OF COURSE.  
23 AND ONE OF THE FIRST PROGRAMS THAT WE EXPECT WILL  
24 ROLL OUT IS THE ALPHA CLINICS EXPANSION PROGRAM IN  
25 THE EARLY 2022.

**BETH C. DRAIN, CA CSR NO. 7152**

1 AFTER THAT, IN THE COURSE OF THE ENSUING  
2 YEAR, WE EXPECT THAT WE'LL BE ROLLING OUT ONE OF THE  
3 FIRST COMPETENCY HUBS CALLED THE SHARED LABS, WHICH  
4 ALSO IS STIPULATED IN PROP 14.

5 ALSO WITHIN THIS UPCOMING YEAR, WE DO  
6 BELIEVE, IT'S NOT SPECIFICALLY SPECIFIED IN THE  
7 PROPOSITION, BUT IT'S ESSENTIAL IS TO ROLL OUT THE  
8 MANUFACTURING NETWORK PROPOSAL BECAUSE WE KNOW THAT  
9 OUR PROGRAMS NEED THAT.

10 AND THEN OVER THE COURSE OF THE NEXT YEAR  
11 OR SO, TO REALLY GAIN BETTER INTELLIGENCE AND MORE  
12 INFORMATION SO WE CAN START CRAFTING WHAT THE  
13 COMMUNITY CARE CENTERS OF EXCELLENCE WOULD LOOK  
14 LIKE. AT THE SAME TIME, WE WILL BE RECRUITING A  
15 WHOLE NEW DEPARTMENT OF MEDICAL AFFAIRS AND POLICY  
16 THAT WILL BE CRITICAL IN WORKING TO SUPPORT THE  
17 AAWG, ITS PRIORITIES AND INITIATIVES, AS WELL AS  
18 IMPLEMENTING AND INFORMING THE BEST DIRECTION FOR  
19 THE ALPHA CLINICS NETWORK AND THE COMMUNITY CARE  
20 CENTERS OF EXCELLENCE AS THE SO-CALLED LABORATORIES  
21 WHERE WE NEED TO FIGURE OUT THE BEST WAY TO PROVIDE  
22 ACCESS AND ASSISTANCE FOR PATIENTS TO TRULY GAIN  
23 ACCESS FOR ALL THE COMMUNITIES UNDERSERVED AS WELL  
24 AS ALL THOSE IN NEED.

25 SO THAT'S KIND OF WHAT IT LOOKS LIKE. YOU

**BETH C. DRAIN, CA CSR NO. 7152**

1 WILL EXPECT TO SEE MORE EDUCATION-RELATED PROGRAMS  
2 TO BUILD ON THE ONRAMPS AS DISCUSSED, AS WELL AS, IN  
3 THE EARLY PART OF 2022, YOU WILL SEE A BASIC  
4 DISCOVERY, AT LEAST DISCUSSIONS OF THEM, THAT WILL  
5 BE BROUGHT MID-YEAR OR SO TO THE BOARD, MAYBE EVEN A  
6 LITTLE EARLIER. I'LL HAVE TO DEFER TO MY TEAM  
7 BECAUSE THEY'RE BETTER AT KEEPING THE TIMELINES  
8 THERE'S SO MUCH GOING ON, WITH BASIC FOUNDATIONAL  
9 DISCOVERY. CURRENTLY OUR DISCOVERY PROGRAM THAT IS  
10 OPEN FOR ACCEPTING APPLICATIONS IS CALLED CANDIDATE  
11 DISCOVERY, WHICH MEANS THAT THE NATURE OF THOSE  
12 TYPES OF GRANTS IS FOR DISCOVERY RESEARCH RELATED TO  
13 THERAPEUTIC DEVELOPMENT, BUT THERE IS AN IMPORTANT  
14 ROLE FOR FOUNDATIONAL AND MECHANISTIC DISCOVERY  
15 RESEARCH, BASIC SCIENCE RESEARCH, TO BETTER  
16 UNDERSTAND THE BIOLOGY DISEASE MECHANISMS. SO WE  
17 WILL BE REOPENING THE DISCOVERY CALLED DISC-0  
18 PROGRAM ANNOUNCEMENT EARLY IN 2022.

19 IN ANY CASE, THAT'S KIND OF JUST A BASIC  
20 UNDERSTANDING. WE WILL, AS TIME GOES ON, THE CIRM  
21 TEAM WILL MAKE SURE THAT THE BOARD IS WELL INFORMED  
22 IN THE PROCESS THAT WE USUALLY UNDERGO TO MAKE SURE  
23 THAT WE ENGAGE WITH BOARD MEMBERS APPROPRIATELY IN  
24 THE SUBCOMMITTEES PRIOR TO BRINGING CONCEPT  
25 PROPOSALS AND BUDGETS TO THE FULL BOARD. SO IT WILL

**BETH C. DRAIN, CA CSR NO. 7152**

1 BE ANOTHER BUSY YEAR NEXT YEAR.

2 CHAIRMAN THOMAS: THANK YOU. YSABEL.

3 MS. DURON: THANK YOU, MR. CHAIR.

4 MARIA, J.T. HAS SAID IT WELL AND SAID A  
5 LOT OF WHAT I COMMEND YOU FOR, A VERY STRONG PLAN.  
6 I THINK, AND I EVEN HEARD YOU SAY IN THESE LAST  
7 COMMENTS, I THINK WHAT CONCERNS ME MOST IS WHAT YOU  
8 KNOW ALWAYS CONCERNS ME, AND THAT IS LACK OF WORDS  
9 HERE. I SEE THE WORD "DIVERSE," AND THAT CAN MEAN  
10 MANY THINGS TO MANY PEOPLE. I WOULD LIKE TO SEE  
11 MORE SPECIFIC LANGUAGE AND PERHAPS, AND FORGIVE ME  
12 IF I WAS MIA DURING THE STRATEGIC PLAN WRITING AND I  
13 DIDN'T ADD COMMENTS, SO SLAP ME WITH A WET NOODLE  
14 FOR BEING ABSENT ON THAT, BUT I'M REALLY CONCERNED  
15 THAT WITHOUT SPECIFIC LANGUAGE THAT REFERENCES THE  
16 INCLUSION, THE EQUITY AND INCLUSION, THE RACIAL,  
17 ETHNIC, AND UNDERSERVED POPULATIONS IN THE LANGUAGE  
18 ON THE PIECE OF PAPER, THAT THOSE WHO DO NOT  
19 CONSIDER THESE ASPECTS SEE THE WORD "DIVERSE" AND  
20 THINK THEY HAVE TAKEN CARE OF THE ISSUE.

21 SO I AM WONDERING, AND I WOULD STILL VOTE  
22 APPROVAL, IF WE CAN'T STRENGTHEN THE LANGUAGE ON THE  
23 PAPER THAT SHOWS HOW COMMITTED AND INTENTIONED WE  
24 ARE TO MAKE SURE THAT IN FACT WHEN WE SAY ALL  
25 CALIFORNIANS, WE MEAN ALL CALIFORNIANS AND WE'RE

**BETH C. DRAIN, CA CSR NO. 7152**

1 VERY SPECIFIC ABOUT WHO THOSE CALIFORNIANS ARE SO  
2 THAT THEY THEMSELVES READ THIS AND KNOW IT INCLUDES  
3 THEM. SO I'M JUST LOOKING FOR SOME SHARPER LANGUAGE  
4 THAT WE CAN ADD WITHIN THE PLAN SO WHEN IT HITS THE  
5 LEGISLATURE, THEY SEE IT AS WELL AND KNOW THAT WE  
6 ARE REFERENCING ALL OF OUR CALIFORNIANS AND  
7 PARTICULARLY SOME OF OUR MOST VULNERABLE AND  
8 UNDERSERVED COMMUNITIES, AND THAT THEY HAVE TO STEP  
9 UP TO THE PLATE AND SUPPORT THIS AS WELL.

10 THEY CAN'T GET AWAY WITH JUST THE WORD  
11 IT'S DIVERSE OR SERVING THE DIVERSE POPULATION OF  
12 CALIFORNIA. TO ME THAT'S NOT GOOD ENOUGH. THE  
13 COMMUNITY CENTERS ARE FABULOUS, BUT LET'S MAKE SURE  
14 THAT THE COMMUNITIES KNOW THAT THOSE ARE FOR THEM.

15 SO INCLUSION AND WORDS ARE SO IMPORTANT IN  
16 THIS DAY AND AGE. WE HAVE SEEN WORDS MISUSED OVER  
17 AND OVER AND OVER AGAIN DURING THIS PERIOD OF COVID.  
18 AND WE NEED TO EXPLAIN OURSELVES VERY CLEARLY, VERY  
19 DELIBERATELY, AND VERY INTENTIONALLY. AND SO I HOPE  
20 THAT MAYBE YOU CAN ADD SOME WORDS OR PHRASES TO THIS  
21 AT THE VERY BEGINNING THAT EXPRESSES AND REPEATS AND  
22 REPEATS OUR COMMITMENT TO DIVERSITY, EQUITY, AND  
23 INCLUSION. THANK YOU.

24 DR. MILLAN: THANK YOU, YSABEL. I TOOK  
25 SOME NOTES, AND WE VERY MUCH WELCOME THOSE

**BETH C. DRAIN, CA CSR NO. 7152**

1 ADDITIONAL WORDS. AND WE WILL INCORPORATE THEM. I  
2 DO BELIEVE WE DO HAVE WORDS SUCH AS UNDERSERVED, ET  
3 CETERA, BUT WE WILL DEFINITELY STRENGTHEN THEM  
4 BECAUSE IF YOU WHO LOOK FOR THESE DO NOT SEE THEM,  
5 THEN WE CLEARLY HAVEN'T DONE ENOUGH TO MAKE SURE  
6 THAT IT'S VERY CLEAR. SO WE WILL DEFINITELY BE  
7 RECEPTIVE OF THOSE ADDITIONAL WORDS. AND IT'S IN  
8 ELECTRONIC FORMAT SO THAT'S SOMETHING THAT CAN BE  
9 INCORPORATED. THANK YOU VERY MUCH.

10 CHAIRMAN THOMAS: THANK YOU, YSABEL AND  
11 MARIA. I THINK SENATOR TORRES HAS SOME THOUGHTS  
12 FURTHER ON THIS THEME.

13 MR. TORRES: I INTRODUCED MARIA TO THE  
14 CHANCELLOR'S OFFICE AT UC MERCED. THEY'RE IN  
15 COMMUNICATION ALREADY WITH NOT ONLY TALKING ABOUT  
16 DIVERSITY, BUT HOW DO WE ESTABLISH A COMMUNITY CARE  
17 CLINIC AND SHARED LABS AT UC MERCED, WHICH, AS YOU  
18 KNOW AND ADRIANA KNOWS ESPECIALLY, COVERS AN  
19 INCREDIBLE PART OF NORTH CENTRAL CALIFORNIA, WHICH  
20 IS SO IN NEED OF MEDICAL FACILITIES AND RESOURCES  
21 AND WOULD BE A PERFECT LOCATION FOR POTENTIAL  
22 CLINICAL TRIALS WHICH WOULD INCREASE OUR DIVERSITY  
23 RANGE.

24 NO. 2, WE HAD OUR FIRST INAUGURAL MEETING  
25 OF THE WORKING GROUP ON AFFORDABILITY AND

**BETH C. DRAIN, CA CSR NO. 7152**

1 ACCESSIBILITY DECEMBER 1ST. THANK YOU, KEVIN MARKS  
2 AND MARIA, FOR HELPING US WRITE THE BYLAWS WHICH  
3 WERE ADOPTED AT THAT TIME AND WHICH WILL  
4 SUBSEQUENTLY BE ADOPTED BY THE FULL BOARD. BUT WE  
5 ALSO TALKED ABOUT JUST WHERE WE'RE GOING SO THAT YOU  
6 ALL KNOW. OF THE 17 MEMBER BOARD, WE HAVE MANY OF  
7 OUR BOARD MEMBERS WHO ARE ON THERE, DAN BERNAL, AL  
8 ROWLETT, ADRIANA PADILLA, DAVID HIGGINS. AND  
9 ALLISON BRASHEAR HAD TO RESIGN BECAUSE SHE LEFT AS  
10 THE DEAN OF UC DAVIS. BUT J.T. WAS VERY THOUGHTFUL  
11 IN GETTING DR. PAT LEVITT FROM THE CHILDREN'S  
12 HOSPITAL IN LOS ANGELES TO TAKE ALLISON'S POSITION.

13 SO WE HAVE SOME GOOD REPRESENTATION OF THE  
14 CHILDREN'S HEALTHCARE FIELD. TED GOLDSTEIN WHO  
15 DEVELOPED THE PROGRAM FOR JAVA AND HAS BEEN WORKING  
16 WITH BLUE ANTHEM, NOW RESIGNED FROM THERE SO HE  
17 COULD WORK WITH US WITHOUT A CONFLICT OF INTEREST.  
18 AND ALSO JAMES DEBENEDETTI, WHO I BROUGHT OVER FROM  
19 COVERED CALIFORNIA. YOU ALSO NEED TO KNOW, AS A  
20 BOARD MEMBER THERE, WE HAVE FIVE BOARD MEMBERS WHO  
21 ARE EMBARKING ON AN AFFORDABILITY AND ACCESSIBILITY  
22 DIMENSION TO OUR NEGOTIATIONS WITH THIRD-PARTY  
23 PAYERS. SO WE ARE MOVING IN CONJUNCTION, THIS  
24 WORKING GROUP AND HOPEFULLY WITH COVERED CALIFORNIA,  
25 IN THAT AREA.

**BETH C. DRAIN, CA CSR NO. 7152**

1 I'M ALSO HAPPY THAT ADRIENNE SHAPIRO FROM  
2 THE SICKLE CELL ADVOCACY GROUP IS ALSO ON THIS  
3 WORKING GROUP. AND DAVID SERRANO-SEWELL, WHO WAS A  
4 FORMER BOARD MEMBER OF CIRM AND CO-LED THE EFFORT TO  
5 ESTABLISH THE STEM CELL LABS ACROSS THE STATE. IT'S  
6 GOING TO BE VERY IMPORTANT AS WE CONSIDER THE  
7 IDENTIFICATION OF COMMUNITY CARE CLINICS. AND, OF  
8 COURSE, DANA DORNIFE, WHO WROTE THE ECONOMIC IMPACT  
9 REPORT FROM USC IS A DEAN THERE, ON OUR  
10 CONTRIBUTIONS TO THE STATE OF CALIFORNIA AS AN  
11 AGENCY. AND, LASTLY, MY GOOD FRIEND DR. HARLAN  
12 LEVINE, WHO HEADS UP BUSINESS STRATEGIES AS  
13 PRESIDENT OF THE CITY OF HOPE, HAS AGREED TO COME ON  
14 BOARD AS OUR PATIENT NAVIGATOR.

15 SO WE HAVE A VERY IMPRESSIVE GROUP OF 17  
16 PEOPLE, AND I THINK THAT AS WE MOVE FORWARD, WE'RE  
17 GOING TO BE IN CONJUNCTION WITH A NUMBER OF STATE  
18 AND FEDERAL AGENCIES THAT ARE MOVING IN SIMILAR  
19 DIRECTIONS AND HOPE TO WORK CLOSELY WITH MY FORMER  
20 CHIEF OF STAFF, WHO IS NOW THE SECRETARY OF HEALTH  
21 AND HUMAN SERVICES, XAVIER BECERRA, TO MAKE SURE  
22 THAT WE ARE IN SYNC WITH FEDERAL POLICIES THAT WILL  
23 HELP US IMPLEMENT OUR MANDATE TO CREATE AFFORDABLE,  
24 ACCESSIBLE, DIVERSE ACCESS FOR CLINICAL TRIALS,  
25 ESPECIALLY FOR PATIENTS IN CALIFORNIA. THANK YOU,

1 J.T.

2 CHAIRMAN THOMAS: THANK YOU, ART. GEORGE.

3 DR. BLUMENTHAL: THANK YOU. FIRST OF ALL,  
4 I'D LIKE TO THANK MARIA AND THE ENTIRE TEAM FOR  
5 CREATING THIS DOCUMENT, WHICH I THINK REALLY SETS  
6 FORTH AN EXCITING FUTURE FOR CIRM AND FOR STEM CELL  
7 RESEARCH AND DEVELOPMENT IN CALIFORNIA. I THINK  
8 IT'S A GREAT DOCUMENT. AND, YES, I DO SUPPORT  
9 YSABEL'S SUGGESTION. I THINK THAT WOULD BE A VERY  
10 HELPFUL MODIFICATION.

11 MY QUESTION REALLY RELATES BACK TO THE  
12 PREVIOUS STRATEGIC PLAN FOR CIRM. WHEN I THINK BACK  
13 ON THE PREVIOUS PLAN AND PERHAPS THE OUTGROWTH OF  
14 THE PREVIOUS STRATEGIC PLAN, THERE WERE VERY  
15 SPECIFIC NUMERICAL GOALS THAT WERE SET FOR  
16 ACHIEVEMENT. YOU CAN ALMOST THINK OF THEM AS  
17 ACCOUNTABILITY MEASURES, A SET OF VERY SPECIFIC  
18 GOALS THAT WE DISCUSSED PERIODICALLY IN OUR BOARD  
19 MEETINGS AS A RESULT OF THE PREVIOUS PLAN. IS THERE  
20 A PLAN TO ESTABLISH SIMILAR GOALS FOR THIS PLAN, AND  
21 KIND OF HOW DO YOU SEE THAT DEVELOPING?

22 DR. MILLAN: THANK YOU SO MUCH. IT IS  
23 ABSOLUTELY HOW WE OPERATE AT CIRM. SO WE TAKE THE  
24 STRATEGIC PLAN AS OUR FRAMEWORK. WE CREATE ANNUAL  
25 GOALS WHICH ARE MEASURABLE GOALS. AND THEN FROM

**BETH C. DRAIN, CA CSR NO. 7152**

1 THOSE ANNUAL GOALS, EACH TEAM CREATES QUARTERLY  
2 GOALS THAT ARE MEASURABLE. AND THESE GOALS BUILD  
3 UPON ACHIEVING THE ANNUAL GOALS THAT THEN ROLL INTO  
4 THE FIVE-YEAR GOALS.

5 WHAT YOU WERE REFERRING TO IS IN THE PAST  
6 STRATEGIC PLAN WE HAD WHAT WAS CALLED THE BIG SIX  
7 GOALS. SO WE SAID EVERYTHING WAS 50. FIFTY NEW  
8 CLINICAL TRIALS, 50 NEW CANDIDATES, 50 PERCENT OF  
9 PROGRAMS PARTNERED. AND WE WILL HAVE SOMETHING  
10 SIMILAR. THE PAST STRATEGIC PLAN WAS VERY  
11 OPERATIONAL. IT WAS SETTING UP SYSTEMS. THIS  
12 STRATEGIC PLAN SEEKS TO CREATE REALLY NOVEL MODELS,  
13 BUT WE DO STILL BELIEVE THERE'S AN OPPORTUNITY TO  
14 CREATE MEASURABLE METRICS RELATED TO THE ADVANCEMENT  
15 OF THE STRATEGIC GOALS.

16 THANK YOU FOR THE QUESTION. THAT IS  
17 SOMETHING THAT IS EMBEDDED IN HOW WE OPERATE AT  
18 CIRM. IN FACT, THIS WEEK WE HAVE WHAT'S CALLED AN  
19 ALL-HANDS MEETING. WE HAVE QUARTERLY ALL-HANDS  
20 MEETINGS. AS A TEAM WE ARE ABLE TO ASSEMBLE AND  
21 GIVE UPDATES. EACH TEAM, EACH GROUP PRESENTS AN  
22 UPDATE ON HOW THEY DID AGAINST THE PAST QUARTER'S  
23 GOALS AND THEN COMMIT TO THE NEXT QUARTER'S GOALS.  
24 AND IT'S A REALLY GREAT EVENT. IN THE TIMES PRIOR  
25 TO THE RECENT, TO ASSEMBLE TO REALLY UNDERSTAND HOW

**BETH C. DRAIN, CA CSR NO. 7152**

1 THE GOALS RELATE BETWEEN THE GROUPS, HOW THINGS ARE  
2 GOING, AND TO REALLY BECOME INFORMED HOW WE ARE ALL  
3 MOVING IN THE SAME DIRECTION TOWARD ACHIEVING THE  
4 STRATEGIC GOALS ACCORDING TO THE MISSION. THANK YOU  
5 SO MUCH FOR YOUR QUESTION.

6 CHAIRMAN THOMAS: THANK YOU, GEORGE.  
7 MARIA, IF YOU COULD JUST ON AN ANNUAL BASIS PERHAPS  
8 REVISIT YOUR GOALS WITH THE BOARD SO THAT THEY KNOW  
9 WHAT IS LYING IN THE FUTURE FOR THE ENSUING YEAR,  
10 THAT WOULD BE VERY HELPFUL.

11 DR. MILLAN: THANK YOU, J.T. I THINK  
12 THAT'S A GREAT SUGGESTION, AND I INTEND TO DO THAT  
13 IN THE PRESIDENT'S REPORT. THANK YOU.

14 CHAIRMAN THOMAS: AL FROM BERLIN.

15 MR. ROWLETT: I WANTED TO ACKNOWLEDGE,  
16 MARIA, THE PROCESS. AS J.T. INDICATED, IT IS VERY  
17 CHALLENGING TO DEVELOP A STRATEGIC PLAN WHEN YOU  
18 DON'T KNOW IF THE ORGANIZATION IS GOING TO GO  
19 FORWARD. AND IN LIGHT OF THAT, YOUR PROCESS WAS  
20 QUITE INCLUSIVE. AND THE OUTREACH TO OTHER BOARD  
21 MEMBERS I FOUND TO BE VERY, VERY HELPFUL TOWARDS MY  
22 PARTICIPATION. I WANTED TO ACKNOWLEDGE THE STAFF'S  
23 WORK.

24 AND FOR FEAR OF REPEATING SOME OF THE  
25 OTHER WONDERFUL THINGS THAT HAVE BEEN SAID BY OUR

**BETH C. DRAIN, CA CSR NO. 7152**

1 CHAIR AND OUR VICE CHAIR, AGAIN, CONGRATULATIONS ON  
2 THE PLAN.

3 THEN, LASTLY, I, AS ALWAYS, ENDORSE  
4 YSABEL 'S ASSERTIONS REGARDING DEI AND ANY EFFORT TO  
5 BE MORE DELIBERATE AND, PERHAPS NOT THE BEST WORD,  
6 BUT AS WE CAN BE MORE EFFECTIVE IN THE INCORPORATION  
7 OF DEI LANGUAGE IN OUR STRATEGIC PLAN, SENDING A  
8 MESSAGE TO THE CITIZENS AND THE INDIVIDUALS THAT  
9 BENEFIT FROM THE ORGANIZATION THAT THE TRUE INTENT  
10 OF CIRM AND THE GOALS OF CIRM REGARDING COMING UP  
11 WITH CURES THAT CHANGE THE TRAJECTORY OF LIVES OF  
12 THE PEOPLE THAT VOTED FOR THE PROPOSITION AND THOSE  
13 THAT DIDN'T SUPPORT THE PROPOSITION, THAT MAKES A  
14 DIFFERENCE TO ME, CHANGING TRAJECTORY OF THEIR  
15 LIVES. AND I THINK OUR STRATEGIC PLAN DOES A GREAT  
16 JOB AT REALLY IMPROVING THE OVERALL COMMUNICATION TO  
17 THOSE INDIVIDUALS AND ORGANIZATIONS. AGAIN, WELL  
18 DONE. THANK YOU FOR YOUR EFFORTS AND INCLUDING ME  
19 AND OTHER PATIENT ADVOCATES IN THE DEVELOPMENT OF  
20 THIS PLAN.

21 DR. MILLAN: THANK YOU SO MUCH.

22 CHAIRMAN THOMAS: ANY OTHER COMMENTS FROM  
23 MEMBERS OF THE BOARD? DO WE HAVE ANY COMMENTS FROM  
24 MEMBERS OF THE PUBLIC?

25 MS. BONNEVILLE: I DON'T SEE ANY HANDS

**BETH C. DRAIN, CA CSR NO. 7152**

1 RAISED.  
2 CHAIRMAN THOMAS: OKAY. MARIA, THEN WILL  
3 YOU PLEASE CALL THE ROLL.  
4 MS. BONNEVILLE: LAUREN ALVING.  
5 DR. ALVING: YES.  
6 MS. BONNEVILLE: KIM BARRETT.  
7 DR. BARRETT: YES.  
8 MS. BONNEVILLE: DAN BERNAL.  
9 MR. BERNAL: YES.  
10 MS. BONNEVILLE: GEORGE BLUMENTHAL.  
11 DR. BLUMENTHAL: YES.  
12 MS. BONNEVILLE: MICHAEL BOTCHAN. LINDA  
13 BOXER.  
14 DR. BOXER: YES.  
15 MS. BONNEVILLE: LEONDRA CLARK-HARVEY.  
16 DEBORAH DEAS.  
17 DR. DEAS: YES.  
18 MS. BONNEVILLE: ANNE-MARIE DULIEGE.  
19 DR. DULIEGE: YES.  
20 MS. BONNEVILLE: YSABEL DURON.  
21 MS. DURON: MAY I SAY YES WITH  
22 RESERVATIONS?  
23 MS. BONNEVILLE: HOW ABOUT WE'LL JUST  
24 COUNT IT AS A YES.  
25 MS. DURON: JUST WANT TO SEE THE UPTICK IN

**BETH C. DRAIN, CA CSR NO. 7152**

1 LANGUAGE. YES.  
2 MS. BONNEVILLE: NOTED. THANK YOU. MARK  
3 FISCHER-COLBRIE.  
4 DR. FISCHER-COLBRIE: YES.  
5 MS. BONNEVILLE: FRED FISHER. ELENA  
6 FLOWERS.  
7 DR. FLOWERS: YES.  
8 MS. BONNEVILLE: JUDY GASSON.  
9 DR. GASSON: YES.  
10 MS. BONNEVILLE: LARRY GOLDSTEIN.  
11 DR. GOLDSTEIN: YES.  
12 MS. BONNEVILLE: DAVID HIGGINS.  
13 DR. HIGGINS: YES.  
14 MS. BONNEVILLE: STEPHEN JUELSGAARD.  
15 MR. JUELSGAARD: YES.  
16 MS. BONNEVILLE: RICH LAJARA.  
17 MR. LAJARA: YES.  
18 MS. BONNEVILLE: PAT LEVITT. LINDA  
19 MALKAS. DAVE MARTIN.  
20 DR. MARTIN: YES.  
21 MS. BONNEVILLE: SHLOMO MELMED.  
22 DR. MELMED: YES.  
23 MS. BONNEVILLE: CHRISTINE MIASKOWSKI.  
24 DR. MIASKOWSKI: YES.  
25 MS. BONNEVILLE: LAUREN MILLER-ROGEN.

**BETH C. DRAIN, CA CSR NO. 7152**

1 MS. MILLER-ROGEN: YES.  
2 MS. BONNEVILLE: ADRIANA PADILLA.  
3 DR. PADILLA: YES.  
4 MS. BONNEVILLE: JOE PANETTA.  
5 MR. PANETTA: YES.  
6 MS. BONNEVILLE: AL ROWLETT.  
7 MR. ROWLETT: YES.  
8 MS. BONNEVILLE: BARRY SELICK.  
9 DR. SELICK: YES.  
10 MS. BONNEVILLE: MICHAEL STAMOS.  
11 DR. STAMOS: YES.  
12 MS. BONNEVILLE: JONATHAN THOMAS.  
13 CHAIRMAN THOMAS: YES.  
14 MS. BONNEVILLE: ART TORRES.  
15 MR. TORRES: AYE.  
16 MS. BONNEVILLE: KRISTINA VUORI.  
17 DR. VUORI: YES.  
18 MS. BONNEVILLE: KAROL WATSON.  
19 DR. WATSON: YES.  
20 MS. BONNEVILLE: THANK YOU THE MOTION  
21 CARRIES.  
22 CHAIRMAN THOMAS: THANK YOU, MARIA. THAT  
23 WAS ABOUT AS UNANIMOUS AS YOU CAN POSSIBLY GET.  
24 DR. MILLAN, THANK YOU SO MUCH AGAIN TO YOU  
25 AND YOUR TEAM. CONGRATULATIONS. WE LOOK FORWARD TO

**BETH C. DRAIN, CA CSR NO. 7152**

1 IMPLEMENTING THE PLAN GOING FORWARD AND TO TAKING  
2 CIRM TO THE NEXT GREAT LEVEL.

3 DR. MILLAN: THANK YOU, CHAIRMAN THOMAS,  
4 AND TO THE BOARD FOR YOUR SUPPORT.

5 CHAIRMAN THOMAS: BETH, HOW ARE YOU DOING  
6 AT THE MOMENT?

7 THE REPORTER: A BREAK WILL BE FINE  
8 ANYTIME YOU CHOOSE. IT WORKS FOR ME WHATEVER YOU  
9 LIKE.

10 CHAIRMAN THOMAS: OKAY. LET'S JUST GET  
11 VERY QUICKLY TO THE NEXT TWO-SECOND ITEM HERE. SO  
12 WE HAVE A CONSENT CALENDAR, AS YOU CAN SEE FROM THE  
13 AGENDA. WE HAVE THREE ITEMS ON THAT: CONSIDERATION  
14 OF THE SCIENCE SUBCOMMITTEE MISSION STATEMENT,  
15 CONSIDERATION OF THE FINANCE SUBCOMMITTEE MISSION  
16 STATEMENT, THE CONSIDERATION OF MINUTES FROM  
17 EX-NUMBER OF MONTHS BEFORE TODAY.

18 THE FACT THAT THESE ARE ON CONSENT ISN'T,  
19 CERTAINLY WITH RESPECT TO ITEMS 5 AND 6, ANY  
20 STATEMENT ON THE AMOUNT OF TIME THAT WAS SPENT.  
21 THERE WAS CONSIDERABLE DISCUSSION ON THESE ITEMS,  
22 BUT IT WAS FELT THAT THESE COULD BE CONSENT ITEMS.  
23 SO WE GET A MOTION ON THE CONSENT CALENDAR, ARE  
24 THERE ANY ITEMS THAT ANY MEMBERS WISH TO REMOVE FROM  
25 THE CONSENT CALENDAR ITSELF? OKAY. HEARING NONE,

**BETH C. DRAIN, CA CSR NO. 7152**

1 DO WE HAVE A MOTION TO APPROVE THE CONSENT CALENDAR?

2 DR. BLUMENTHAL: SO MOVED.

3 CHAIRMAN THOMAS: MOVED BY BLUMENTHAL. IS  
4 THERE A SECOND?

5 DR. BARRETT: SECOND.

6 MS. BONNEVILLE: I THINK IT WAS KIM WAS  
7 THE SECOND; IS THAT CORRECT?

8 DR. BARRETT: YES.

9 MS. BONNEVILLE: THANK YOU.

10 CHAIRMAN THOMAS: OKAY. MOVED AND  
11 SECONDED. ANY COMMENT BY MEMBERS OF THE BOARD? ANY  
12 COMMENTS BY MEMBERS OF THE PUBLIC?

13 MS. BONNEVILLE: THERE ARE NO HANDS  
14 RAISED.

15 CHAIRMAN THOMAS: MARIA, WILL YOU CALL THE  
16 ROLL.

17 MS. BONNEVILLE: LAUREN ALVING.

18 DR. ALVING: YES.

19 MS. BONNEVILLE: KIM BARRETT.

20 DR. BARRETT: YES.

21 MS. BONNEVILLE: DAN BERNAL.

22 MR. BERNAL: AYE.

23 MS. BONNEVILLE: GEORGE BLUMENTHAL.

24 DR. BLUMENTHAL: YES.

25 MS. BONNEVILLE: MICHAEL BOTCHAN. LINDA

**BETH C. DRAIN, CA CSR NO. 7152**

1 BOXER.  
2 DR. BOXER: YES.  
3 MS. BONNEVILLE: LEONDR A CLARK-HARVEY.  
4 DEBORAH DEAS.  
5 DR. DEAS: YES.  
6 MS. BONNEVILLE: ANNE-MARIE DULIEGE.  
7 DR. DULIEGE: YES.  
8 MS. BONNEVILLE: YSABEL DURON.  
9 MS. DURON: YES.  
10 MS. BONNEVILLE: MARK FISCHER-COLBRIE.  
11 DR. FISCHER-COLBRIE: YES.  
12 MS. BONNEVILLE: FRED FISHER. ELENA  
13 FLOWERS.  
14 DR. FLOWERS: YES.  
15 MS. BONNEVILLE: JUDY GASSON.  
16 DR. GASSON: YES.  
17 MS. BONNEVILLE: LARRY GOLDSTEIN.  
18 DR. GOLDSTEIN: YES.  
19 MS. BONNEVILLE: DAVID HIGGINS.  
20 DR. HIGGINS: YES.  
21 MS. BONNEVILLE: STEPHEN JUELSGAARD.  
22 MR. JUELSGAARD: YES.  
23 MS. BONNEVILLE: RICH LAJARA.  
24 MR. LAJARA: YES.  
25 MS. BONNEVILLE: LINDA MALKAS. DAVE

**BETH C. DRAIN, CA CSR NO. 7152**

1 MARTIN.  
2 DR. MARTIN: YES.  
3 MS. BONNEVILLE: SHLOMO MELMED.  
4 DR. MELMED: YES.  
5 MS. BONNEVILLE: CHRISTINE MIASKOWSKI.  
6 DR. MIASKOWSKI: YES.  
7 MS. BONNEVILLE: LAUREN MILLER-ROGEN.  
8 MS. MILLER-ROGEN: YES.  
9 MS. BONNEVILLE: ADRIANA PADILLA.  
10 DR. PADILLA: YES.  
11 MS. BONNEVILLE: JOE PANETTA.  
12 MR. PANETTA: YES.  
13 MS. BONNEVILLE: AL ROWLETT.  
14 MR. ROWLETT: YES.  
15 MS. BONNEVILLE: BARRY SELICK.  
16 DR. SELICK: YES.  
17 MS. BONNEVILLE: MICHAEL STAMOS.  
18 DR. STAMOS: YES.  
19 MS. BONNEVILLE: JONATHAN THOMAS.  
20 CHAIRMAN THOMAS: YES.  
21 MS. BONNEVILLE: ART TORRES.  
22 MR. TORRES: AYE.  
23 MS. BONNEVILLE: KRISTINA VUORI.  
24 DR. VUORI: YES.  
25 MS. BONNEVILLE: KAROL WATSON.

**BETH C. DRAIN, CA CSR NO. 7152**

1 DR. WATSON: YES.

2 MS. BONNEVILLE: THE MOTION CARRIES.

3 THANK YOU.

4 CHAIRMAN THOMAS: BETH, I WANT TO DO ONE  
5 MORE ITEM BECAUSE IT IS RELATED TO WHAT WE JUST  
6 VOTED ON. IF YOU WILL BEAR WITH US A BIT LONGER  
7 HERE.

8 SO WE'RE GOING TO TAKE, SINCE WE JUST  
9 ADOPTED THE SCIENCE AND FINANCE SUBCOMMITTEE MISSION  
10 STATEMENTS, I'M GOING TO MOVE ITEM 14 UP, WHICH IS  
11 AN ACTION ITEM, WHICH IS IP AND INDUSTRY  
12 SUBCOMMITTEE MISSION STATEMENT, FOR DISCUSSION HERE.  
13 AND I'LL TURN THIS ITEM OVER TO MR. JUELSGAARD.

14 MR. JUELSGAARD: THANK YOU, MR. CHAIRMAN.  
15 CAN WE DISPLAY THE NEW PROPOSED IP AND INDUSTRY  
16 SUBCOMMITTEE MISSION?

17 MS. BONNEVILLE: DOUG HAS THAT TO DISPLAY.  
18 HE'LL BE PUTTING THAT UP.

19 MR. JUELSGAARD: THANKS. SO LET ME JUST  
20 GIVE A LITTLE BACKGROUND BEFORE WE GET TO THE  
21 MISSION STATEMENT. WHEN I JOINED CIRM BACK IN 2011,  
22 REALLY THE INVOLVEMENT OF INDUSTRY WAS FAIRLY  
23 MEAGER. THERE WAS A REFERENCE TO GERON'S  
24 INVOLVEMENT EARLY ON AT THAT POINT, EARLIER WHEN WE  
25 WERE TALKING ABOUT OS. BUT IT WAS FAR AND FEW

**BETH C. DRAIN, CA CSR NO. 7152**

1 BETWEEN AS FAR AS COMPANIES IN THE PHARMACEUTICAL,  
2 BIOTECH INDUSTRY WHO WERE INVOLVED IN THE  
3 REGENERATIVE MEDICINE SPACE. THAT HAS CHANGED  
4 REMARKEDLY AND DECIDEDLY IN THE INTERVENING YEARS.  
5 AND WHEN WE'VE ADDED ON GENE THERAPY AS AN  
6 ADDITIONAL AREA THAT WE WILL CONSIDER FOR FUNDING,  
7 IT'S ALSO GREATLY INCREASED THE INVOLVEMENT OF  
8 INDUSTRY.

9 SO THERE IS A LOT MORE INTEREST THESE DAYS  
10 IN INDUSTRY IN THE REGENERATIVE MEDICINE SPACE AND  
11 IN GENE THERAPY. AND WE ARE SEEING THAT IN THE  
12 INCREASED NUMBER OF APPLICATIONS FOR FUNDING THAT WE  
13 ARE SEEING. SO AS A RESULT OF THAT, WHEN WE MET, WE  
14 TALKED ABOUT THAT CHANGED CIRCUMSTANCE AND WHAT THAT  
15 MIGHT MEAN FOR THIS COMMITTEE AND THEN ULTIMATELY  
16 FOR THE ORGANIZATION ITSELF.

17 I WANT TO BASICALLY FOCUS ON THE PROPOSED  
18 MISSION STATEMENT, NOT SO MUCH THE HISTORICAL ONE.  
19 SO THERE WERE -- THE FIRST THING WE DID WAS WE  
20 ADDED, AND YOU WILL SEE THAT OUTLINED IN NO. 2 IN  
21 THE PROPOSED STATEMENT, THE NOTION THAT THERE WILL  
22 BE A POSSIBILITY OF DISPUTES COMING DOWN THE ROAD AS  
23 WE CONTINUE WITH THIS ORGANIZATION IN DEALING, NOT  
24 ONLY WITH INDUSTRY, BUT ALSO WITH ACADEMIC CENTERS,  
25 ET CETERA. USUALLY WHEN MONEY IS ON THE TABLE, THAT

**BETH C. DRAIN, CA CSR NO. 7152**

1 IS, NOT WHEN MONEY IS GOING OUT FROM CIRM, BUT WHEN  
2 IT'S SUPPOSED TO BE COMING BACK, THE ISSUE OF  
3 WHETHER OR NOT WE HAVE INTELLECTUAL PROPERTY  
4 COVERING PRODUCTS THAT HAVE BEEN PRODUCED WHICH  
5 INVOLVE CIRM FUNDING AND THINGS OF THAT SORT WILL  
6 BEGIN TO SHOW UP.

7 AND SO ONE OF THE THINGS THAT WE THOUGHT  
8 WOULD BE ADVISABLE IS TO HAVE A SUBGROUP OF THE  
9 BOARD, THAT IS, THIS COMMITTEE, BE INVOLVED IN  
10 OVERSEEING THOSE SORTS OF DISPUTES AND THEIR  
11 ULTIMATE RESOLUTION OR DISPOSITION. OBVIOUSLY THOSE  
12 THINGS WOULD BE BROUGHT TO THE ATTENTION OF THE  
13 BOARD AS THEY -- AT THE APPROPRIATE TIME. SOMEBODY  
14 NEEDS TO KIND OF HELP GUIDE MANAGEMENT'S APPROACH TO  
15 DEALING WITH THESE DISPUTES.

16 THE THIRD ONE IS ESPECIALLY IMPORTANT TO  
17 ME, AND THAT IS NOW THAT WE REFLECT ON THE FACT THAT  
18 INDUSTRY IS MUCH MORE INVOLVED IN THE REGENERATIVE  
19 MEDICINE SPACE AND IN GENE THERAPY, I THINK IT'S  
20 TIME THAT WE EMBRACE INDUSTRY MORE THAN WE HAVE  
21 BEEN. THEY'RE GOING TO BE OUR PARTNERS OR WE SHOULD  
22 MAKE THEM OUR PARTNERS GOING FORWARD IN SO MANY OF  
23 THE THINGS THAT GO ON IN BRINGING PRODUCTS TO  
24 PATIENTS. INDUSTRY IS VERY GOOD AT PHASE III  
25 CLINICAL TRIALS, AT REGULATORY FILINGS, AND

**BETH C. DRAIN, CA CSR NO. 7152**

1 REGULATORY APPROVALS, AND ESTABLISHING A MARKETPLACE  
2 FOR A PRODUCT, ALL OF THOSE SORTS OF THINGS. THAT'S  
3 WHERE THEIR EXPERTISE LIES AND WHERE CIRM'S DOESN'T.

4 IN ANY EVENT, THE NOTION OF NO. 3 IS TO  
5 MORE WILLINGLY BECOME INVOLVED OR -- I'M SORRY --  
6 INVITE INDUSTRY INTO THE GREAT CIRM TENT TO WORK  
7 WITH INDUSTRY ON THOSE AREAS WHERE THEY CAN REALLY  
8 LEND VALUE. SO I'LL JUST PAUSE RIGHT THERE AND SEE  
9 IF THERE ARE ANY QUESTIONS. AND IF NOT, I MOVE  
10 THAT -- EVEN IF THERE ARE, I MOVE THAT THIS MISSION,  
11 PROPOSED MISSION STATEMENT BE ADOPTED.

12 CHAIRMAN THOMAS: SECOND. STEVE, I HAVE  
13 JUST A COMMENT JUST TO ADD ON YOUR POINT THREE  
14 THERE, THAT AS WE ALL KNOW, IN THE VERY EARLY DAYS  
15 THE OVERWHELMING PERCENTAGE OF GRANTS WENT TO  
16 ACADEMIA. THE RATIO OF ACADEMIA TO INDUSTRY HAS  
17 BEEN STEADILY REDUCING, AND AT THIS POINT NOW I  
18 THINK WE ARE OVER 40 PERCENT OF OUR AWARDS ARE GOING  
19 TO INDUSTRY. SO THIS IS A PARTICULARLY SALIENT  
20 POINT HERE THAT STEVE RAISES AND DEFINITELY WARRANTS  
21 NEW AND ADDITIONAL ATTENTION.

22 ARE THERE ANY COMMENTS BY MEMBERS OF THE  
23 BOARD ON THE MOTION? ANY COMMENTS FROM MEMBERS OF  
24 THE PUBLIC?

25 MS. BONNEVILLE: I SEE NO HANDS RAISED.

**BETH C. DRAIN, CA CSR NO. 7152**

1           CHAIRMAN THOMAS: WE HAVE A COMMENT.

2           DR. MILLAN: I COULDN'T LET THIS TIME PASS  
3 WITHOUT JUST EXPRESSING HOW INSTRUMENTAL BOARD  
4 MEMBER JUELSGAARD'S LEADERSHIP AND INPUT HAS BEEN IN  
5 THE MATTERS THAT ARE OUTLINED HERE IN THIS MISSION  
6 STATEMENT AS A SINGLE PERSON, JUST DEALING WITH SO  
7 MANY COMPLEX ASPECTS OF HOW WE CAN BEST SUPPORT OUR  
8 PROGRAMS WHILE MAINTAINING THE INTEREST OF  
9 CALIFORNIA STAKEHOLDERS, WITH HIS EXPERTISE IN TERMS  
10 OF JUST INDUSTRY, IN TERMS OF DRUG DEVELOPMENT, AND  
11 INTELLECTUAL PROPERTY AND HOW ALL THIS COMBINES. SO  
12 IT'S A REALLY EXCITING TIME.

13           I ALSO WANTED TO HIGHLIGHT THAT BRINGING  
14 ON OUR GENERAL COUNSEL, KEVIN MARKS, ALONG WITH BEN  
15 HUANG WHO'S BEEN HERE AT CIRM, TO SUPPORT THIS  
16 EFFORT IS REALLY GOING TO BRING US, I THINK, TO  
17 REALLY EXCITING TIMES. SO I WANTED TO JUST MAKE  
18 THAT COMMENT BECAUSE I WANTED TO EXPRESS THAT  
19 GRATITUDE AND ACKNOWLEDGE BOARD MEMBER JUELSGAARD  
20 FOR ALL THAT HE'S DONE FOR THE CIRM TEAM IN REALLY  
21 HELPING US TO ADDRESS IMPORTANT MATTERS IN THE  
22 TOPICS RAISED HERE IN THIS MISSION STATEMENT. THANK  
23 YOU SO MUCH FOR THAT TIME.

24           MR. JUELSGAARD: THANK YOU, MARIA.

25           DR. MARTIN: I SECOND STEVE'S MOTION.

**BETH C. DRAIN, CA CSR NO. 7152**

1 CHAIRMAN THOMAS: THANK YOU, DAVE. DAVID  
2 HIGGINS, YOU HAVE YOUR HAND UP.

3 DR. HIGGINS: I DIDN'T MEAN TO. I'M  
4 SORRY.

5 CHAIRMAN THOMAS: NICE TO SEE YOU MADE IT  
6 TO YOUR PLACE THERE.

7 ANY OTHER COMMENTS BY MEMBERS OF THE  
8 BOARD? AND AS I UNDERSTAND, NO MORE COMMENTS OR NO  
9 COMMENTS FROM MEMBERS OF THE PUBLIC. SO WITH THAT,  
10 MARIA, WILL YOU PLEASE CALL THE ROLL.

11 MS. BONNEVILLE: LAUREN ALVING.

12 DR. ALVING: YES.

13 MS. BONNEVILLE: KIM BARRETT.

14 DR. BARRETT: YES.

15 MS. BONNEVILLE: DAN BERNAL.

16 MR. BERNAL: AYE.

17 MS. BONNEVILLE: GEORGE BLUMENTHAL.

18 DR. BLUMENTHAL: YES.

19 MS. BONNEVILLE: MICHAEL BOTCHAN. LINDA  
20 BOXER.

21 DR. BOXER: YES.

22 MS. BONNEVILLE: LEONDRA CLARK-HARVEY.  
23 DEBORAH DEAS.

24 DR. DEAS: YES.

25 MS. BONNEVILLE: ANNE-MARIE DULIEGE.

**BETH C. DRAIN, CA CSR NO. 7152**

1 DR. DULIEGE: YES.  
2 MS. BONNEVILLE: YSABEL DURON.  
3 MS. DURON: YES.  
4 MS. BONNEVILLE: MARK FISCHER-COLBRIE.  
5 DR. FISCHER-COLBRIE: YES.  
6 MS. BONNEVILLE: FRED FISHER.  
7 DR. FISHER: YES.  
8 MS. BONNEVILLE: ELENA FLOWERS.  
9 DR. FLOWERS: YES.  
10 MS. BONNEVILLE: JUDY GASSON.  
11 DR. GASSON: YES.  
12 MS. BONNEVILLE: LARRY GOLDSTEIN.  
13 DR. GOLDSTEIN: YES.  
14 MS. BONNEVILLE: DAVID HIGGINS.  
15 DR. HIGGINS: YES.  
16 MS. BONNEVILLE: STEPHEN JUELSGAARD.  
17 MR. JUELSGAARD: YES.  
18 MS. BONNEVILLE: RICH LAJARA.  
19 MR. LAJARA: YES.  
20 MS. BONNEVILLE: LINDA MALKAS. DAVE  
21 MARTIN.  
22 DR. MARTIN: YES.  
23 MS. BONNEVILLE: SHLOMO MELMED.  
24 DR. MELMED: YES.  
25 MS. BONNEVILLE: CHRISTINE MIASKOWSKI.

**BETH C. DRAIN, CA CSR NO. 7152**

1 DR. MIASKOWSKI: YES.  
2 MS. BONNEVILLE: LAUREN MILLER-ROGEN.  
3 MS. MILLER-ROGEN: YES.  
4 MS. BONNEVILLE: ADRIANA PADILLA.  
5 DR. PADILLA: YES.  
6 MS. BONNEVILLE: JOE PANETTA.  
7 MR. PANETTA: YES.  
8 MS. BONNEVILLE: AL ROWLETT.  
9 MR. ROWLETT: YES.  
10 MS. BONNEVILLE: BARRY SELICK.  
11 DR. SELICK: YES.  
12 MS. BONNEVILLE: MICHAEL STAMOS.  
13 DR. STAMOS: YES.  
14 MS. BONNEVILLE: JONATHAN THOMAS.  
15 CHAIRMAN THOMAS: YES.  
16 MS. BONNEVILLE: ART TORRES.  
17 MR. TORRES: AYE.  
18 MS. BONNEVILLE: KRISTINA VUORI.  
19 DR. VUORI: YES.  
20 MS. BONNEVILLE: KAROL WATSON.  
21 DR. WATSON: YES.  
22 MS. BONNEVILLE: THE MOTION CARRIES.  
23 THANK YOU.  
24 CHAIRMAN THOMAS: THANK YOU, MARIA. THANK  
25 YOU, STEVE, FOR ALL YOUR HARD WORK. DOUBLE ECHO

**BETH C. DRAIN, CA CSR NO. 7152**

1 WHAT DR. MILLAN SAID FOR EVERYTHING YOU CONTRIBUTED,  
2 ALL THESE AND OTHER MATTERS. SO THANK YOU.

3 OKAY. BETH, HOW MUCH OF A BREAK WOULD YOU  
4 LIKE HERE?

5 THE REPORTER: ABOUT FIVE MINUTES.

6 CHAIRMAN THOMAS: OKAY. SO IT IS 10:46.  
7 SO HOW ABOUT WE COME BACK AT 10:52 TO GIVE BETH AN  
8 EXTRA MINUTE. WE'LL TAKE A BREAK AND RESUME AT  
9 10:52 ON THE NOSE.

10 (A RECESS WAS TAKEN.)

11 MS. BONNEVILLE: I WANT TO MAKE SURE GIL  
12 IS READY BECAUSE HE'S NEXT ON OUR AGENDA.

13 DR. SAMBRANO: I AM READY.

14 MS. BONNEVILLE: THERE YOU ARE. THANKS,  
15 GIL. OKAY. J.T., I THINK WE ARE GOOD. I HOPE SO.

16 CHAIRMAN THOMAS: NOW RESUMING THE ACTION  
17 ITEM PORTION OF THE AGENDA. WE ARE ON ITEM 8,  
18 CONSIDERATION OF INCREASE TO THE EDUCATION 3 SUMMER  
19 PROGRAM TO ACCELERATE REGENERATIVE MEDICINE  
20 KNOWLEDGE AWARDS PROGRAM BUDGET. DR. SAMBRANO WILL  
21 PRESENT.

22 DR. SAMBRANO: OKAY. THANK YOU, MR.  
23 CHAIRMAN. GOOD MORNING TO EVERYONE. I AM HOPEFULLY  
24 SHARING MY SCREEN AND YOU CAN SEE THE SLIDES. SO  
25 THIS WILL BE A RELATIVELY SHORT PRESENTATION.

**BETH C. DRAIN, CA CSR NO. 7152**

1 SO BACK IN MAY OF THIS YEAR, THE ICOC  
2 APPROVED THE CONCEPT PLAN FOR OUR SPARK TRAINING  
3 PROGRAM, WHICH IS A HIGH SCHOOL SUMMER RESEARCH  
4 EXPERIENCE PROGRAM, SO THAT WE COULD LAUNCH THE CALL  
5 FOR APPLICATIONS.

6 AND SO JUST AS A REMINDER OF WHAT THE  
7 SPARK PROGRAM IS, THIS IS AN INTERNSHIP PROGRAM THAT  
8 WE HAVE NOW SUPPORTED TWO ITERATIONS OF. THE  
9 OBJECTIVE IS TO PROVIDE HIGH SCHOOL STUDENTS WITH  
10 HANDS-ON TRAINING IN STEM CELL RESEARCH THROUGH  
11 SUMMER INTERNSHIPS AND TO REALLY TRY TO INSPIRE THEM  
12 TO PURSUE SCIENCE IN GENERAL, BUT MOST SPECIFICALLY  
13 STEM CELL AND REGENERATIVE MEDICINE. AND SO THE  
14 STUDENTS GET AN OPPORTUNITY DURING THE SUMMER TO  
15 PARTICIPATE IN LABS AS WELL AS GET OTHER  
16 SUPPLEMENTAL TYPE OF TRAINING AND EXPERIENCE.

17 AND SO THIS PROGRAM WAS LAUNCHED. THE  
18 CONCEPT WAS, ONCE IT WAS APPROVED, IT WAS APPROVED  
19 TO SUPPORT UP TO TEN AWARDS WITH A TOTAL BUDGET OF  
20 5.1 MILLION. AND SO NOW THE APPLICATIONS HAVE BEEN  
21 SUBMITTED; THEY HAVE BEEN REVIEWED BY OUR GRANTS  
22 WORKING GROUP.

23 AND SO IT TURNS OUT THAT THE GRANTS  
24 WORKING GROUP RECOMMENDED 11 APPLICATIONS WITH A  
25 TOTAL APPLICANT REQUEST OF ABOUT 5.33 MILLION. SO

**BETH C. DRAIN, CA CSR NO. 7152**

1 THE DIFFERENCE BETWEEN THE AMOUNT THAT WAS ALLOCATED  
2 SHOWN IN THE FUNDS AVAILABLE VERSUS THE AMOUNT THAT  
3 IS IN THE RECOMMENDED FOR FUNDING IS A DIFFERENCE OF  
4 232,462.

5 NOW, THE APPLICATION REVIEW SUBCOMMITTEE  
6 IN THE NEXT ITEM BEFORE THE BOARD IS GOING TO  
7 DETERMINE WHICH APPLICATIONS TO FUND UNDER THIS  
8 PROGRAM. HOWEVER, MAKING THIS BUDGET ADJUSTMENT BY  
9 THE FULL BOARD WOULD ALLOW THE APPLICATION REVIEW  
10 SUBCOMMITTEE THE MAXIMUM FLEXIBILITY TO FUND ALL THE  
11 RECOMMENDED APPLICATIONS IF THEY FEEL IT'S  
12 APPROPRIATE AND DESIRE TO DO SO.

13 AND SO OUR REQUEST, THEN, IS TO INCREASE  
14 THE ALLOCATION TO THE 20/21 SPARK TRAINING PROGRAM  
15 FROM THE 5.1 MILLION TO 5,332,462 TO SUPPORT UP TO  
16 11 AWARDS. SO THAT IS OUR REQUEST. MR. CHAIRMAN.

17 CHAIRMAN THOMAS: THANK YOU, DR. SAMBRANO.  
18 DO WE HAVE A MOTION TO THAT EFFECT?

19 DR. HIGGINS: SO MOVED.

20 CHAIRMAN THOMAS: MOVED BY DAVID. DO WE  
21 HAVE A SECOND?

22 MR. BERNAL: SECOND.

23 CHAIRMAN THOMAS: WE HAVE A MOTION AND A  
24 SECOND. DO WE HAVE ANY COMMENTS OR QUESTIONS ON  
25 THIS ITEM FROM MEMBERS OF THE BOARD? HEARING NONE,

**BETH C. DRAIN, CA CSR NO. 7152**

1 DO WE HAVE ANY PUBLIC COMMENT, MARIA?

2 MS. BONNEVILLE: WE DO NOT.

3 DR. STAMOS: QUICK CLARIFICATION.

4 MS. BONNEVILLE: MICHAEL, IS IT A GENERAL  
5 COMMENT?

6 DR. STAMOS: YES. GENERAL COMMENT. THE  
7 QUESTION IS IF THE COMMITTEE DECIDES ONLY TO AWARD  
8 TEN VERSUS ELEVEN BECAUSE IT'S IN THEIR PURVIEW,  
9 WILL THEN THE BUDGET NECESSARILY REDUCE BACK TO WHAT  
10 IT WAS APPROVED AT PREVIOUSLY?

11 CHAIRMAN THOMAS: YES.

12 DR. SAMBRANO: YES, IT WOULD. SO ANY  
13 REMAINING FUNDS FROM ANY PROGRAM THAT COMES UNDER  
14 THE BUDGET, THE REMAINING AMOUNT GOES INTO THE  
15 UNALLOCATED POOL.

16 CHAIRMAN THOMAS: ANY OTHER COMMENTS OR  
17 QUESTIONS? MARIA, WILL YOU PLEASE CALL THE ROLL.

18 MS. BONNEVILLE: YES. DAN BERNAL.

19 MR. BERNAL: AYE.

20 MS. BONNEVILLE: GEORGE BLUMENTHAL.

21 DR. BLUMENTHAL: YES.

22 MS. BONNEVILLE: LEONDRA CLARK-HARVEY.

23 DR. CLARK-HARVEY: YES.

24 MS. BONNEVILLE: ANNE-MARIE DULIEGE.

25 DR. DULIEGE: YES.

**BETH C. DRAIN, CA CSR NO. 7152**

1 MS. BONNEVILLE: MARK FISCHER-COLBRIE.  
2 DR. FISCHER-COLBRIE: YES.  
3 MS. BONNEVILLE: FRED FISHER.  
4 DR. FISHER: YES.  
5 MS. BONNEVILLE: DAVID HIGGINS.  
6 DR. HIGGINS: YES.  
7 MS. BONNEVILLE: STEPHEN JUELSGAARD. RICH  
8 LAJARA.  
9 MR. LAJARA: YES.  
10 MS. BONNEVILLE: DAVE MARTIN.  
11 DR. MARTIN: YES.  
12 MS. BONNEVILLE: LAUREN MILLER-ROGEN.  
13 MS. MILLER-ROGEN: YES.  
14 MS. BONNEVILLE: ADRIANA PADILLA.  
15 DR. PADILLA: YES.  
16 MS. BONNEVILLE: JOE PANETTA.  
17 MR. PANETTA: YES.  
18 MS. BONNEVILLE: AL ROWLETT.  
19 MR. ROWLETT: YES.  
20 MS. BONNEVILLE: JONATHAN THOMAS.  
21 CHAIRMAN THOMAS: YES.  
22 MS. BONNEVILLE: THE MOTION CARRIES.  
23 CHAIRMAN THOMAS: THANK YOU, MARIA. ON TO  
24 ITEM NO. 9, FOLLOWING ON NO. 8, CONSIDERATION OF  
25 APPLICATIONS SUBMITTED IN RESPONSE TO EDUCATION 3,

**BETH C. DRAIN, CA CSR NO. 7152**

1 SUMMER PROGRAM TO ACCELERATE REGENERATIVE MEDICINE  
2 KNOWLEDGE AWARDS PROGRAM BUDGET. DR. SAMBRANO. AND  
3 WHEN YOU'RE MAKING THE PRESENTATION, WOULD YOU  
4 PLEASE NOTE WHICH OF THE PROPOSED AWARDEES ARE NEW  
5 PROGRAMS FOR THE SPARK PROGRAM? THANK YOU.

6 DR. SAMBRANO: CERTAINLY I CAN DO THAT  
7 AFTER THEY ARE APPROVED, ASSUMING THEY ARE APPROVED.

8 SO I AM SHARING A NEW SLIDE DECK, WHICH I  
9 HOPE YOU CAN SEE. SO THIS IS THE RECOMMENDATIONS  
10 FROM THE GRANTS WORKING GROUP RELATED TO THE CIRM  
11 SPARK TRAINING PROGRAM.

12 JUST A REMINDER, THAT THIS PROGRAM BELONGS  
13 WITHIN OUR EDUCATION PILLAR OF THE FIVE MAJOR  
14 PILLARS THAT WE CONTINUE TO FUND AND SUPPORT. YOU  
15 HAVE SEEN ALREADY THIS YEAR APPLICATIONS THAT HAVE  
16 COME THROUGH AND BEEN APPROVED FOR THE RESEARCH  
17 TRAINING PROGRAM THAT SUPPORTS THE PRE,  
18 POST-DOCTORAL, AND CLINICAL FELLOWS, AS WELL AS THE  
19 BRIDGES PROGRAM THAT SUPPORTS UNDERGRADUATE AND  
20 MASTER'S DEGREE STUDENTS. AND SO AWARDS FOR THOSE  
21 TWO TRAINING PROGRAMS HAVE BEEN APPROVED.

22 SO TODAY WE ARE SEEKING APPROVAL FOR  
23 RECOMMENDATIONS RELATED TO THE SPARK PROGRAM, WHICH  
24 IS OUR HIGH SCHOOL SUMMER RESEARCH EXPERIENCE. I  
25 JUST SHOWED YOU THIS SLIDE IN THE PREVIOUS

**BETH C. DRAIN, CA CSR NO. 7152**

1 PRESENTATION. AND JUST TO NOTE, THE PROGRAM TAKES  
2 OFF OF WHAT WAS ORIGINALLY THE CREATIVITY AWARDS  
3 THAT BEGAN IN 2012. SO WE'VE BEEN SUPPORTING THIS  
4 PROGRAM SINCE 2012 AT THE VARIOUS INSTITUTIONS  
5 THROUGHOUT CALIFORNIA. THERE HAVE BEEN TEN PROGRAMS  
6 ACROSS CALIFORNIA THAT HAVE BEEN SUPPORTED OVER THE  
7 COURSE OF SEVERAL YEARS. THERE ARE SEVEN THAT ARE  
8 CURRENTLY ACTIVE IN NORTHERN AND SOUTHERN  
9 CALIFORNIA.

10 SO THE PROGRAM IS ONE THAT WE HAVE FELT  
11 HAS BEEN SUCCESSFUL IN WHAT IT INTENDED TO DO AS IT  
12 WAS CREATED UNDER THOSE FIRST TWO ITERATIONS. WE  
13 HAVE HAD ABOUT 530 STUDENTS COMPLETE THEIR  
14 INTERNSHIPS SINCE 2012, AND SOME OF THIS DATA HERE  
15 IS WHAT WAS PRESENTED DURING THE CONCEPT  
16 PRESENTATION, BUT I THINK MAY BE WORTH HIGHLIGHTING  
17 AGAIN. OF TRAINEES, MANY OF THESE ARE STILL IN HIGH  
18 SCHOOL, BUT OF 171 ALUMNI WHO REPORTED COLLEGE  
19 ATTENDANCE, WE HAD ABOUT 40 PERCENT THAT WERE  
20 ATTENDING OR ATTENDED A UC SCHOOL, 26 PERCENT THAT  
21 ATTENDED ANOTHER CALIFORNIA SCHOOL SUCH AS STANFORD,  
22 CALTECH, OR A CALIFORNIA STATE UNIVERSITY, 33  
23 PERCENT OF THE STUDENTS WENT ON TO SCHOOLS OUTSIDE  
24 OF CALIFORNIA, INCLUDING INSTITUTIONS SUCH AS YALE,  
25 COLUMBIA, HARVARD, JOHNS HOPKINS, DUKE, AND

**BETH C. DRAIN, CA CSR NO. 7152**

1 PRINCETON. OF THE 141 DECLARED MAJORS, 96 PERCENT  
2 WERE IN BIOLOGY OR SOME OTHER STEM-RELATED FIELD.  
3 SO THE VAST MAJORITY GOING ON INTO SCIENCE CAREERS.

4 THIS IS A GRAPHICAL REPRESENTATION OF SOME  
5 OF THAT DATA THAT I JUST PRESENTED IN TERMS OF THE  
6 CALIFORNIA COLLEGE DISTRIBUTION OF THE STUDENTS WHO  
7 REPORTED WHERE THEY ARE GOING AS WELL AS THOSE WHO  
8 ARE OUTSIDE OF CALIFORNIA, MANY ATTENDING IVY LEAGUE  
9 SCHOOLS OR OTHER PRESTIGIOUS UNIVERSITIES AFTER HIGH  
10 SCHOOL.

11 SO FOR THE 20/21 PROGRAM, THERE ARE SOME  
12 UPDATES THAT WE MADE TO THE PROGRAM, INCLUDING  
13 EXPANDING THE ALLOWABLE SCOPE OF RESEARCH THAT THE  
14 INTERNS COULD PARTICIPATE IN TO INCLUDE NOT JUST  
15 STEM CELL SCIENCE, BUT ALSO GENE THERAPY AND OTHER  
16 RELATED REGENERATIVE MEDICINE RESEARCH.

17 WE ALLOWED INSTITUTIONS TO PARTNER WITH  
18 OTHER ORGANIZATIONS TO INCREASE THE AVAILABILITY OF  
19 HOST LABORATORIES AS WELL AS THE DIVERSITY OF THOSE  
20 LABORATORIES IN TERMS OF THE OPPORTUNITIES FOR GENE  
21 THERAPY AND STEM CELL SCIENCE.

22 WE PROVIDED MORE FORMAL REQUIREMENTS TO  
23 MAINTAIN AND STRENGTHEN THE FOCUS ON DIVERSITY,  
24 EQUITY, AND INCLUSION. SO WHAT THIS MEANS IS HAVING  
25 THEM DEVELOP A SPECIFIC PLAN FOR HOW THEY'RE GOING

**BETH C. DRAIN, CA CSR NO. 7152**

1 TO RECRUIT AND INCLUDE UNDERREPRESENTED AND  
2 UNDERSERVED STUDENTS AND BRING THEM INTO THE  
3 PROGRAM. ALSO TO REQUIRE AN ALUMNI TRACKING PLAN  
4 WHICH IS CRITICAL IN ASSESSING THE PROGRAM OVER THE  
5 COURSE OF TIME, BOTH TO HELP THEM IDENTIFY GAPS IN  
6 THEIR PROGRAM, ELEMENTS THAT THEY NEED TO IMPROVE IN  
7 ORDER TO MOVE FORWARD.

8 AND THEN WE ALSO CHANGED THE BUDGET  
9 STRUCTURE TO INCREASE THE AWARD AMOUNTS TO REFLECT  
10 THE PRESENT ECONOMY AND TO AFFORD MORE FLEXIBILITY  
11 FOR RECRUITING AND APPOINTING A DIVERSE COHORT THAT  
12 INCLUDES SOCIAL ECONOMICALLY DISADVANTAGED STUDENTS.

13 THE SCORING SYSTEM THAT THE GRANTS WORKING  
14 GROUP USED IN ASSIGNING MERIT TO THESE APPLICATIONS  
15 WAS ON A SCALE OF ONE TO A HUNDRED, WITH A SCORE OF  
16 85 TO A HUNDRED MEANING THAT THEY WOULD RECOMMEND  
17 FOR FUNDING IF FUNDS ARE AVAILABLE. THE REVIEW  
18 CRITERIA THAT WERE UTILIZED TO ASSIGN THE SCORE WERE  
19 THE FOLLOWING FOUR KEY QUESTIONS: FIRST, DOES THE  
20 PROPOSED PROGRAM HOLD THE NECESSARY SIGNIFICANCE AND  
21 POTENTIAL FOR IMPACT? IS THE TRAINING PROGRAM PLAN  
22 WELL PLANNED AND DESIGNED? IS IT PRACTICAL AND  
23 ACHIEVABLE? AND DOES IT HAVE A TRACK RECORD AND  
24 OUTCOMES OF THE PRIOR TRAINING PROGRAMS THAT HAS  
25 DEMONSTRATED SUCCESS?

**BETH C. DRAIN, CA CSR NO. 7152**

1 SO THIS IS A SUMMARY TABLE OF THE  
2 RECOMMENDATIONS FROM THE GRANTS WORKING GROUP. AS  
3 MENTIONED EARLIER, THERE WERE 11 APPLICATIONS THAT  
4 WERE RECOMMENDED FOR A TOTAL APPLICANT REQUEST OF  
5 5.33 MILLION. THERE WERE THREE THAT WERE NOT  
6 RECOMMENDED FOR FUNDING.

7 SO OUR CIRM TEAM RECOMMENDATION IS TO FUND  
8 ALL 11 PROJECTS THAT HAVE A SCORE OF 85 OR GREATER.  
9 AND SO THAT CONCLUDES MY PRESENTATION. MR.  
10 CHAIRMAN.

11 CHAIRMAN THOMAS: THANK YOU, DR. SAMBRANO.  
12 BEFORE WE GET TO COMMENTS, DO WE HAVE A  
13 MOTION TO APPROVE?

14 DR. DULIEGE: I MOVE.

15 CHAIRMAN THOMAS: MOVED BY ANNE-MARIE.  
16 SECONDED BY?

17 DR. FISHER: SECOND.

18 CHAIRMAN THOMAS: GREAT. OKAY. MOVED AND  
19 SECONDED. COMMENTS OR QUESTIONS FROM MEMBERS OF THE  
20 BOARD? YSABEL.

21 MS. DURON: THANK YOU VERY MUCH, MR.  
22 CHAIR. I'M NOT ALLOWED TO TALK ABOUT THIS PROGRAM,  
23 BUT WHAT I REALLY WOULD LIKE, GIL, IS FOR US TO ALSO  
24 INCLUDE THE DEMOGRAPHIC BREAKDOWN OF THE  
25 PARTICIPANTS WHO HAVE BEEN IN SPARK. I THINK -- I

**BETH C. DRAIN, CA CSR NO. 7152**

1 LOVE THE PICTURES, ET CETERA, BUT I THINK, GIVEN  
2 THERE ARE MANY HIGH SCHOOLS WHO DO NOT BARELY TEACH  
3 BASIC SCIENCES AND KIDS AREN'T TRACKED TOWARD STEM  
4 PROGRAMS AND DON'T KNOW THEY CAN BECOME THESE  
5 SCIENTISTS OF THE FUTURE, WHO DON'T EVEN KNOW IF  
6 THEY UNDERSTAND WHAT STEM IS, I WOULD LIKE US TO BE  
7 ABLE TO SHOW EXAMPLES OF SUCCESS FROM THESE  
8 COMMUNITIES. I WOULD LOVE TO ALWAYS BE ABLE TO TALK  
9 ABOUT SPARK AND THE NUMBERS OF KIDS OF COLOR WHO ARE  
10 COMING OUT OF VULNERABLE POPULATIONS AND LOW-INCOME  
11 COMMUNITIES. SO I WOULD LOVE IF YOU COULD SHOW IN  
12 THE DEMOGRAPHICS OR IN YOUR LIST OF ALL OF THESE  
13 WONDERFUL THINGS ABOUT THESE PARTICIPANTS, IF WE CAN  
14 ALSO GET A DEMOGRAPHIC BREAKDOWN. I THINK THAT  
15 WOULD HELP ALL OF US IN TALKING ABOUT SPARK WHEREVER  
16 WE GO AND TO WHOMEVER WE SPEAK WHY THIS SHOWS A REAL  
17 BIG ACCOMPLISHMENT FOR CIRM, THAT WE ARE GETTING  
18 KIDS FROM THESE VULNERABLE POPULATIONS INTO THE  
19 MAINSTREAM OF SCIENCE AND BECOMING, HOPEFULLY, OUR  
20 FUTURE SCIENTISTS AND RESEARCHERS. THANK YOU.

21 CHAIRMAN THOMAS: THANK YOU, YSABEL. GIL,  
22 DO YOU WANT TO COMMENT ON THAT?

23 DR. SAMBRANO: SURE. I THINK THAT'S A  
24 GREAT SUGGESTION, AND IT IS AND DOES ALIGN WITH WHAT  
25 WE INTEND TO DO. I THINK OVER THE LAST TWO

**BETH C. DRAIN, CA CSR NO. 7152**

1 ITERATIONS OF THIS PROGRAM THAT WAS NOT A SPECIFIC  
2 REQUIREMENT THAT WE HAD. SO I THINK THE DATA THAT  
3 WE HAVE FOR THAT PROGRAM IS A LITTLE BIT SPARSE IN  
4 TERMS OF RACE, ETHNIC, AND GENDER DIVERSITY. BUT  
5 UNDER THESE PROGRAMS THAT WE ARE HOPING TO FUND, THE  
6 REQUIREMENTS HAVE INCREASED. SO OUR HOPE IS THAT,  
7 EVEN WITHIN THE FIRST YEAR, WE WILL BE ABLE TO HAVE  
8 BETTER REPORTING ACROSS DIFFERENT PROGRAMS IN TERMS  
9 OF WHO IS COMING INTO THE PROGRAM AND BETTER  
10 OUTCOMES AS THE PROGRAMS PROGRESS.

11 ONE OF THE OTHER THINGS THAT I THINK CAME  
12 OUT OF THE GRANTS WORKING GROUP MEETING WAS THAT  
13 THEY OBSERVED, AND YOU MAY HAVE SEEN IT IN THE  
14 COMMENTS IN THE SUMMARIES, THAT SOME PROGRAMS HAD  
15 BETTER PLANS THAN OTHERS IN ADDRESSING HOW THEY WERE  
16 GOING TO TARGET AND RECRUIT UNDERSERVED MEMBERS OF  
17 THE COMMUNITY INTO THE INTERNSHIP PROGRAM. AND SO  
18 THE SHARING OF THAT INFORMATION ACROSS PROGRAMS IS  
19 IMPORTANT, AND SO THAT IS ANOTHER ELEMENT THAT WE  
20 INTEND TO INCORPORATE TO TRY TO TAKE BEST PRACTICES  
21 AND GOOD IDEAS FROM ONE PROGRAM THAT MAY HELP OTHERS  
22 ACHIEVE THE SAME THING OR PERHAPS BETTER. SO THANK  
23 YOU FOR YOUR SUGGESTION.

24 CHAIRMAN THOMAS: THANK YOU, GIL. I'LL  
25 JUST NOTE ANECDOTALLY, AS EVERYBODY HERE KNOWS, I'VE

**BETH C. DRAIN, CA CSR NO. 7152**

1 SAID IT A BUNCH OF TIMES, THIS IS ONE OF MY ABSOLUTE  
2 FAVORITE PROGRAMS THAT WE FUND. IT'S THE STARTING  
3 GATE FOR BUILDING UP THE WORKFORCE PIPELINE AND THE  
4 LEVEL OF ENTHUSIASM THAT THESE KIDS APPROACH THIS  
5 PROGRAM WITH AND THE AMOUNT OF KNOWLEDGE THEY GET  
6 OUT OF IT IS TRULY REMARKABLE.

7 BUT THE POINT I WANTED TO RAISE  
8 SPECIFICALLY HERE, YSABEL, IS I'VE GONE TO EVERY  
9 SPARK END-OF-PROGRAM CELEBRATION OVER THE YEARS.  
10 AND IT IS A, WITHOUT FAIL EVERY YEAR, REMARKABLY  
11 DIVERSE GROUP OF KIDS THAT HAVE GONE THROUGH THE  
12 PROGRAM. SO IT IS SOMETHING THAT THE PROGRAMS  
13 THEMSELVES HAVE CLEARLY SOUGHT TO FURTHER, AND WE  
14 ABSOLUTELY, AS ALWAYS, APPRECIATE YOUR COMMENTS.  
15 AND SEE IF WE CAN CONTINUE TO EVEN INCREASE THAT  
16 EXPOSURE GOING FORWARD. OKAY.

17 FRED, I THINK YOU WERE NEXT.

18 DR. FISHER: ALONG THE LINES OF WHAT WE'VE  
19 BEEN TALKING ABOUT, AS WE MAKE OUR WAY TO MORE  
20 EFFECTIVELY EVALUATING THE DEI COMPONENTS OF ALL THE  
21 PROPOSALS, THAT PRIORITY EXISTS HERE TOO. SO I'M  
22 HOPEFUL THAT IN THE FUTURE WE CAN HAVE DATA ABOUT  
23 ACCESS AND INCLUSION OF UNDERSERVED OR  
24 UNDERREPRESENTED STUDENTS IN THIS PROGRAM, NOT JUST  
25 BECAUSE IT HELPS US TALK ABOUT THE PROGRAM BETTER,

**BETH C. DRAIN, CA CSR NO. 7152**

1 BUT IT HELPS US EVALUATE THE EFFECTIVENESS OF  
2 ACHIEVING THAT PRIORITY.

3 AND, GIL, I DIDN'T SEE, OR MAYBE I MISSED  
4 IT, ON THE REVIEW CRITERIA THAT YOU LISTED, I DIDN'T  
5 SEE DEI PRIORITIES LISTED AS ONE OF THOSE REVIEW  
6 CRITERIA. DID I MISS IT, OR IS IT NOT IN THERE YET?

7 DR. SAMBRANO: IT'S THERE. IT'S IN THE  
8 SUBQUESTION. SO I JUST SHOWED YOU KIND OF THE HIGH  
9 LEVEL SUMMARY OF IT, BUT IT IS DEFINITELY INCLUDED.  
10 AND I WILL ADD THAT THE APPLICATIONS DID ASK FOR  
11 DEMOGRAPHIC INFORMATION TO BE INCLUDED, AND SO THAT  
12 WAS PART OF THE EVALUATION. AS YOU MAY RECALL,  
13 THERE WERE MANY COMMENTS RELATED TO THAT BY  
14 REVIEWERS FROM MANY OF THE PROGRAMS. SOME DID  
15 BETTER THAN OTHERS IN THEIR APPROACHES.

16 DR. FISHER: SO I JUST WANTED TO JUST  
17 ILLUMINATE THAT FOR THE OTHER PEOPLE IN THIS MEETING  
18 THAT MAY NOT HAVE SEEN THAT OR MAY NOT KNOW THAT.  
19 SO THANK YOU. AND WE CAN A YEAR FROM NOW BE  
20 REPORTING ON THAT TOO. I THINK THAT WOULD HELP.

21 CHAIRMAN THOMAS: THANK YOU, FRED. I  
22 THINK ADRIANA WAS NEXT, THEN ANNE-MARIE, THEN  
23 DEBORAH. SO ADRIANA.

24 DR. PADILLA: YES, THANK YOU. JUST I'M  
25 VERY HAPPY TO SEE THE NUMBER OF PROGRAMS THAT ARE

**BETH C. DRAIN, CA CSR NO. 7152**

1 APPLYING FOR THIS GRANT AWARD. AND I'M SURE THAT  
2 THEY'RE ALL WORKING VERY HARD TO RECRUIT DIVERSE  
3 STUDENTS FROM THEIR LOCAL AREAS, BUT I CAN'T HELP  
4 BUT NOTICE THAT IT'S ALL NORTHERN CALIFORNIA AND  
5 SOUTHERN CALIFORNIA AND NOTHING IN THE CENTRAL  
6 VALLEY OR OTHER AREAS OF UNDERSERVED LOCATIONS IN  
7 CALIFORNIA.

8 IS THERE ANYTHING IN THE REVIEW CRITERIA,  
9 GIL, ABOUT REACHING OUT TO DIFFERENT AREAS THAT HAVE  
10 NOT HAD THE OPPORTUNITY TO PUT TOGETHER PROGRAMS TO  
11 HELP THE LOCAL STUDENTS FROM THESE UNDERSERVED AREAS  
12 OF CALIFORNIA?

13 DR. SAMBRANO: THERE'S AN OPPORTUNITY FOR  
14 ALL THE APPLICANTS, WHEN THEY SUBMITTED THE  
15 APPLICATION, TO BRING IN A PARTNER. THAT COULD BE  
16 FROM ANYWHERE. SO THAT WAS PART OF IT, BUT I THINK  
17 ALSO THEY HAVE THE OPPORTUNITY ONCE FUNDED TO EXPAND  
18 ANY PARTNERSHIPS. SO IT IS SOMETHING THAT WE CAN  
19 CERTAINLY ENCOURAGE PROGRAMS THAT ARE FUNDED TO DO  
20 AS THEY EXPAND THEIR OUTREACH AND/OR THINK OF  
21 STRATEGIES FOR OUTREACH IN ORDER TO BRING IN A MORE  
22 DIVERSE SET OF STUDENTS INTO THE PROGRAM. SO IT CAN  
23 CERTAINLY BE A PART OF IT.

24 THERE ARE A COUPLE OF PROGRAMS IN THERE  
25 THAT ARE -- ONE IS THE INLAND EMPIRE AND ONE IN

**BETH C. DRAIN, CA CSR NO. 7152**

1 CENTRAL CALIFORNIA THAT IS INCLUDED AS WELL.

2 DR. PADILLA: OKAY. GREAT. NICE TO HEAR.  
3 THANK YOU.

4 CHAIRMAN THOMAS: THANK YOU. ANNE-MARIE.

5 DR. DULIEGE: SO EXCELLENT PRESENTATION,  
6 GIL. THANK YOU. AND LIKE YOU, JONATHAN, AND LIKE  
7 ALL OF US, WE REALLY ADORE THIS PROGRAM.

8 GIL, CAN YOU GIVE US A ROUGH IDEA OF HOW  
9 MANY STUDENTS DO YOU THINK WILL BE IMPACTED BY THIS  
10 NEW GRANT? WE HEAR THAT THERE'S TEN INSTITUTIONS.  
11 SO HOW MANY STUDENTS DOES THIS POTENTIALLY  
12 REPRESENT?

13 DR. SAMBRANO: SO WHAT WE WERE TARGETING  
14 WAS ABOUT 500 WITH TEN INSTITUTIONS. SO WITH ELEVEN  
15 IT WOULD ADD MAYBE ABOUT 50 MORE. SO ABOUT 550  
16 INTERNS OVER THE COURSE OF THIS PROGRAM.

17 DR. DULIEGE: THANK YOU.

18 CHAIRMAN THOMAS: DEBORAH.

19 DR. DEAS: YES. I NOTICE IN THE SELECTION  
20 CRITERIA ONE OF THE CRITERIA WAS HAVING A TRACK  
21 RECORD ABOUT OUTCOMES. AND I THINK THIS GOES ALONG  
22 WITH ADRIANA'S COMMENT. IF THAT IS A CRITERIA, THEN  
23 WE INADVERTENTLY OR THE UNINTENTIONAL CONSEQUENCE IS  
24 THOSE PROGRAMS THAT HAVE NOT HAD SPARK WOULD NOT  
25 HAVE A TRACK RECORD, THEREFORE, WOULD NOT RANK

**BETH C. DRAIN, CA CSR NO. 7152**

1 HIGHLY TO BE ACCEPTED AS A PROGRAM. AM I CORRECT ON  
2 THAT?

3 DR. SAMBRANO: SO NOT NECESSARILY. I  
4 THINK CERTAINLY HAVING A SPARK PROGRAM PREVIOUSLY  
5 HELPS, BUT THE TRACK RECORD REALLY IS ABOUT ANY  
6 SUMMER PROGRAM THAT MIGHT BE SIMILAR. AND SO  
7 ACTUALLY IN THIS GROUP OF RECOMMENDED APPLICATIONS  
8 THERE ARE FIVE NEW PROGRAMS THAT HAVE NEVER HAD A  
9 SPARK PROGRAM BEFORE. AND SO MANY OF THEM HAVE AN  
10 EXISTING SUMMER PROGRAM, AND SO THE TRACK RECORD IS  
11 REPRESENTED IN THOSE IN TERMS OF HOW THEY DID EVEN  
12 THOUGH IT'S NOT NECESSARILY OR SPECIFICALLY SPARK.

13 DR. DEAS: THANK YOU.

14 CHAIRMAN THOMAS: OKAY. ARE THERE ANY  
15 OTHER COMMENTS OR QUESTIONS FROM MEMBERS OF THE  
16 BOARD? ANY COMMENTS FROM MEMBERS OF THE PUBLIC?

17 I JUST WANT TO REMIND EVERYBODY, WHICH I  
18 WAS REMISS IN, WE ARE NOW IN THE APPLICATION REVIEW  
19 SUBCOMMITTEE PORTION OF THE AGENDA. SO THE VOTERS  
20 ON THIS MOTION WILL BE THOSE MEMBERS FROM THAT  
21 SUBCOMMITTEE. SO WITH THAT, MARIA, WILL YOU PLEASE  
22 CALL THE ROLL.

23 MS. BONNEVILLE: SURE. AS A REMINDER, IF  
24 YOU HAVE A CONFLICT, YOU WOULD SAY YES OR NO EXCEPT  
25 FOR THOSE WITH WHICH I HAVE A CONFLICT.

**BETH C. DRAIN, CA CSR NO. 7152**

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25

MS. BONNEVILLE: DAN BERNAL.  
MR. BERNAL: YES.  
MS. BONNEVILLE: ANNE-MARIE DULIEGE.  
DR. DULIEGE: YES.  
MS. BONNEVILLE: YSABEL DURON.  
MS. DURON: YES, EXCEPT FOR THOSE WITH  
WHICH I HAVE A CONFLICT.  
MS. BONNEVILLE: MARK FISCHER-COLBRIE.  
DR. FISCHER-COLBRIE: YES.  
MS. BONNEVILLE: FRED FISHER.  
DR. FISHER: YES.  
MS. BONNEVILLE: ELENA FLOWERS.  
DR. FLOWERS: YES, EXCEPT THOSE FOR WHICH  
I HAVE A CONFLICT.  
MS. BONNEVILLE: LEONDRA CLARK-HARVEY.  
DR. CLARK-HARVEY: YES.  
MS. BONNEVILLE: DAVID HIGGINS.  
DR. HIGGINS: YES.  
MS. BONNEVILLE: STEPHEN JUELSGAARD.  
MR. JUELSGAARD: YES.  
MS. BONNEVILLE: RICH LAJARA.  
MR. LAJARA: YES.  
MS. BONNEVILLE: DAVE MARTIN.  
DR. MARTIN: YES.  
MS. BONNEVILLE: CHRISTINE MIASKOWSKI.

**BETH C. DRAIN, CA CSR NO. 7152**

1 DR. MIASKOWSKI: YES, EXCEPT FOR THOSE  
2 WITH WHICH I HAVE A CONFLICT.

3 MS. BONNEVILLE: LAUREN MILLER-ROGEN.

4 MS. MILLER-ROGEN: YES.

5 MS. BONNEVILLE: ADRIANA PADILLA.

6 DR. PADILLA: YES.

7 MS. BONNEVILLE: JOE PANETTA.

8 MR. PANETTA: YES.

9 MS. BONNEVILLE: AL ROWLETT.

10 MR. ROWLETT: YES.

11 MS. BONNEVILLE: JONATHAN THOMAS.

12 CHAIRMAN THOMAS: YES.

13 MS. BONNEVILLE: ART TORRES. KAROL  
14 WATSON.

15 DR. WATSON: YES, EXCEPT FOR THOSE WITH  
16 WHICH I HAVE A CONFLICT.

17 MS. BONNEVILLE: THANK YOU SO MUCH. THE  
18 MOTION CARRIES.

19 CHAIRMAN THOMAS: THANK YOU, MARIA. THANK  
20 YOU, GIL. AND, GIL, ARE YOU NOW AT LIBERTY TO  
21 ANSWER THE QUESTION I ASKED AT THE OUTSET?

22 DR. SAMBRANO: YES, ABSOLUTELY, MR.  
23 CHAIRMAN. SO, YES, WE DO HAVE FIVE NEW PROGRAMS AT  
24 FIVE INSTITUTIONS THAT INCLUDE CHARLES DREW  
25 UNIVERSITY, UC RIVERSIDE, UC SAN DIEGO, THE

**BETH C. DRAIN, CA CSR NO. 7152**

1 SANFORD-BURNHAM RESEARCH INSTITUTE, AND CHILDREN'S  
2 HOSPITAL OF LOS ANGELES. THOSE ARE NEW, NEVER  
3 BEFORE HAD A SPARK PROGRAM. SO WE CERTAINLY WELCOME  
4 THEM TO THAT SPARK OVERALL PROGRAM.

5 CHAIRMAN THOMAS: THANK YOU. AND  
6 ABSOLUTELY SECOND THAT COMMENT.

7 OKAY. ON TO NOW --

8 MR. TORRES: I WAS MUTE. WAS I CALLED ON  
9 THAT ROLL CALL?

10 MS. BONNEVILLE: YES, YOU WERE.

11 MR. TORRES: VOTE IS AYE.

12 MS. BONNEVILLE: EXCEPT FOR THOSE WITH  
13 WHICH YOU HAVE A CONFLICT?

14 MR. TORRES: EXCEPT FOR THOSE WITH WHICH I  
15 HAVE A CONFLICT.

16 MS. BONNEVILLE: THANK YOU SO MUCH.

17 MR. TORRES: THAT MARIA TOLD ME ABOUT.

18 CHAIRMAN THOMAS: ON TO ITEM NO. 10,  
19 CONSIDERATION OF REVISED CIRM RESEARCH BUDGET FOR  
20 THE FISCAL YEAR. AND POUNEH IS GOING TO GIVE A  
21 PRESENTATION; BUT, LARRY, WOULD YOU LIKE TO FRAME  
22 THIS UP AS CHAIR OF THE SCIENCE SUBCOMMITTEE?

23 DR. GOLDSTEIN: SURE. THANK YOU, J.T. SO  
24 IN MY ROLE AS CHAIR OF THE SCIENCE SUBCOMMITTEE, I  
25 MET WITH POUNEH AND OTHER MEMBERS OF CIRM STAFF TO

**BETH C. DRAIN, CA CSR NO. 7152**

1 DISCUSS HOW SOME OF THE NUMBERS WERE GENERATED. IN  
2 PARTICULAR, AS YOU WILL SEE THE NUMBER FOR THE  
3 TRANSLATIONAL GRANTS, I'M SATISFIED THAT THEY USED  
4 THE APPROPRIATE APPROACH. IT THEN WENT TO THE  
5 SCIENCE SUBCOMMITTEE, WHICH APPROVED IT UNANIMOUSLY.

6 AND I GUESS THE ONLY THING I DO WANT TO  
7 ADD IS THAT THAT TRANSLATIONAL PIECE IS ABSOLUTELY  
8 CRITICAL TO GETTING INTERESTING IDEAS AND CANDIDATE  
9 THERAPIES INTO HUMAN CLINICAL TRIALS. THOSE OF YOU  
10 WHO HAVE NEVER DONE THIS MAY NOT APPRECIATE JUST HOW  
11 DIFFICULT IT IS TO MAKE IT FROM AN INTERESTING IDEA  
12 OR REAGENT THROUGH THE FDA AND ON TO THE INITIATION  
13 OF TRIALS. AND SO I THINK THAT THE BUDGET INCREASE  
14 IS WARRANTED. POUNEH CAN, OF COURSE, ANSWER ANY  
15 QUESTIONS ABOUT THE DETAILS. AND I THINK AT THIS  
16 POINT LET ME JUST TURN IT OVER TO POUNEH.

17 MS. SIMPSON: SO GOOD MORNING, EVERYBODY.  
18 I'M POUNEH SIMPSON, THE DIRECTOR OF FINANCE. THANK  
19 YOU FOR THE OPPORTUNITY TO PRESENT THE RESEARCH  
20 BUDGET TO YOU TODAY.

21 JUST TO GET STARTED, AS A REMINDER, AFTER  
22 THE PASSAGE OF PROP 14, THE CIRM TEAM PRESENTED A  
23 PROPOSED FISCAL YEAR 21/22 RESEARCH BUDGET IN JUNE.  
24 THE ICOC APPROVED THAT BUDGET WITH THE UNDERSTANDING  
25 THAT A NEW CONCEPT PROPOSAL WOULD BE BROUGHT FORTH

**BETH C. DRAIN, CA CSR NO. 7152**

1 WITH THE ROLLOUT OF THE FIVE-YEAR STRATEGIC PLAN  
2 THAT DR. MILLAN JUST PRESENTED. SO TODAY WE'RE  
3 GOING TO BE PRESENTING THAT MID-YEAR BUDGET PROPOSAL  
4 WITH THE AGENDA OF JUST FIRST DOING A RECAP OF WHAT  
5 THE BOARD APPROVED IN JUNE AND THEN PRESENTING THE  
6 MID-YEAR BUDGET TO YOU.

7 SO WITH SLIDE 3 WE'LL JUST GET STARTED  
8 WITH WHAT WAS APPROVED IN JUNE. THE BOARD APPROVED  
9 \$360 MILLION IN RESEARCH GRANTS, WHICH WE HAVE  
10 APPLICATIONS IN PROGRESS FOR FOR THIS FISCAL YEAR.  
11 AND NOW I'LL PRESENT THE CHANGES THAT WE WOULD LIKE  
12 TO MAKE TO THIS.

13 SO IN THIS CHART YOU SEE THE DIFFERENT  
14 PROGRAMS, PILLAR PROGRAMS, THAT WE FUND. AND IN  
15 COLUMN 2 IS THE BUDGET THAT WAS APPROVED BY THE  
16 BOARD, \$360 MILLION. WE ARE PROPOSING AN ADDITION  
17 OF 114 MILLION AS PART OF THE MID-YEAR: 34 MILLION  
18 IN TRANSLATIONAL GRANTS AND 80 MILLION IN  
19 INFRASTRUCTURE GRANTS.

20 WITH REGARDS TO THE 34 MILLION IN  
21 TRANSLATIONAL GRANTS, THE APPROVED FUNDING LEVEL FOR  
22 THIS CATEGORY WAS PREVIOUSLY BENCHMARKED TO COSTS IN  
23 PRIOR FUNDING ROUNDS. HOWEVER, THERE WAS AN  
24 INCREASED TREND IN THE FIRST ROUND OF FUNDING IN  
25 OCTOBER OF THIS FISCAL YEAR. THIS MID-YEAR

**BETH C. DRAIN, CA CSR NO. 7152**

1 ADJUSTMENT SUPPORTS ADDITIONAL GRANTS FOR THE SECOND  
2 CYCLE IN THIS FISCAL YEAR BASED ON THAT INCREASING  
3 TREND.

4 THE 80 MILLION IN INFRASTRUCTURE GRANTS IS  
5 THE FISCAL COMPONENT OF THE PROGRAMS ANTICIPATED IN  
6 THE STRATEGIC PLAN THAT DR. MILLAN PRESENTED.

7 SO JUST TO POINT OUT THE MID-YEAR BUDGET  
8 REQUEST WILL BE FOLLOWED BY A MORE DETAILED CONCEPT  
9 PROPOSAL AND GRANT DETAILS.

10 AND SO, FINALLY, IN THE LAST COLUMN, IS  
11 THE TOTAL PROPOSED RESEARCH BUDGET THAT WE ARE  
12 REQUESTING FOR A TOTAL OF \$474 MILLION. SO TODAY WE  
13 ARE ASKING THE ICOC TO APPROVE THE \$114 MILLION  
14 INCREASE. AND I'LL STOP AT THIS POINT TO ANSWER ANY  
15 QUESTIONS. AND IF THERE AREN'T ANY, I'LL MOVE TO  
16 THE ADMINISTRATIVE BUDGET.

17 CHAIRMAN THOMAS: DO WE HAVE A -- FRED,  
18 HOLD ON ONE SECOND. DO WE HAVE A MOTION TO APPROVE  
19 THE RESEARCH BUDGET?

20 DR. FISHER: I'LL MOVE.

21 DR. MIASKOWSKI: SECOND.

22 MS. BONNEVILLE: YES. FRED AND CHRISTINE.

23 CHAIRMAN THOMAS: THANK YOU. FRED.

24 DR. FISHER: ARE THERE SPECIFIC PRIORITIES  
25 CONNECTED TO THE INFRASTRUCTURE BUDGET? OR WHERE

**BETH C. DRAIN, CA CSR NO. 7152**

1 WOULD I FIND INFORMATION ABOUT THAT?

2 MS. SIMPSON: SO I'M GOING TO DEFER TO DR.  
3 MILLAN ON THAT.

4 DR. MILLAN: AS PRESENTED DURING THE  
5 STRATEGIC PLAN, ONE OF THE MAJOR INFRASTRUCTURE  
6 PROGRAMS THAT'S LIKELY TO ROLL OUT FIRST IS THE  
7 ALPHA CLINICS EXPANSION PROGRAM. AND THOUGH WE  
8 DON'T HAVE AN EXACT BUDGET FOR THAT, THAT WOULD BE  
9 PRESENTED ALONG WITH THE CONCEPT PROPOSAL. THIS IS  
10 AN ESTIMATED PROJECTED BUDGET THAT WOULD ALLOW US TO  
11 SUPPORT MAKING ACTIVE THE APPLICATIONS FOR THAT  
12 PARTICULAR CONCEPT, UPON BOARD APPROVAL OF COURSE.

13 DR. FISHER: JUST A QUICK FOLLOW-UP. HOW  
14 DOES THIS COMPARE TO THE INFRASTRUCTURE SPENDING  
15 FROM THE PROP 71 PROGRAM?

16 CHAIRMAN THOMAS: SO I CAN GIVE YOU -- TO  
17 BEGIN WITH, AT THE VERY OUTSET WHEN WE WERE BUILDING  
18 THE VARIOUS INSTITUTES, THE 12 DIFFERENT INSTITUTES,  
19 WHICH ARE EITHER FREESTANDING BUILDINGS OR  
20 RENOVATIONS OF EXISTING BUILDINGS, WE SPENT ABOUT, I  
21 THINK IT WAS, 270 MILLION ON INFRASTRUCTURE IN THE  
22 EARLY DAYS. WE HAVE HAD SINCE THEN A NUMBER OF  
23 PROGRAMS THAT HAVE COME UNDER THE TERM  
24 "INFRASTRUCTURE" WHICH ARE NOT BRICK AND MORTAR, BUT  
25 ARE TERMED THAT FOR VARIOUS REASONS, WHICH INCLUDE

**BETH C. DRAIN, CA CSR NO. 7152**

1 THE ALPHA CLINICS, THE IPSC CELL BANK, AND THE  
2 GENOMICS CENTERS OF EXCELLENCE. I DON'T HAVE AN  
3 EXACT NUMBER OFF THE TOP OF MY HEAD, BUT IT'S TENS  
4 OF MILLIONS MORE ON TOP OF THAT.

5 GIL, WOULD YOU HAPPEN TO HAVE AN IDEA ON  
6 THOSE LATTER THREE?

7 DR. SAMBRANO: I DON'T UNFORTUNATELY.

8 CHAIRMAN THOMAS: OKAY. THAT'S THE SCOPE.

9 DR. MILLAN: SO WE SPENT IN THE PROP 71  
10 ERA APPROXIMATELY 480 MILLION PLUS A LITTLE BIT MORE  
11 FOR INFRASTRUCTURE. AND AS J.T. HAD MENTIONED, A  
12 LOT OF THAT WAS IN THE EARLY DAYS OF BUILDING THE  
13 LABS WHEN THEY WERE REQUIRED IN ORDER TO CONDUCT THE  
14 RESEARCH. AND THEN THE LATER PROGRAMS WERE  
15 PROGRAMMATIC INFRASTRUCTURE, SUCH AS ALPHA CLINICS  
16 NETWORK AND CREATION OF IPSC BANKS FOR RESEARCH AND  
17 THE GENOMICS INITIATIVE, WHICH WAS APPROXIMATELY IN  
18 THE \$50 MILLION RANGE AS A PROGRAM INFRASTRUCTURE.

19 THIS PROJECTION IS BASED ON BENCHMARKS FOR  
20 WHAT THE ALPHA CLINICS PROGRAMS HAD RECEIVED FOR  
21 FUNDING IN THE PAST. AND, AGAIN, THESE WILL BE MORE  
22 FINELY TUNED IN TERMS OF THE ACTUAL BUDGET ASK ONCE  
23 THE CONCEPT IS MORE READY TO BRING TO THE BOARD.

24 DR. FISHER: HELPFUL. THANKS.

25 DR. MILLAN: AND THERE WILL BE NO BRICKS

**BETH C. DRAIN, CA CSR NO. 7152**

1 AND MORTAR INVESTMENT INTO THE EXPANSION. THIS WILL  
2 BE ALL PROGRAM BASED.

3 CHAIRMAN THOMAS: OKAY. THANK YOU.  
4 DEBORAH.

5 DR. DEAS: YES. MY QUESTION WAS SIMILAR  
6 TO FRED'S. I WANTED TO SORT OF UNDERSTAND MORE  
7 ABOUT THIS INFRASTRUCTURE BUDGET INCREASE AND ALSO  
8 TRYING TO UNDERSTAND WHY AN INFRASTRUCTURE LINE ITEM  
9 BUDGET WASN'T INCLUDED AT THE BEGINNING. WHEN WE  
10 LOOK AT THE MID-YEAR ADJUSTMENT, IT'S A THIRD  
11 INCREASE OF THE ENTIRE BUDGET. SO IT'S SIGNIFICANT.

12 AND SOME OF THE COMMENTS MADE EARLIER  
13 ANSWERED MY CONCERN, BUT I JUST THINK IN THE FUTURE,  
14 WHEN WE ARE MAKING MID-YEAR ADJUSTMENTS, WE NEED TO  
15 MORE CAREFULLY DELINEATE AND EXPLAIN UP FRONT WHAT  
16 THEY ARE BECAUSE THIS THIRD OF THE BUDGET INCREASE  
17 IS VERY SIGNIFICANT FOR A MID-YEAR ADJUSTMENT.

18 DR. MILLAN: MAY I COMMENT, CHAIRMAN  
19 THOMAS?

20 CHAIRMAN THOMAS: SURE.

21 DR. MILLAN: DEAN DEAS, WE HAD ALREADY  
22 ESTIMATED IN JUNE THAT WE WOULD BE BRINGING A  
23 SIGNIFICANT ASK TO THIS MEETING BECAUSE WE DID NOT  
24 YET HAVE A STRATEGIC PLAN, WHICH WE JUST ROLLED OUT  
25 TODAY. SO THIS IS AN UNUSUAL YEAR, AND WE DON'T

**BETH C. DRAIN, CA CSR NO. 7152**

1 TYPICALLY HAVE MID-YEAR ADJUSTMENTS. WE DON'T  
2 EXPECT WE WILL IN THE FUTURE YEARS UNLESS SOMETHING  
3 UNFORESEEABLE HAPPENS. AND IT'S REALLY JUST RELATED  
4 TO THE TIMING OF THE ROLLOUT OF THE STRATEGIC PLAN  
5 AND THE FACT THAT THE INFRASTRUCTURE TYPICALLY AS A  
6 FUNDING ROUND TENDS TO BE A PRETTY HEFTY BUDGET  
7 ASSOCIATED WITH IT.

8 DR. DEAS: YES. THAT SATISFIES MY  
9 CONCERN. I'M JUST POINTING OUT THAT IN THE  
10 PRESENTATION WE NEED TO CLEARLY STATE THAT SO THE  
11 PUBLIC UNDERSTANDS IT AS WELL.

12 DR. MILLAN: THANK YOU SO MUCH.

13 CHAIRMAN THOMAS: THANK YOU, DEBORAH.  
14 FRED.

15 DR. FISHER: JUST QUICKLY, SINCE -- AND I  
16 PARTICULARLY APPRECIATED DR. MILLAN'S LAST COMMENT,  
17 WHICH IS THE FUNDING IS NOT FOR BRICKS AND MORTAR,  
18 WHICH WAS REALLY HELPFUL AND PROBABLY PART OF THE  
19 QUESTION I SHOULD HAVE ASKED IN THE FIRST PLACE,  
20 KNOWING HOW MUCH BRICKS AND MORTAR INVESTMENT  
21 HAPPENED IN THE FIRST ERA OF FUNDING. MAYBE AT SOME  
22 POINT WE COME UP WITH A NEW NAME FOR WHAT THIS IS  
23 BECAUSE IT REALLY IS PROGRAMMATIC. IT REALLY IS  
24 DIRECT SERVICE. THOSE ALPHA CLINICS, THEY ARE  
25 THERE, THEY ARE HELPING PEOPLE, THEY ARE PROVIDING

**BETH C. DRAIN, CA CSR NO. 7152**

1 SERVICES, THEY ARE RUNNING CLINICAL TRIALS THERE.  
2 SO IT'S REALLY -- INFRASTRUCTURE IS KIND OF A  
3 COUNTER-INTUITIVE WORD TO DESCRIBE WHAT IS ACTUALLY  
4 GOING ON. AND IT'S PROBABLY IN EVERYBODY'S BEST  
5 INTEREST THAT WE FIND A LABEL FOR IT THAT ACTUALLY  
6 HELPS PEOPLE UNDERSTAND WHAT WE ARE SPENDING THE  
7 MONEY ON.

8 CHAIRMAN THOMAS: THANK YOU, FRED. ANY  
9 OTHER COMMENTS OR QUESTIONS FROM MEMBERS OF THE  
10 BOARD? IS THERE ANY PUBLIC COMMENT?

11 MS. BONNEVILLE: NO HANDS RAISED.

12 CHAIRMAN THOMAS: HEARING NONE, MARIA,  
13 PLEASE CALL THE ROLL.

14 MS. BONNEVILLE: SURE. LAUREN ALVING.

15 DR. ALVING: YES.

16 MS. BONNEVILLE: KIM BARRETT.

17 DR. BARRETT: YES.

18 MS. BONNEVILLE: DAN BERNAL. GEORGE  
19 BLUMENTHAL.

20 DR. BLUMENTHAL: YES.

21 MS. BONNEVILLE: MICHAEL BOTCHAN. LINDA  
22 BOXER. LEONDRA CLARK-HARVEY. DEBORAH DEAS.

23 DR. DEAS: YES.

24 MS. BONNEVILLE: ANNE-MARIE DULIEGE.

25 DR. DULIEGE: YES.

**BETH C. DRAIN, CA CSR NO. 7152**

1 MS. BONNEVILLE: YSABEL DURON.  
2 MS. DURON: YES.  
3 MS. BONNEVILLE: MARK FISCHER-COLBRIE.  
4 DR. FISCHER-COLBRIE: YES.  
5 MS. BONNEVILLE: FRED FISHER.  
6 DR. FISHER: YES.  
7 MS. BONNEVILLE: ELENA FLOWERS.  
8 DR. FLOWERS: YES.  
9 MS. BONNEVILLE: JUDY GASSON.  
10 DR. GASSON: YES.  
11 MS. BONNEVILLE: LARRY GOLDSTEIN.  
12 DR. GOLDSTEIN: YES.  
13 MS. BONNEVILLE: DAVID HIGGINS.  
14 DR. HIGGINS: YES.  
15 MS. BONNEVILLE: STEPHEN JUELSGAARD.  
16 MR. JUELSGAARD: YES.  
17 MS. BONNEVILLE: RICH LAJARA.  
18 MR. LAJARA: YES.  
19 MS. BONNEVILLE: PAT LEVITT. LINDA  
20 MALKAS. DAVE MARTIN.  
21 DR. MARTIN: YES.  
22 MS. BONNEVILLE: SHLOMO MELMED.  
23 DR. MELMED: YES.  
24 MS. BONNEVILLE: CHRISTINE MIASKOWSKI.  
25 DR. MIASKOWSKI: YES.

**BETH C. DRAIN, CA CSR NO. 7152**

1 MS. BONNEVILLE: LAUREN MILLER-ROGEN.  
2 MS. MILLER-ROGEN: YES.  
3 MS. BONNEVILLE: ADRIANA PADILLA.  
4 DR. PADILLA: YES.  
5 MS. BONNEVILLE: JOE PANETTA.  
6 MR. PANETTA: YES.  
7 MS. BONNEVILLE: AL ROWLETT.  
8 MR. ROWLETT: YES.  
9 MS. BONNEVILLE: BARRY SELICK.  
10 DR. SELICK: YES.  
11 MS. BONNEVILLE: MICHAEL STAMOS.  
12 DR. STAMOS: YES.  
13 MS. BONNEVILLE: JONATHAN THOMAS.  
14 CHAIRMAN THOMAS: YES.  
15 MS. BONNEVILLE: ART TORRES.  
16 MR. TORRES: AYE.  
17 MS. BONNEVILLE: KRISTINA VUORI.  
18 DR. VUORI: YES.  
19 MS. BONNEVILLE: KAROL WATSON.  
20 DR. WATSON: YES.  
21 MS. BONNEVILLE: THANK YOU. THE MOTION  
22 CARRIES.  
23 CHAIRMAN THOMAS: THANK YOU. POUNEH,  
24 BEFORE YOU GO ON HERE, WE'RE GOING TO MOVE ANOTHER  
25 ITEM OUT OF ORDER BECAUSE IT BEARS ON THE SECOND

**BETH C. DRAIN, CA CSR NO. 7152**

1 BUDGET AGENDA TOPIC. SO WE'RE GOING TO TAKE ITEM  
2 17, CONSIDERATION OF ICOC PATIENT ADVOCATE MEMBER  
3 COMPENSATION, UP AT THIS POINT IN ADVANCE OF HEARING  
4 ABOUT AND VOTING ON THE ADMINISTRATIVE BUDGET  
5 BECAUSE THIS IS AN ITEM THAT APPEARS IN THE  
6 ADMINISTRATIVE BUDGET. SO I'M GOING TO PRESENT ON  
7 THIS.

8 SO A LITTLE BIT OF BACKGROUND HERE. WHEN  
9 CIRM WAS FIRST ESTABLISHED BY PROP 71, PATIENT  
10 ADVOCATES WERE TO BE GIVEN A PER DIEM OF A HUNDRED  
11 DOLLARS FOR MEETINGS THAT THEY MADE AT THAT POINT.  
12 AT THE SAME TIME WE HAD AN AMOUNT THAT WENT TO THE  
13 MEMBERS OF THE GWG, WHO WERE SCIENTIFIC MEMBERS,  
14 WHICH WAS DUBBED A DAILY CONSULTING RATE OF \$750.  
15 AND A FEW YEARS WENT BY; AND AFTER THE PASSAGE OF SB  
16 1064, THE PATIENT ADVOCATE PER DIEM WAS CHANGED TO A  
17 DAILY CONSULTING RATE WITH RESPECT PARTICULARLY TO  
18 THOSE MEMBERS WHO WERE PART OF THE GWG. AND THE  
19 BOARD MADE A DECISION THAT THE DAILY CONSULTING RATE  
20 FOR THE PATIENT ADVOCATES IN THAT CONTEXT SHOULD BE  
21 THREE-QUARTERS OF WHAT THE SCIENTIFIC MEMBERS WERE  
22 GETTING OR \$562.50.

23 THE PATIENT ADVOCATES PLAY, IN ADDITION TO  
24 THE EXCEPTIONALLY IMPORTANT ROLE, A CONSIDERABLE  
25 ROLE THAT GOES ABOVE AND BEYOND THE PARTICIPATION OF

**BETH C. DRAIN, CA CSR NO. 7152**

1 THE ICOC AND SUBCOMMITTEE LEVEL. AND SO AS YEARS  
2 WENT BY, WHILE THEY WERE ONLY GETTING COMPENSATED  
3 FOR THE EXTRA AMOUNT FOR THE GWG, BOB DECIDED IN  
4 WRITING PROP 14 THAT THE DAILY CONSULTING RATE FOR  
5 THE PATIENT ADVOCATES SHOULD EXTEND TO ALL MEETINGS  
6 THAT THEY MAKE AS SORT OF A MAKEUP AND REFLECTION OF  
7 THE EXTRAORDINARY COMMITMENT THEY MAKE TO THE  
8 ORGANIZATION. WE NOW HAVE LAYERED ON TOP OF THAT,  
9 AMONG OTHER THINGS, THE PARTICIPATION IN THE AAWG,  
10 WHICH IS GOING TO TAKE UP A LOT OF TIME FOR THEM.

11 SO THE MEASURE, AS I SAY, INCREASED THE  
12 SCOPE TO WHICH THE DAILY CONSULTING RATE WOULD  
13 APPLY, AND IT'S NOW UP TO THE BOARD TO VOTE ON THE  
14 AMOUNT OF THAT DAILY CONSULTING RATE AS MORE BROADLY  
15 APPLIED. AND AS YOU SEE IN THE MEMO, WHICH WAS  
16 PREPARED BY JAMES HARRISON ON THE SUBJECT, THE  
17 RECOMMENDATION IS THAT THE 562.50 THE GOING RATE FOR  
18 THE PATIENT ADVOCATES AS APPLIED ACROSS THE BOARD  
19 FOR THEIR PARTICIPATION IN THE VARIOUS MATTERS THAT  
20 WE HAVE DISCUSSED HERE. DO I HEAR A MOTION TO  
21 APPROVE?

22 BY THE WAY, PATIENT ADVOCATES, SINCE THIS  
23 APPLIES TO YOU, PLEASE IF YOU WOULD REFRAIN FROM  
24 MOVING, SECONDING, COMMENTING, OR WHATEVER. SO DO  
25 WE HEAR A MOTION TO APPROVE?

**BETH C. DRAIN, CA CSR NO. 7152**

1 DR. DULIEGE: I MOVE.

2 CHAIRMAN THOMAS: ANNE-MARIE MOVES. IS  
3 THERE A SECOND?

4 DR. HIGGINS: HIGGINS' DOG SECONDS.

5 MR. TORRES: I CAN SECOND.

6 DR. MELMED: I SECOND.

7 CHAIRMAN THOMAS: I THINK SHLOMO WAS FIRST  
8 ON THE SECOND. WE GOT LOTS OF SECONDS. QUESTIONS  
9 OR COMMENTS FROM MEMBERS OF THE BOARD? ANY COMMENTS  
10 FROM MEMBERS OF THE PUBLIC?

11 MS. BONNEVILLE: THERE ARE NONE.

12 CHAIRMAN THOMAS: HEARING NONE, MARIA,  
13 WILL YOU PLEASE CALL THE ROLL.

14 MS. BONNEVILLE: LAUREN ALVING.

15 DR. ALVING: YES.

16 MS. BONNEVILLE: KIM BARRETT.

17 DR. BARRETT: YES.

18 MS. BONNEVILLE: GEORGE BLUMENTHAL.

19 DR. BLUMENTHAL: YES.

20 MS. BONNEVILLE: MICHAEL BOTCHAN. LINDA  
21 BOXER. DEBORAH DEAS.

22 DR. DEAS: YES.

23 MS. BONNEVILLE: ANNE-MARIE DULIEGE.

24 DR. DULIEGE: YES.

25 MS. BONNEVILLE: JUDY GASSON.

**BETH C. DRAIN, CA CSR NO. 7152**

1 DR. GASSON: YES.  
2 MS. BONNEVILLE: LARRY GOLDSTEIN.  
3 DR. GOLDSTEIN: YES.  
4 MS. BONNEVILLE: STEPHEN JUELSGAARD.  
5 MR. JUELSGAARD: YES.  
6 MS. BONNEVILLE: PAT LEVITT. LINDA  
7 MALKAS. DAVE MARTIN.  
8 DR. MARTIN: YES.  
9 MS. BONNEVILLE: SHLOMO MELMED.  
10 DR. MELMED: YES.  
11 MS. BONNEVILLE: JOE PANETTA.  
12 MR. PANETTA: YES.  
13 MS. BONNEVILLE: BARRY SELICK.  
14 DR. SELICK: YES.  
15 MS. BONNEVILLE: MICHAEL STAMOS.  
16 DR. STAMOS: YES.  
17 MS. BONNEVILLE: JONATHAN THOMAS.  
18 CHAIRMAN THOMAS: YES.  
19 MS. BONNEVILLE: ART TORRES.  
20 MR. TORRES: AYE.  
21 MS. BONNEVILLE: KRISTINA VUORI.  
22 DR. VUORI: YES.  
23 MS. BONNEVILLE: THE MOTION CARRIES.  
24 CHAIRMAN THOMAS: THANK YOU, MARIA. AND  
25 THANK YOU ALL ON BEHALF OF THE PATIENT ADVOCATES.

**BETH C. DRAIN, CA CSR NO. 7152**

1 OKAY. POUNEH, NOW WE WILL MOVE ON TO  
2 CONSIDERATION OF REVISED CIRM ADMINISTRATIVE BUDGET  
3 FOR FISCAL YEAR 21/22. AND BEFORE YOU START, I JUST  
4 WANTED TO HAVE AL, AS CHAIRMAN OF THE FINANCE  
5 COMMITTEE, IF YOU WOULD, AL, JUST SAY A FEW WORDS  
6 ABOUT THIS ITEM.

7 MR. ROWLETT: I APPRECIATE THE WORK OF  
8 POUNEH AND THE STAFF AND THE MEMBERS OF THE FINANCE  
9 SUBCOMMITTEE. WE DID MEET AND REVIEWED THE  
10 PRESENTATION THAT'S GOING TO BE PRESENTED TO YOU.  
11 AND AFTER SOME DISCUSSION, IT WAS APPROVED  
12 UNANIMOUSLY.

13 CHAIRMAN THOMAS: THANK YOU, AL. POUNEH,  
14 PLEASE PROCEED TO THE PRESENTATION.

15 MS. SIMPSON: BE HAPPY TO. SO WE'RE GOING  
16 TO BE PUTTING UP THE POWERPOINT PRESENTATION FOR THE  
17 ADMINISTRATIVE BUDGET, AND I WILL START WITH THE  
18 AGENDA. GIVE ME A SECOND FOR THAT TO COME UP ON THE  
19 SCREEN.

20 SO WITH THIS BUDGET, AGAIN, IT'S A UNIQUE  
21 YEAR. SO IN THE AGENDA WE'RE GOING TO HIGHLIGHT TWO  
22 PARTS. THE FIRST PART IS WHAT THE ICOC APPROVED IN  
23 JUNE AND WHAT THE MAJOR DRIVERS OF THAT BUDGET WERE.  
24 AND THEN THE SECOND PART, WHICH IS A MID-YEAR  
25 REVISION, THAT WE ARE BRINGING TO YOU TODAY.

**BETH C. DRAIN, CA CSR NO. 7152**

1 SO STARTING WITH WHAT THE BOARD APPROVED  
2 IN JUNE. AGAIN, THIS WAS A UNIQUE YEAR. WE  
3 TYPICALLY JUST PRESENT THE ADMINISTRATIVE BUDGET  
4 ONCE IN JUNE FOR A JULY 1 START OF THE FISCAL YEAR.  
5 HOWEVER, BECAUSE THE STRATEGIC PLAN WAS BEING  
6 DEVELOPED, WE NOTED, WHEN WE PRESENTED THE BUDGET IN  
7 JUNE, THAT WE WOULD BE COMING BACK WITH SOME  
8 ADJUSTMENTS AS A RESULT OF THE STRATEGIC PLAN.

9 SO THE BUDGET THAT WAS APPROVED BY THE  
10 BOARD WAS THE START OF THE LAUNCH OF THE PROP 14  
11 INITIATIVES, THE DEVELOPMENT OF THE STRATEGIC PLAN,  
12 PERSONNEL BUILDING OF THE NINE POSITIONS THAT WERE  
13 APPROVED BY THE BOARD, AND THE INCREASE IN THE  
14 NUMBER OF REVIEWS OF THE PROGRAMS ANNOUNCED, AND  
15 THEN AN ORGANIZATIONAL RESTRUCTURE THAT WAS  
16 PRESENTED TO THE BOARD IN OCTOBER, WHICH IS  
17 REFLECTED IN THE DEPARTMENTAL LEVEL BUDGETS THAT  
18 WERE PROVIDED TO YOU IN THE APPENDIX.

19 SO THAT'S KIND OF AN OVERVIEW OF WHAT WAS  
20 APPROVED IN JUNE. AND THEN I'D LIKE TO KIND OF MOVE  
21 INTO WHAT WE'RE PRESENTING TO YOU AS PART OF THE  
22 MID-YEAR BUDGET IN SLIDE 6.

23 SO IN SLIDE 6 YOU HAVE THE DIFFERENT  
24 CATEGORIES THAT WE USUALLY PRESENT OUR BUDGET IN THE  
25 FIRST COLUMN. THE SECOND COLUMN IS WHAT THE BOARD

**BETH C. DRAIN, CA CSR NO. 7152**

1 APPROVED, \$21.1 MILLION, AS PART OF THE 21/22 FISCAL  
2 YEAR. IN THE THIRD COLUMN IS THE TOTAL THAT WE ARE  
3 REQUESTING THE BUDGET GO TO, A TOTAL OF \$23 MILLION.  
4 AND THE FOURTH COLUMN IS THE VARIANCE IN THE  
5 DIFFERENT CATEGORIES OF WHAT WE ARE ASKING TO  
6 INCREASE OR DECREASE.

7 SO IN THE NEXT FEW SLIDES, I'M GOING TO  
8 PROVIDE SOME MORE DETAILS TO YOU ON WHAT THOSE  
9 INCREASES AND DECREASES ARE. SO SLIDE 7, THE VERY  
10 FIRST CATEGORY IS THE PERSONNEL SERVICES THAT DRIVE  
11 OUR -- THERE'S THREE CATEGORIES OF INCREASES, TWO  
12 CATEGORIES OF DECREASES.

13 SO ON SLIDE 8 I'M GOING TO START WITH  
14 EMPLOYEE EXPENSES. USUALLY THAT IS OUR LARGEST  
15 CATEGORY OF INCREASE. IN THIS SCENARIO WE ARE  
16 ASKING FOR AN INCREASE OF SIX NEW POSITIONS IN THIS  
17 MID-YEAR BUDGET THAT RELATE TO THE STRATEGIC PLAN  
18 LAUNCH OF THE NEW PROGRAMS THAT ARE NEEDED THAT DR.  
19 MILLAN JUST PROVIDED AN OVERVIEW OF TO MANAGE THE  
20 OPERATIONAL DEMANDS AND THE PORTFOLIO SIZE OF THESE  
21 NEW PROGRAMS AND THE PERSONNEL COSTS, WHICH INCLUDES  
22 A BASE SALARY AND BENEFITS WHICH CAN BE UP TO 45  
23 PERCENT OF THE SALARY.

24 THE SECOND PART OF THIS CATEGORY IS THE  
25 INCREASE IN THE PATIENT ADVOCATE CONSULTING PER

**BETH C. DRAIN, CA CSR NO. 7152**

1 DIEM. SO THAT'S WHAT THE CHAIR JUST WENT OVER.

2 IT'S A REQUIREMENT OF PROP 14. THE TOTAL IN THIS  
3 CATEGORY IS 1.2 MILLION INCREASE OR 8 PERCENT.

4 AND THE NEXT CATEGORY OF INCREASE FOR US  
5 IS EXTERNAL SERVICES. HERE WE HAVE A COUPLE OF  
6 CONTRACTS THAT ARE NEEDED TO HELP US GO PAPERLESS AS  
7 PART OF THE MOVE AND AS PART OF BEING OPERATIONAL IN  
8 A REMOTE ENVIRONMENT. AND SOME SAVINGS WERE  
9 CAPTURED IN THIS CATEGORY IN CONSULTING SERVICES  
10 WHERE WE DID NOT NEED TO USE UP THE EXISTING  
11 CONTRACTS. THE NET IMPACT OF THAT IS AN INCREASE OF  
12 \$165,000 OR 8 PERCENT.

13 THE NEXT CATEGORY OF INCREASE IS OFFICE  
14 EXPENSES. IN THIS CATEGORY WE ARE CAPTURING ANY  
15 COSTS OF SOFTWARE UPGRADES OR NEW SOFTWARE NEEDED,  
16 EQUIPMENT REFRESH, SERVER AND NETWORK REFRESH, MEDIA  
17 ROOM AUDIOVISUAL PLANNING, AND MODIFICATIONS IN THE  
18 NEW OFFICE. THE NET INCREASE IS \$720,000.

19 AND THE NEXT TWO CATEGORIES ARE AREAS  
20 WHERE WE WERE ABLE TO FIND SAVINGS. SO IN THE AREA  
21 OF TRAVEL, OBVIOUSLY BECAUSE OF SOME OF THE  
22 RESTRICTIONS OF COVID-19, WE WERE ABLE TO REDUCE  
23 IN-PERSON MEETINGS AND TRAININGS AND CONFERENCES FOR  
24 A NET SAVINGS OF \$57,000.

25 THE LAST CATEGORY WE WERE ABLE TO

**BETH C. DRAIN, CA CSR NO. 7152**

1 RECAPTURE 154,000 IN SAVINGS BECAUSE ONE OF OUR  
2 CLINICAL PROGRAM REVIEWS WENT VIRTUAL INSTEAD OF IN  
3 PERSON, AND TWO OF THE REVIEWS WERE POSTPONED UNTIL  
4 NEXT FISCAL YEAR.

5 SO, FINALLY, I WOULD LIKE TO ACKNOWLEDGE  
6 THAT, WHILE WE WILL BE ACTIVELY MANAGING COSTS AND  
7 MAINTAINING EXPENSES, THERE ARE EXTERNAL FACTORS  
8 THAT COULD AFFECT OUR PROJECTED BUDGET PLANS. AND  
9 THOSE INCLUDE POTENTIAL MOVE COSTS THAT WE HAVE NOT  
10 ANTICIPATED, TIMING AND SUCCESS OF THE RECRUITMENT  
11 OF THE POSITIONS THAT ARE BEING PROPOSED, AND THEN  
12 THE EFFECTS OF COVID-19 ON TRAVEL AND WORK  
13 ACTIVITIES.

14 WITH THAT, I WOULD LIKE TO ASK THE  
15 COMMITTEE TO APPROVE THE MID-YEAR BUDGET FOR  
16 ADMINISTRATION. AND I'M HAPPY TO TAKE ANY QUESTIONS  
17 RELATED TO THAT.

18 CHAIRMAN THOMAS: THANK YOU, POUNEH. DO  
19 WE HAVE A MOTION TO APPROVE BEFORE --

20 DR. STAMOS: SO MOVED.

21 CHAIRMAN THOMAS: THAT WAS MOVED BY?

22 DR. STAMOS: MICHAEL.

23 CHAIRMAN THOMAS: MICHAEL. THANK YOU,  
24 MICHAEL.

25 DR. BLUMENTHAL: SECOND.

**BETH C. DRAIN, CA CSR NO. 7152**

1 CHAIRMAN THOMAS: SECONDED BY GEORGE.

2 OKAY. DO WE HAVE COMMENTS, QUESTIONS? DAVID.

3 DR. MARTIN: JUST A QUESTION ABOUT  
4 RELOCATION. WHAT WAS THE MOTIVATION FOR RELOCATING  
5 TO SOUTH SAN FRANCISCO?

6 CHAIRMAN THOMAS: DR. MILLAN, WOULD YOU  
7 ADDRESS THAT PLEASE.

8 DR. MILLAN: ABSOLUTELY. AND THEN I'D  
9 LIKE TO THEN REFER THIS QUESTION TO KEVIN MARKS,  
10 WHO'S HELPING US IN OUR FACILITY SEARCH.

11 SO OUR LEASE FOR THE OAKLAND OFFICE WAS UP  
12 ACTUALLY LAST YEAR. WE EXTENDED THE LEASE BY  
13 ANOTHER YEAR. BECAUSE IT WAS A ONE-YEAR LEASE  
14 EXTENSION, IT CAME AT A PREMIUM. SO FOR FISCAL  
15 REASONS -- AND THE REASON WHY WE SPENT THAT WAS  
16 BECAUSE WE DIDN'T KNOW WHAT THE OUTCOME OF THE  
17 PROPOSITION WOULD BE, SO IT DIDN'T MAKE SENSE TO  
18 MOVE OFFICES. SO WE DECIDED THAT IT WAS WORTH IT AT  
19 THAT POINT TO STAY PUT AND THEN DETERMINE WHAT THE  
20 MARKET LOOKED LIKE AND WHAT RENTS LOOKED LIKE AS  
21 SOON AS WE FOUND OUT THE OUTCOME OF PROP 14.

22 WITH THE PASSAGE OF PROP 14, WE THEN  
23 EMBARKED ON AN EVALUATION OF WHETHER WE WOULD STAY  
24 THERE OR LOOK FOR NEW OFFICES. AND WE SET  
25 PARAMETERS FOR THAT THAT THE BOARD APPROVED.

**BETH C. DRAIN, CA CSR NO. 7152**

1 CHAIRMAN THOMAS, VICE CHAIR TORRES, AND I DIRECTED  
2 THIS SEARCH. AND I DELEGATED THE LEAD ON KIND OF  
3 THE ON-THE-GROUND ACTIVITIES TO KEVIN MARKS WHO IS  
4 HERE, I BELIEVE, ON THIS CALL AND IS HAPPY TO ANSWER  
5 ANY QUESTIONS BEYOND WHAT I JUST EXPLAINED. THANK  
6 YOU.

7 DR. MARTIN: THANK YOU.

8 MR. MARKS: IN SHORT, THERE WERE A NUMBER  
9 OF FACTORS THAT WENT INTO THE EVALUATION OF  
10 PROPERTIES. AND WE LOOKED AT VARIOUS GEOGRAPHIC  
11 AREAS, INCLUDING OAKLAND, SAN FRANCISCO, AND SOUTH  
12 SAN FRANCISCO. WE WERE LOOKING AT SHEPHERDING OUR  
13 FISCAL RESPONSIBILITIES TO THE STATE OF CALIFORNIA  
14 AND LOOKING AT AN ATTRACTIVE COST OPTION FOR THE NEW  
15 OFFICE SPACE. OUR EXISTING SPACE, THE PROPOSAL WAS  
16 DRASTICALLY INCREASED IN THE QUOTES THAT WE  
17 RECEIVED, WHICH NECESSITATED MORE OF A MOVE.

18 WE WERE ALSO LOOKING FOR A LOCATION THAT  
19 COULD BETTER ACCOMMODATE EMPLOYEE COMMUTES. SO ALL  
20 THOSE FACTORS WENT INTO THE SELECTION OF PROPERTY.  
21 WE NARROWED IT DOWN TO ABOUT FOUR PROPERTIES THAT WE  
22 ADVANCED THE NEGOTIATION ON. WE ARE IN ADVANCED  
23 STAGE OF NEGOTIATIONS WITH ONE PARTICULAR PROPERTY  
24 AS YOU NOTED IN SOUTH SAN FRANCISCO. THE LEASE HAS  
25 YET TO BE EXECUTED, BUT WE HOPE TO DO SO SHORTLY.

**BETH C. DRAIN, CA CSR NO. 7152**

1 CHAIRMAN THOMAS: THANKS, KEVIN AND MARIA.  
2 OTHER QUESTIONS OR COMMENTS FROM MEMBERS  
3 OF THE BOARD? OKAY. COMMENTS FROM MEMBERS OF THE  
4 PUBLIC?

5 MS. BONNEVILLE: NO.

6 CHAIRMAN THOMAS: HEARING NONE, MARIA,  
7 PLEASE CALL THE ROLL.

8 MS. BONNEVILLE: LAUREN ALVING. KIM  
9 BARRETT.

10 DR. BARRETT: YES.

11 MS. BONNEVILLE: DAN BERNAL. GEORGE  
12 BLUMENTHAL.

13 DR. BLUMENTHAL: YES.

14 MS. BONNEVILLE: MICHAEL BOTCHAN. LINDA  
15 BOXER. LEONDRA CLARK-HARVEY. DEBORAH DEAS.

16 DR. DEAS: YES.

17 MS. BONNEVILLE: ANNE-MARIE DULIEGE.

18 DR. DULIEGE: YES.

19 MS. BONNEVILLE: YSABEL DURON.

20 MS. DURON: YES.

21 MS. BONNEVILLE: MARK FISCHER-COLBRIE.

22 DR. FISCHER-COLBRIE: YES.

23 MS. BONNEVILLE: FRED FISHER.

24 DR. FISHER: YES.

25 MS. BONNEVILLE: ELENA FLOWERS.

**BETH C. DRAIN, CA CSR NO. 7152**

1 DR. FLOWERS: YES.  
2 MS. BONNEVILLE: JUDY GASSON.  
3 DR. GASSON: YES.  
4 MS. BONNEVILLE: LARRY GOLDSTEIN.  
5 DR. GOLDSTEIN: YES.  
6 MS. BONNEVILLE: DAVID HIGGINS.  
7 DR. HIGGINS: YES.  
8 MS. BONNEVILLE: STEPHEN JUELSGAARD.  
9 MR. JUELSGAARD: YES.  
10 MS. BONNEVILLE: RICH LAJARA.  
11 MR. LAJARA: YES.  
12 MS. BONNEVILLE: PAT LEVITT. LINDA  
13 MALKAS. DAVE MARTIN.  
14 DR. MARTIN: YES.  
15 MS. BONNEVILLE: SHLOMO MELMED.  
16 DR. MELMED: YES.  
17 MS. BONNEVILLE: CHRISTINE MIASKOWSKI.  
18 DR. MIASKOWSKI: YES.  
19 MS. BONNEVILLE: LAUREN MILLER-ROGEN.  
20 MS. MILLER-ROGEN: YES.  
21 MS. BONNEVILLE: ADRIANA PADILLA.  
22 DR. PADILLA: YES.  
23 MS. BONNEVILLE: JOE PANETTA.  
24 MR. PANETTA: YES.  
25 MS. BONNEVILLE: AL ROWLETT.

**BETH C. DRAIN, CA CSR NO. 7152**

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25

MR. ROWLETT: YES.

MS. BONNEVILLE: BARRY SELICK.

DR. SELICK: YES.

MS. BONNEVILLE: MICHAEL STAMOS.

DR. STAMOS: YES.

MS. BONNEVILLE: JONATHAN THOMAS.

CHAIRMAN THOMAS: YES.

MS. BONNEVILLE: ART TORRES.

MR. TORRES: AYE.

MS. BONNEVILLE: KRISTINA VUORI.

DR. VUORI: YES.

MS. BONNEVILLE: KAROL WATSON.

DR. WATSON: YES.

MS. BONNEVILLE: THANK YOU. THE MOTION  
CARRIES.

CHAIRMAN THOMAS: THANK YOU, MARIA.

OKAY. SO WE HAVE TWO ACTION ITEMS LEFT,  
BUT THEY WILL FOLLOW ONE OF THE CLOSED SESSION  
ITEMS. AND SO WHAT WE'RE GOING TO DO NOW IS GOING  
TO ADJOURN TO CLOSED SESSION. AND I'LL HAVE KEVIN  
READ THE CLOSED SESSION TOPICS. AND THEN WE WILL  
COME OUT, WE'LL VOTE AT THAT POINT ON ITEMS 15 AND  
16. BUT BEFORE WE DO ANY OF THAT, WE PURPOSELY PUT  
THIS TO THE END OF THE MEETING SO IF THERE ARE  
MEMBERS OF THE PUBLIC WHO HAVE COMMENTS ON ANYTHING

**BETH C. DRAIN, CA CSR NO. 7152**

1 IN PARTICULAR THEY WANT TO DISCUSS, I WANTED TO GIVE  
2 THEM THE OPPORTUNITY TO DO THAT BEFORE WE GO INTO  
3 CLOSED SESSION.

4 DO WE HAVE ANY COMMENTS FROM MEMBERS OF  
5 THE PUBLIC ON ANY TOPIC OF INTEREST?

6 MS. BONNEVILLE: THERE ARE NO HANDS  
7 RAISED.

8 CHAIRMAN THOMAS: OKAY. THANK YOU. SO,  
9 KEVIN, WILL YOU LEAD US THROUGH THE LANGUAGE AS WE  
10 ADJOURN INTO CLOSED SESSION?

11 MS. BONNEVILLE: J.T., I THOUGHT WE WERE  
12 GOING TO TAKE A BREAK FIRST, AND THEN WE'LL COME  
13 BACK AND GO INTO CLOSED SESSION BECAUSE WE HAVE TO  
14 PUT EVERYONE INTO A BREAKOUT ROOM.

15 CHAIRMAN THOMAS: I THOUGHT WE WERE JUST  
16 GOING TO READ THIS AND THEN HAVE THEM GO OUT.  
17 WHATEVER. FOLLOWING MARIA'S LEAD, AS ALWAYS, SO CAN  
18 WE TAKE A TEN-MINUTE BREAK HERE FOR FOLKS TO GET  
19 LUNCH. AND THEN WE WILL COME BACK AND THEN KEVIN  
20 WILL TAKE US INTO CLOSED SESSION. SO GET WHATEVER  
21 AND BRING IT BACK. THIS WILL BE A WORKING CLOSED  
22 SESSION WITH YOUR LUNCH.

23 DR. DULIEGE: CAN WE HAVE THE LINK NOW, OR  
24 WILL WE HAVE IT LATER, OR IS IT A DIFFERENT THING?

25 CHAIRMAN THOMAS: THAT'S A MARIA QUESTION.

**BETH C. DRAIN, CA CSR NO. 7152**

1 THAT'S ABOVE MY PAY GRADE.

2 MS. BONNEVILLE: YOU RECEIVED THE  
3 DOCUMENTS -- ANNE-MARIE, I'M GOING TO CALL YOU.  
4 OTHERS RECEIVED THE DOCUMENTS, SO I'LL GIVE YOU A  
5 CALL RIGHT NOW.

6 DR. DULIEGE: THANK YOU. THANK YOU VERY  
7 MUCH.

8 (A RECESS WAS TAKEN.)

9 CHAIRMAN THOMAS: IF EVERYBODY IS WITHIN  
10 EARSHOT, IF YOU COULD START COLLECTING HERE AGAIN.

11 MS. BONNEVILLE: SO I THINK WE CAN HAVE  
12 KEVIN READ CLOSED SESSION LANGUAGE, AND THEN DOUG  
13 WILL BRING US INTO A BREAKOUT ROOM FOR JUST THE  
14 BOARD MEMBERS FOR CLOSED SESSION. KEVIN AND I WILL  
15 ALSO BE IN THERE. AND THEN WHEN WE COME OUT OF  
16 CLOSED SESSION (INAUDIBLE).

17 MR. MARKS: MR. CHAIRMAN, WHENEVER YOU'RE  
18 READY.

19 CHAIRMAN THOMAS: I'M SET. MARIA, DO YOU  
20 SEE MOST BACK AT THIS POINT?

21 MS. BONNEVILLE: SURE.

22 CHAIRMAN THOMAS: OKAY. KEVIN, PLEASE.

23 MR. MARKS: MR. CHAIRMAN, MEMBERS OF THE  
24 BOARD, WE'LL NOW BE MOVING INTO CLOSED SESSION  
25 PURSUANT TO GOVERNMENT CODE 11126(A) AND THE HEALTH

**BETH C. DRAIN, CA CSR NO. 7152**

1 AND SAFETY CODE SECTION 125290.30(F)(3)(D).

2 CHAIRMAN THOMAS: OKAY. THANK YOU.

3 MS. BONNEVILLE: DOUG, CAN YOU GET  
4 EVERYONE INTO CLOSED SESSION?

5 (THE BOARD THEN WENT INTO CLOSED  
6 SESSION, NOT REPORTED, NOR HEREIN TRANSCRIBED. AT  
7 THE CONCLUSION OF THE CLOSED SESSION, THE FOLLOWING  
8 WAS HEARD IN OPEN SESSION AS FOLLOWS:)

9 CHAIRMAN THOMAS: THANK YOU. I BELIEVE  
10 EVERYBODY IS BACK FROM CLOSED SESSION. WE HAVE TWO  
11 ITEMS LEFT.

12 MR. MARKS: EXCUSE ME, MR. CHAIRMAN. I  
13 NEED TO BRING US OUT OF CLOSED SESSION BEFORE WE  
14 START. SORRY. WE ARE NOW OFFICIALLY OUT OF CLOSED  
15 SESSION. NO DECISIONS OR ACTION WERE TAKEN BY THE  
16 BOARD.

17 CHAIRMAN THOMAS: OKAY. THANK YOU. WE  
18 HAVE TWO ITEMS LEFT ON THE AGENDA WHICH I'M GOING TO  
19 TURN OVER TO JUDY.

20 DR. GASSON: THANK YOU VERY MUCH, MR.  
21 CHAIRMAN. WE ARE GOING TO CONSIDER ITEM NO. 16  
22 FIRST, AND THAT IS CONSIDERATION OF COMPENSATION FOR  
23 THE CEO AND PRESIDENT. THE GOVERNANCE SUBCOMMITTEE  
24 HAS MADE A RECOMMENDATION TO THE FULL BOARD, WHICH  
25 HAS BEEN DISCUSSED. AND I AM ASKING NOW FOR A

**BETH C. DRAIN, CA CSR NO. 7152**

1 MOTION FROM A MEMBER OF THE BOARD TO GO FORWARD.

2 DR. VUORI: I WOULD LIKE TO MAKE A MOTION  
3 TO RECOMMEND 3 PERCENT SALARY INCREASE FOR DR.  
4 MILLAN RETROACTIVE TO JULY 1ST. THIS IS A SIMILAR  
5 INCREASE IN SALARY AS WELL AS THE TIMING AS FOR THE  
6 CIRM STAFF AS A WHOLE.

7 DR. GASSON: THANK YOU VERY MUCH. DO WE  
8 HAVE A SECOND?

9 DR. BLUMENTHAL: SECOND.

10 DR. GASSON: THANK YOU VERY MUCH, GEORGE.  
11 ANY QUESTIONS OR COMMENTS FROM THE MEMBERS OF THE  
12 BOARD? HEARING NONE, ARE THERE QUESTIONS OR  
13 COMMENTS FROM THE MEMBERS OF THE PUBLIC AT THIS  
14 TIME?

15 MS. BONNEVILLE: THERE ARE NO HANDS  
16 RAISED, JUDY.

17 DR. GASSON: MARIA, WOULD YOU CALL THE  
18 ROLL PLEASE.

19 MS. BONNEVILLE: LAUREN ALVING. KIM  
20 BARRETT.

21 DR. BARRETT: YES.

22 MS. BONNEVILLE: DAN BERNAL.

23 MR. BERNAL: AYE.

24 MS. BONNEVILLE: GEORGE BLUMENTHAL.

25 DR. BLUMENTHAL: YES.

**BETH C. DRAIN, CA CSR NO. 7152**

1 MS. BONNEVILLE: MICHAEL BOTCHAN. LINDA  
2 BOXER. LEONDRA CLARK-HARVEY.  
3 DR. CLARK-HARVEY: YES.  
4 MS. BONNEVILLE: DEBORAH DEAS.  
5 DR. DEAS: YES.  
6 MS. BONNEVILLE: ANNE-MARIE DULIEGE.  
7 DR. DULIEGE: YES.  
8 MS. BONNEVILLE: YSABEL DURON.  
9 MS. DURON: YES.  
10 MS. BONNEVILLE: MARK FISCHER-COLBRIE.  
11 DR. FISCHER-COLBRIE: AYE.  
12 MS. BONNEVILLE: FRED FISHER.  
13 DR. FISHER: YES.  
14 MS. BONNEVILLE: ELENA FLOWERS.  
15 DR. FLOWERS: YES.  
16 MS. BONNEVILLE: JUDY GASSON.  
17 DR. GASSON: YES.  
18 MS. BONNEVILLE: LARRY GOLDSTEIN.  
19 DR. GOLDSTEIN: YES.  
20 MS. BONNEVILLE: DAVID HIGGINS.  
21 DR. HIGGINS: YES.  
22 MS. BONNEVILLE: STEPHEN JUELSGAARD.  
23 MR. JUELSGAARD: YES.  
24 MS. BONNEVILLE: RICH LAJARA.  
25 MR. LAJARA: YES.

**BETH C. DRAIN, CA CSR NO. 7152**

1 MS. BONNEVILLE: PAT LEVITT. LINDA  
2 MALKAS. DAVE MARTIN.  
3 DR. MARTIN: YES.  
4 MS. BONNEVILLE: SHLOMO MELMED. CHRISTINE  
5 MIASKOWSKI.  
6 DR. MIASKOWSKI: YES.  
7 MS. BONNEVILLE: LAUREN MILLER-ROGEN.  
8 ADRIANA PADILLA.  
9 DR. PADILLA: YES.  
10 MS. BONNEVILLE: JOE PANETTA. AL ROWLETT.  
11 MR. ROWLETT: YES.  
12 MS. BONNEVILLE: BARRY SELICK. MICHAEL  
13 STAMOS.  
14 DR. STAMOS: YES.  
15 MS. BONNEVILLE: JONATHAN THOMAS.  
16 CHAIRMAN THOMAS: YES.  
17 MS. BONNEVILLE: ART TORRES.  
18 MR. TORRES: AYE.  
19 MS. BONNEVILLE: KRISTINA VUORI.  
20 DR. VUORI: YES.  
21 MS. BONNEVILLE: KAROL WATSON.  
22 DR. GASSON: THANK YOU, MARIA.  
23 NOW I'D LIKE TO MOVE ON TO ACTION ITEM NO.  
24 15, WHICH IS CONSIDERATION OF COMPENSATION FOR THE  
25 ICOC CHAIR AND VICE CHAIR. MAY I HAVE A MOTION

**BETH C. DRAIN, CA CSR NO. 7152**

1 PLEASE ON THE TABLE?

2 DR. VUORI: I WOULD LIKE TO MAKE A MOTION  
3 TO INCREASE THE COMPENSATION FOR CHAIR AND VICE  
4 CHAIR BY 3 PERCENT RETROACTIVE TO JULY 1ST SIMILAR  
5 TO WHAT CIRM STAFF RECEIVED AND AT THE SAME TIME.

6 DR. GASSON: THANK YOU VERY MUCH. DO WE  
7 HAVE A SECOND?

8 DR. BLUMENTHAL: SECOND.

9 DR. GASSON: THANK YOU VERY MUCH, GEORGE.  
10 DO WE HAVE COMMENTS FROM THE MEMBERS OF THE BOARD?  
11 HEARING NONE, DO WE HAVE COMMENTS FROM THE PUBLIC?

12 MS. BONNEVILLE: WE DO NOT.

13 DR. GASSON: THANK YOU VERY MUCH, MARIA.  
14 WOULD YOU CALL THE ROLL PLEASE.

15 MS. BONNEVILLE: LAUREN ALVING. KIM  
16 BARRETT.

17 DR. BARRETT: YES.

18 MS. BONNEVILLE: DAN BERNAL.

19 MR. BERNAL: AYE.

20 MS. BONNEVILLE: GEORGE BLUMENTHAL.

21 DR. BLUMENTHAL: YES.

22 MS. BONNEVILLE: MICHAEL BOTCHAN. LINDA  
23 BOXER. LEONDRA CLARK-HARVEY.

24 DR. CLARK-HARVEY: YES.

25 MS. BONNEVILLE: DEBORAH DEAS. ANNE-MARIE

**BETH C. DRAIN, CA CSR NO. 7152**

1 DULIEGE.  
2 DR. DULIEGE: YES.  
3 MS. BONNEVILLE: YSABEL DURON.  
4 MS. DURON: YES.  
5 MS. BONNEVILLE: MARK FISCHER-COLBRIE.  
6 DR. FISCHER-COLBRIE: AYE.  
7 MS. BONNEVILLE: FRED FISHER.  
8 DR. FISHER: YES.  
9 MS. BONNEVILLE: ELENA FLOWERS.  
10 DR. FLOWERS: YES.  
11 MS. BONNEVILLE: JUDY GASSON.  
12 DR. GASSON: YES.  
13 MS. BONNEVILLE: LARRY GOLDSTEIN.  
14 DR. GOLDSTEIN: YES.  
15 MS. BONNEVILLE: DAVID HIGGINS.  
16 DR. HIGGINS: YES.  
17 MS. BONNEVILLE: STEPHEN JUELSGAARD.  
18 MR. JUELSGAARD: YES.  
19 MS. BONNEVILLE: RICH LAJARA.  
20 MR. LAJARA: YES.  
21 MS. BONNEVILLE: PAT LEVITT. LINDA  
22 MALKAS. DAVE MARTIN.  
23 DR. MARTIN: YES.  
24 MS. BONNEVILLE: SHLOMO MELMED. CHRISTINE  
25 MIASKOWSKI.

**BETH C. DRAIN, CA CSR NO. 7152**

1 DR. MIASKOWSKI: YES.

2 MS. BONNEVILLE: LAUREN MILLER-ROGEN.

3 ADRIANA PADILLA.

4 DR. PADILLA: YES.

5 MS. BONNEVILLE: JOE PANETTA. AL ROWLETT.

6 MR. ROWLETT: YES.

7 MS. BONNEVILLE: BARRY SELICK. MICHAEL

8 STAMOS.

9 DR. STAMOS: YES.

10 MS. BONNEVILLE: KRISTINA VUORI.

11 DR. VUORI: YES.

12 MS. BONNEVILLE: KAROL WATSON.

13 JUST ONE MOMENT. DEBORAH, ARE YOU ON THE  
14 LINE? DEBORAH, WE NEED YOUR VOTE IN ORDER TO TAKE  
15 ACTION ON THIS AGENDA ITEM. I'M GOING TO TRY AND  
16 GET A HOLD OF DEBORAH. WE NEED HER.

17 DR. GASSON: THANK YOU.

18 MS. BONNEVILLE: SHE'S ENTERED THE WAITING  
19 ROOM.

20 DR. DEAS: YES. I LOST INTERNET  
21 CONNECTION.

22 MS. BONNEVILLE: WE JUST TOOK THE VOTE FOR  
23 THE CHAIR AND VICE CHAIR, AND I JUST NEED TO RECORD  
24 YOUR VOTE ON THAT.

25 DR. DEAS: MY VOTE IS YES.

**BETH C. DRAIN, CA CSR NO. 7152**

1 MS. BONNEVILLE: THANK YOU SO MUCH. THE  
2 MOTION CARRIES.

3 DR. GASSON: THANK YOU, MARIA. I WOULD  
4 LIKE TO NOW TURN THE MEETING BACK OVER TO CHAIRMAN  
5 THOMAS.

6 CHAIRMAN THOMAS: THANK YOU, JUDY. THANK  
7 YOU, KRISTINA. THANK YOU, MEMBERS OF THE GOVERNANCE  
8 SUBCOMMITTEE AND MEMBERS OF THE BOARD FOR  
9 UNDERTAKING THAT DIFFICULT EXERCISE. AND THANK YOU  
10 VERY MUCH FOR THE INCREASE. APPRECIATE IT.

11 WE HAVE NO FURTHER MATTERS TO DISCUSS HERE  
12 AS WE DISPENSED WITH EVERYTHING ELSE BEFORE WE WENT  
13 INTO CLOSED SESSION. WOULD LIKE TO THANK MARIANNE  
14 AND DOUG FOR ALL THEIR HELP. AND SPECIAL THANKS TO  
15 MARIA B. FOR ORCHESTRATING THE MEETING, HERDING  
16 EVERYBODY, JUGGLING ALL THE THOUSANDS OF  
17 CONFLICTS -- JUST KIDDING -- AND REALLY DO  
18 APPRECIATE ALL YOUR HELP AS ALWAYS.

19 TO MEMBERS OF THE BOARD AND MEMBERS OF THE  
20 CIRM TEAM, WISH EVERYBODY A VERY HAPPY HOLIDAY  
21 SEASON.

22 JUDY, THANK YOU FOR LIVENING THINGS UP  
23 WITH THE CHRISTMAS SCARF THERE, THE RED AND WHITE  
24 VERY CHRISTMASY LOOKING. AND WE APPRECIATE  
25 EVERYTHING. I THINK IT'S BEEN A VERY SUCCESSFUL

**BETH C. DRAIN, CA CSR NO. 7152**

1 YEAR ON ALL COUNTS, AND WE LOOK FORWARD TO STARTING  
2 2022 WITH OUR NEW STRATEGIC PLAN AND OUR  
3 UNPARALLELED CIRM FAMILY IMPLEMENTING IT GOING  
4 FORWARD TO FURTHER ACCELERATE THE FIELD. SO WITH  
5 THAT, HAPPY HOLIDAYS TO EVERYBODY, AND WE STAND  
6 ADJOURNED.

7 MS. BONNEVILLE: THANK YOU, EVERYONE.  
8 HAPPY HOLIDAYS.

9 (THE MEETING WAS THEN CONCLUDED AT 3:08 P.M.)

10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25

**REPORTER'S CERTIFICATE**

I, BETH C. DRAIN, A CERTIFIED SHORTHAND REPORTER IN AND FOR THE STATE OF CALIFORNIA, HEREBY CERTIFY THAT THE FOREGOING TRANSCRIPT OF THE ZOOM PROCEEDINGS BEFORE THE INDEPENDENT CITIZEN'S OVERSIGHT COMMITTEE AND THE APPLICATION REVIEW SUBCOMMITTEE OF THE CALIFORNIA INSTITUTE FOR REGENERATIVE MEDICINE IN THE MATTER OF ITS REGULAR MEETING HELD ON DECEMBER 14, 2021, WAS HELD AS HEREIN APPEARS AND THAT THIS IS THE ORIGINAL TRANSCRIPT THEREOF AND THAT THE STATEMENTS THAT APPEAR IN THIS TRANSCRIPT WERE REPORTED STENOGRAPHICALLY BY ME AND TRANSCRIBED BY ME. I ALSO CERTIFY THAT THIS TRANSCRIPT IS A TRUE AND ACCURATE RECORD OF THE PROCEEDING.

BETH C. DRAIN, CA CSR 7152  
133 HENNA COURT  
SANDPOINT, IDAHO  
(208) 290-3543